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Abstract 
Albumin is the major protein in the blood and has a wide range of physiological functions 
including the involvement in the transport and metabolism of a variety of drugs, metal 
ions, hormones and fatty acids. 
Cys34 of human albumin is known to be involved in a variety of physiologically 
important redox reactions and is a binding site for a range of therapeutics, particularly 
Au(I) antiarthritic drugs. The importance of His39 and Tyr 84  in the control of the 
reactivity of Cys34 was investigated. The disulfide exchange reaction between Cys34 and 
DTNB was studied over a range of pH values (pH 6-10) for native rHA, octanoate-rHA 
and His39Leu and Tyr 84Phe mutants. A large increase in reactivity toward DTNB was 
observed for the albumin mutant Tyr 84Phe, over this p11 range. This shows that Tyr 84  is 
important in the control of Cys34 reactivity. Wildtype albumin appears to become fully 
deprotonated around pH 8.4, whilst the His39Leu and Tyr 84Phe mutants become fully 
deprotonated around pH 9.1. This suggests that the pKa of the free thiol is higher in both 
mutants than in the wildtype protein and that both His 39  and Tyr 84  contribute to the 
stabilisation of the thiolate. Elevated fatty acid levels had no significant effect on Cys34 
reactivity. 
A novel switchable metal binding site at the interface of domains I and II has been 
identified. "Cd NMR studies show that Cd2 ions bind at two sites on albumin, each 
giving rise to a distinct peak. Competition studies revealed that at one of these sites (site 
A) Zn2 , Cu2 and Ni2 were able to displace '11Cd2t The chemical shift of this site 
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indicates the involvement of 2-3 histidinyl nitrogens for metal coordination. Analysis of 
the X-ray structure of albumin revealed that there is only one site on the molecule where 
2 histidine residues lie close together. At this site, His67 and His247 are located within 5 A 
of each other and additionally, Asn99 and Asp 249  are nearby and are available as potential 
0-ligands for metal binding. It is shown that the His 67Ala mutation disrupts Cd2 and 
Cu2 binding by "Cd NMR and UV/vis spectrophotometric studies respectively. Weak 
CY binding to the fifth coordination site was demonstrated for Cd2 (log Kd = —0.66). 
Cd2 binding was dramatically affected by high fatty-acid loading of albumin. Analysis 
of the X-ray structures suggests that fatty acid binding to site 2 triggers a spring-lock 
mechanism, which disengages the upper (His 67/Asn99) and lower (His247/Asp249) halves of 
the metal site. These findings provide a possible mechanism whereby fatty acid (and 
perhaps other small molecule) binding to albumin could influence the transport and 
delivery of zinc in blood. 
Albumin is a physiologically important antioxidant. Reactions of albumin with H202 and 
NO have been studied. Peptide mapping studies of albumin following reaction with 
H202, revealed that the residues Cys34, Met' 23,  Met298 Met 87  and Met 329  are potential sites 
of peroxide-induced modification. 'H and '5N NMR studies are shown to be useful 
techniques in the study of the S-nitrosylation reactions between low-molecular weight 
thiols and acidified '5N-labelled NaNO2 but were unsuccessful in detecting S-
nitrosylation of albumin. Mass spectrometry was found to be a suitable technique in the 
study of albumin-NO reactions. However, no transfer of NO from low-molecular weight 
S-nitrosothiols to native albumin occurs under the conditions used. 
ri 
Albumin binding studies involving two cytotoxic ruthenium(II) complexes ([(p6-p-
cymene)RuCl(H2NCH2CH2NH2-N,N)]PF6 and [( 6-C6H5C6H5)RuCl(H2NCH2CH2NH2-
N,N)]PF6 ) and a novel platinum(II) complex ([Pt(NP3)CI]Cl) previously shown to have 
affinity toward low-molecular weight thiol compounds were carried out. Gel permeation 
chromatography showed that peaks corresponding to the free Ru(ll) complexes, 
decreased upon the addition of albumin, indicative of binding. Following the addition of 
[Pt(NP3)Cl]Cl, the absorbance of albumin at 398 nm increased, showing binding to have 
occurred. 
Crystallisation trials with MA, and of various albumin-Cu derivatives were carried out. 
Unfortunately, none of the crystals diffracted X-rays to greater than 5.45 A. 
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"Research is to see what everybody else has seen, and to think what nobody else has 
thought." 
Albert Szent-Gyorgi (1893-1986), U S. biochemist 
"The power of accurate observation is frequently called cynicism by those who don't 
have it." 
George Bernard Shaw (1856-1950), Irish author and socialist 
"Research is the process of going up alleys to see if they are blind." 
Marston Bates (1906-1974), U S. zoologist 
"A lot of fellows nowadays have a B.A., M.D., or Ph.D. Unfortunately, they don't have a 
"Fats" Domino, U S. musician 
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Chapter 1 
Introduction 
1.1 Clinical Significance of Albumin 
Human serum albumin (HSA) is the most abundant protein in the circulatory system 
(constituting around 60% of total plasma protein) and is one of the most extensively 
studied. Typically, albumin is present in the blood at a concentration of 42 g L1  and 
contributes 80% to colloid osmotic blood pressure [1]. It is also thought to be primarily 
responsible for the maintenance of blood pH [2]. 
Albumin's most notable feature is its ability to bind reversibly to a vast array of ligands, 
such as fatty acids, hormones, metal ions and drugs. Albumin is the major transport 
protein in the blood and has been described as the most multi-functional transport protein 
known to date [1]. The drug-binding properties of albumin are very important to the 
pharmaceutical industry, as it is possible to alter the distribution, metabolism and efficacy 
of a drug in the body, solely by its affinity to albumin. This is in part due to the protein's 
high abundance in the blood, and also because it can transport and deliver a bound drug 
to its target site through the circulatory system. Many drugs are therefore designed not 
only to be potent in their desired function but also to reversibly bind to serum albumin. 
Some examples of therapeutic agents that show affinity towards albumin are, cisplatin 
[3], auranofin [4], warfarin [5], diazepam [6] and digitoxin [7]. 
15 
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A variety of albumin-associated human disorders exist. 	Hyperalbuminaemia is 
characterised by elevated levels of albumin in the blood, but is thought almost always to 
be due to dehydration rather than by an increased production of the protein. 
Hypoalbuminaemia also exists and can be the consequence of either a reduction in 
albumin synthesis (a symptom of some liver diseases), or of an increased loss of the 
protein, which may be seen in individuals suffering from nephritic syndrome and 
occasionally in patients with extensive burns. Hypoalbuminaemia may also be caused by 
malnutrition [8]. 
Another disorder, analbuminaemia is an extremely rare genetic trait in which the alb 
gene, which encodes albumin, is intact but modified in such a way as that its transcription 
product is non-functional [9]. Remarkably, around half of all patients diagnosed 
analbuminaemic, appear to be completely asymptomatic, but those who do suffer from 
chronic fatigue, lipodystrophy, a decrease in androgen synthesis and hyperlipidaemia [8]. 
The latter it is thought can be attributable (at least in part) to a compensatory increase in 
the levels of other plasma proteins [10]. 
Over 100 other genetic variants of albumin have been identified, usually through routine 
electrophoresis of serum or plasma samples. These variant albumins (or alloalbumins) 
usually carry point mutations in their coding or pre-coding sequence, altering their amino 
acid sequence and their secondary structure. There is evidence to suggest that these 
mutations do not occur completely randomly and that certain sites or hot spots are present 
within the genetic sequence of albumin, where mutations are found more frequently [11]. 
Examples of these hotspots are shown in Table 1.1. 
16 
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Mutation Codon Change Variant Name 
Arg 2 -* His CGT -* CAT Lille, 	Poilibauer, 	Somalia, 	Tokushima, 	Taipei, 
Fukuoka-2, Varese, Wu Yang, Mayo (EW220), 
Komagome-3 and Stirling. 
Arg' - Gin CGA -* CAA Christchurch, 	Gainesville, 	Y, 	Honolulu-2,_  
Fukuoka-3, 	Mayo 	(JW 180), 	Shizuoka 	and 
Kamloops. 
G1u57° -* Lys GAG - AAG Oliphant, Verona, Osaka-2, Phnom Penh, Nagano, 
Iowa City-3, Mayo (MT610, RW246 and SH420), 
Victoria 	(East 	India), 	Saitama- 1, 	Ann 	Arbor, 
London 	(Ontario), 	Lubeck, 	Tokyo-i 	and 
Shinanomachi- 1. 
Table 1.1 Mutations of human serum albumin and proalbumin. The table shows 35 
variants that were given different names (usually the place of discovery), most probably 
because they were originally thought to be different. Detailed studies at the molecular 
level revealed that out of all these variants only 3 different alloalbumins exist. Source: 
ref [11]. 
Interestingly, a research group from the University of Hawaii identified a genetic variant 
of human albumin, which may have an application in the treatment of hyperthyroid 
diseases [12]. This variant appears to have an abnormally high affinity for thyroxin, the 
hormone that is over-expressed in hyperthyroidism. In preliminary tests this variant has 
been shown to be capable of quickly and effectively removing excess thyroxin from the 
body. Thyroxin is responsible for regulating heart rate, body temperature and caloric 
17 
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consumption. Illnesses such as thyroid storm (where thyroxin production increases to 
dangerous levels during pregnancy) and Graves disease (where the body overproduces 
antibodies which stimulate the thyroid gland) can lead to heart disease and cause blood 
clots, often blocking major arteries. One of the main advantages of using this variant in 
the treatment of hyperthyroidism is that it cannot cross the placental barrier and so could 
be used to treat pregnant women without worry of affecting the foetus. It is also thought 
that because the protein has been found to exist naturally in humans, it may be a safer and 
more effective option than other treatments. 
Albumin has also demonstrated functionality as an extracellular antioxidant [13] and has 
been found to have the ability of detoxifying several potentially hazardous chemicals in 
the blood (e.g. bilirubin [14] and cyanide [15]). There is, additionally, some evidence to 
suggest that in humans, serum albumin may inhibit apoptosis in endothelial cells [16]. 
The absence of albumin in rats makes them more susceptible to developing cancer [17]. 
Additionally, succinylated albumin has been reported as having anti-HIV activity [18]. 
Albumin has also been suggested as a possible source of amino acids for various tissues 
[19]. Other potential applications of albumin include the modification of the protein with 
11 'In for use as a selective contrast agent in the detection and treatment of tumours [20], 
whilst albumin chimeric molecules such as HSA-CD4 [21], HSA-Cu, Zn superoxide 
dismutase and rabbit serum albumin-hirudin [22] have been synthesised to increase the 
half-lives and distribution of these protein therapeutics, and reduce immunological 
responses towards them. 
Clinically, human albumin is used in the treatment of patients with severe burns, shock or 
blood loss. Presently, it is produced commercially by extraction from human blood [23] 
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and because of this, periodic shortages of albumin have affected availability worldwide. 
Recently, Delta Biotechnology Ltd. has produced recombinant albumin (Recombumin®) 
in yeast that has successfully passed phase I clinical trials. An intramuscular study on 
500 subjects was conducted under an FDA IND (Food and Drug Administration 
Investigation of a New Drug) in order to evaluate the tolerability and safety of 
Recombumin® compared with human serum albumin. Recombumin®  was administered 
to 250 subjects in ascending doses of up to 65 mg. A significant safety margin was 
demonstrated in this study, considering that the expected highest single dose of albumin 
in currently approved pharmaceutical formulations is 15 mg. An intravenous study on 30 
subjects was also completed to compare the tolerance, safety and pharmacodynamics of 
Recombumin® with human serum albumin. Recombumin®  was administered to 15 
subjects at increasing dose levels up to 50 g and was as well tolerated as the control drug 
human serum albumin [24]. This technology is designed to increase the availability of 
the protein and in certain cases, prevent the need for screening of native albumin for 
infections such as HIV, herpes and hepatitis. 
A review of randomised controlled trials published by The Cochrane Injuries Group cast 
severe doubts regarding the appropriate use of albumin in the treatment of some medical 
conditions [25]. Their review concluded that the relative risk of death in albumin-treated 
patients suffering from hypovolaemia, burns or hypoproteinaemia was 6% higher than in 
those treated by other means. This figure constitutes 6 more deaths per 100 patients 
treated. The Cochrane study has had many critics but after the report's publication, 
albumin usage dropped dramatically in the UK. In February of 2000, the plasma 
products industry launched a £1.4M ($2.2M) international programme to promote 
albumin usage [26]. 
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1.2 Albumin Structure 
1.2.1 Primary, Secondary and Tertiary Structure 
Human albumin is a 66.5 kDa single-chain protein of 585 amino acids. The chain 
contains 35 cysteine residues, which form 17 disulfide bridges, leaving a free thiol at 
Cys34, and a single tryptophan (Trp214). The protein also contains an unusually large 
number of charged amino acids and contains no sites for enzymatic glycosylation. In the 
human body approximately 10% of albumin is glycosylated non-enzymatically [27]. 
This, it is believed occurs primarily on Lys 525  and is thought to alter its properties in such 
a way as to facilitate its ingestion into endothelial cells in preference to unmodified 
albumin [28]. 
The primary structure of the protein is characterised by a distinct loop-link-loop pattern, 
due to the nature of the protein's disulfide bonding (Figure 1.1). Sequence homology 
between human serum albumin and other mammalian albumins is relatively high (Table 
1.2). 
Several albumin-related proteins exist, such as a-fetoprotein, which is the major protein 
component in foetal plasma [29], and vitamin D binding protein [30]. Another protein 
member of particular interest, is Endol6, which is a large multi-domain Ca 2+  
protein found in the sea urchin, both in the extracellular matrix and on the surface of 
endodermal cells during gastrulation [31]. This protein is believed to be the first 
albumin-related protein to be found in an invertebrate organism. 
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Figure 1.1 The loop-link-loop primary structure and amino acid sequence of human 
serum albumin. The loops created by the disulfide bridges (indicated by the black lines 
between residues) are shown within albumin's three domains. Amino acids are identified 
by the standard 3-letter codes. The numbered vertical bars indicate the positions of exons 
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ECCE 	 E 	LPADFVESKCKNYAEAKDVFLGNFLYE1R 360 
ECCDKP L 	C 	E LP AADYVESK1VCKNIAEAKDVFLGNFLYEIR 352 
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LP---L, 
TLDFED/VCKYQEAIGJAFLGSFLYEYR 359 
ECCDK 	C A 	T?OFAEDI\CKNYQEAKDVFLGSFLYEY 359 
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PCFSALEVDE VPKEFNAETFTF 1fCTL 540 
PCFSALELDEVPKAFNAETFTF 	CTL 532 
PCFSGLEVDEYVPKEFNAETFTF}ICTL 540 
PCFSALQVDEYVPKEFSAETFTF4CTL 540 










(;/\FVECco\AvNKE CFSEEGP V 600 
FVDCCC/\IAFDXE/\C [OAEEGP 600 
vSFvr/Cn(:/\j\I)DKE/\CEAVEGP V 599 
V/\FVDKCC/\/\I DKE CFVLEGP V 599 
j\/\FVQKCCO/\[ DHE/\C FAVEGP 597 
I/\LLDCCI'S/\CDKERCFAVEGP 600 
!\cPVDKCIJV\DKDJJCFATEGP 600 
Table 1.2 Conservation of amino acid residues in mammalian pre-albumins. 
Alignments were carried out using ClustaiW (EMBL-EBI). Residues in red are part of 
the pre-albumin sequence and are cleaved prior to secretion. Colour code: yellow = fully 
conserved residues, green = residues with conserved properties and cyan = semi-
conserved residues (in accordance to ClustalW rules). The numbering at the right-hand 
side includes the pre-albumin sequence and so does not represent the amino acid 
numbering of the native protein. Amino acid sequence accession numbers: Human, 
P02768; Macaque, A47391; Canine, S29749; Feline, S57632; Bovine, P02769; Sheep, 
P14639; Pig, P08835; Rabbit, P49065 and Rat, P02770. 
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The x-ray crystal structure of human albumin has been determined, in both free [32,33] 
and fatty acid-bound forms [34]. A summary of all albumin crystal structures solved to 
date is shown in Table 1.3. The secondary structure of human albumin is predominantly 
a-helical. The molecule itself is heart-shaped and consists of three repeating domains, 
constituted of two sub-domains. Figure 1.2 shows a ribbon representation of the albumin 
chain. 
It is now widely accepted that the three albumin domains evolved from a single ancestral 
protein of about 190 amino acids, through a triplication event. Recently, the three 
albumin domains have been individually cloned, expressed in yeast and purified [35]. 
Each domain was then studied separately and the binding properties of several 
pharmaceutically important ligands, towards each were determined. The structural 
effects within each individual domain in acidic and basic environments [36] are discussed 
in Section 1.2.2. 
Albumin is a flexible protein with the ability of changing shape rapidly in solution. This 
is thought to be due to the loop-link-loop nature of the disulfide arrangement within the 
molecule. Albumin has been described as having a "breathing" action [37] constantly 
opening and closing, revealing nooks to which ligands may bind. 
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PDB code Resolution (A) Ligands bound Reference 
1A06 2.50 None  
1BJ5 2.50 5 myristates  
1BKE 3.15 5 myristates, 2 triiodobenzoates [34] 
1BMO 2.50 None [33] 
1E78 2.60 None [38] 
1E7A 2.20 2 propofols [38] 
1E713 2.38 3 halothanes [38] 
1E7C 2.40 5 myristates, 7 halothanes  
1E7E 2.50 lOcaprates  
1 E7 2.43 8 laurates [39] 
1 E7 2.50 8 myristates [39] 
1E7H 2.43 7 palmitates [39] 
1E71 2.70 7 stearates [39] 
1GNI 2.40 7 oleates [40] 
1GNJ 2.60 8 arachidonates [40] 
1119Z 2.50 6 myristates, 1 R-(+) warfarin [41] 
111A2 2.50 1 S-(-) warfarin [41] 
1UOR 2.80 None [32] 
Table 1.3 Summary of human albumin crystal structures available in the 
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Figure 1.2 Tertiary structure of recombinant human albumin. Three-dimensional 
structure of human albumin coloured by domain (I-HI). Note the predominantly a-helical 
structure. PDB code is 1A06 [33]. 
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I .22 pH-Dependent Structural Transitions 
The 3-dimensional structure of albumin rapidly alters under non-physiological 
conditions, particularly with regard to changes in pH. Five pH-dependent isomeric forms 
have been recognised. Albumin's structure under physiological conditions is defined as 
being in the N, or normal form. At a pH of around 4, the albumin molecule denatures to 
what is known as the F, or fast form. Fluorescence studies of both Trp214 [42] and a 
single bound 1 -anilino-8-naphthalenesulfonate molecule [43] led to the conclusion that 
the N to F transition occurs in two steps. The normal protein first alters to an 
intermediate Fl form, and then spontaneously expands to the F form. This change occurs 
at pH 4.3 and requires only about 100 ms to take place [44]. If the pH of an albumin 
solution is reduced further to below 3.5, it undergoes another change to become the E 
(expanded) form. At pH 2.5, the protein is believed to be as expanded as the molecular 
structure allows. The E form is characterised by an increase in intrinsic viscosity [45] 
and approximately three of the disulfide bonds can be reduced with 2-
mercaptoethylamine [46]. 
Dockal and colleagues have isolated the three separate human albumin domains and 
investigated the effect of pH on each [36]. They found that the N to F transition occurs 
primarily in domain III with only minor changes in domain I. Domain II transforms into 
a molten globule-like state as the pH is reduced further, corresponding to the E form [36]. 
Denaturation of the N form of albumin also occurs when the pH is raised. Above pH 8 a 
"structural fluctuation" can be observed; the molecule loosens and loses rigidity. This 
structural isomer is termed the B, or basic form. Circular dichroism indicates that the N 
to B transition involves a relatively minor change in conformation, with only a 10% loss 
27 
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in helix and an 8% increase in 13-sheet [47]. Dockal found that during this transition, 
albumin domains I and II underwent minor structural isomerisation, whilst in domain III 
no structural changes were found [36]. 
Increasing the pH further (>10) results in the fifth structural isoform, termed the A or 
aged form. The name comes from a phenomenon first noticed by Sogami. He found that 
some defatted BSA that had been left in a salt-free solution at pH 9 for 3-4 days had an 
altered isoelectric point [48], thought to be the result of a sulffiydryl-catalyzed disulfide 
interchange reaction. 
1.3 Ligand Binding to Serum Albumin 
1.3.1 Investigations of Ligand Binding 
It was once thought that albumin-ligand interactions are non-specific, with the protein 
behaving like a sponge and the ligands binding to the molecule's surface in a random 
manner. Binding studies are a prolific area of albumin research. Such studies have lead 
to the discovery of several distinct, high affinity ligand-binding sites. 
Much of the early binding studies of albumin made use of equilibrium dialysis and 
spectroscopic methods. Other studies have assayed for ligand binding using radio- and 
fluorescent-labelling, through both direct and competitive binding studies. These types 
of analyses make it possible to measure binding constants, but do not give any 
information as to where on the albumin molecule the ligand is bound. The positions of 
binding sites in the albumin molecule have been examined by techniques such as site- 
directed mutagenesis and through peptide sequencing, following protein digestion in the 
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presence of ligand [49]. Crystallographic studies and modem spectroscopic methods 
have now revolutionised this area of albumin research. Crystal structures have now been 
reported for albumin bound to fatty acids [39,40], the aspirin analogue, 2,3,5-
triiodobenzoate [34], warfarin [41], and the anaesthetics propofol and halothane 
(Brookhaven Protein Databank). NMR spectroscopy, HPLC and mass spectrometry have 
also proven to be invaluable methods for binding studies [50,51]. 
1.3.2 Fatty Acid Binding 
The properties of fatty acid binding are probably the best understood of all known 
ligands. This is due in part to several crystal structures of human albumin determined by 
Curry and co-workers [34,39,40]. Fatty acids are an extremely important source of 
physiological energy in the body. They are released from adipocytes and lipoproteins 
and are transported to their target site, through the circulatory system bound to albumin. 
Most fatty acid in the blood is albumin bound; elevated localised free fatty acid levels can 
be associated with various diseases such as cancer and diabetes [52] and are a symptom 
of analbuminaemia [53]. 
In Curry et al. 's first fatty acid-albumin structure (Figure 1.3) [34], albumin is complexed 
with five myristate molecules, revealing five fatty acid binding sites arranged on the 
albumin molecule in an asymmetric manner. The first myristate (Myr 1) molecule binds 
to sub-domain lB via a salt bridge at Arg 117. Myr 2 binds at the interface between sub-
domains IA, TB and hA. Its methylene tail is predominantly held in place by sub-domain 
IA, while residues Arg257 and Ser287 on sub-domain hA, and TyrlSO on TB, anchor its 
carboxylate end. Both Myr 3 and Myr 4 are located within sub-domain lilA. The 
carboxylate group of Myr 3 is bound across the interface between sub-domains 1113 and 
RE 
Chapter 1 	 Introduction 
lILA. to residues Ser342, Arg348 (from JIB) and Arg485 (from lilA). Myr 4 is also appears to 
be held in place at its carboxylate end by 3 hydrogen bond partners. These are Arg410, 
Tyr411 and Ser485, which are all situated on sub-domain lilA. The final myristate in the 
structure (Myr 5) is bound to sub-domain TuB in a similar orientation as Myr 1 is to sub-
domain TB, and is anchored at its carboxylate end by Lys575. 
Curry and colleagues also determined the crystal structures of albumin with long- and 
medium-chain fatty acids [39], as well as mono- and poly-unsaturated fatty acids [48]. 
These structures revealed a variety of other binding sites including sites I and II, which 
are discussed in section 1.3.3. Site II appears to be a high-affinity long-chain fatty acid 
binding site. 
From comparisons of the crystal structures of fatty acid-bound albumin and fatty acid 
free albumin [33], it is clear that some domain rotations take place. Albumin, upon 
binding of the fatty acid molecules, appears to "open up". Domain II appears to facilitate 
this conformational change, acting as a spring to allow domains I and III to separate 
slightly (Figure 1.3). These structures show how albumin distrorts to accommodate 
ligands and provides the best indications to date as to how the fatty acids interact with the 
amino acid residues in the albumin chain. It is likely that because fatty acids invoke such 
a change in structure that binding of fatty acid to albumin may affect the binding of 
molecules at other sites. Structural information of this kind is invaluable in the design 
and development of novel therapeutics. 
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Figure 1.3 Comparison between unliganded (left) and myristic acid bound (right) 
human albumin. Domains I, II and Ill are coloured blue, green and red respectively; 
fatty acid myristate molecules are labelled 1-5. Both structures were drawn from the 
coordinates in the Brookhaven Protein Databank. The PDB code for unliganded albumin 
is 1A06 [33] and for fatty acid bound albumin the code is IBJ5 [34]. 
1.3.3 Ligand Binding Sites I and II 
Two important ligand-binding sites referred to as sites I and II, were first identified by 
Sudlow and colleagues, through studies of competitive binding [54]. A large body of 
evidence indicates that these specialised regions are located within specialised cavities of 
subdomains hA and hA respectively [9]. These sites are often thought of as being the 
main binding sites for small organic compounds. Each of these sites boasts the ability of 
binding a wide range of ligands. However site I appears to be more selective than site II. 
Examples of ligands, which bind to site I are warfarin, salicylate and the haemoglobin 
metabolite, bilirubin [55]. Others ligands that show specificity include haemin [56], 
dicarboxylic fatty acids [57], and a variety of dyes and indicator compounds [9]. It is 
difficult to define a typical site I ligand due to the diverse nature of the compounds that 
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show affinity, although most appear to be bulky heterocyclic anions, with a charge 
distribution centred within the molecule. 
The 2.8 A crystal structure of human albumin [32] revealed that the amino acids which 
line the specialised cavities of sites I and II have an asymmetric charge distribution. This 
causes them to have a hydrophobic surface on one side and a hydrophilic surface on the 
other. The cavities have been described as "sock-shaped" [1] with the "leg" region of the 
sock being the hydrophilic side and the more open "foot" region, the hydrophobic side. 
This explains why both sites are selective for the binding of anions. The crystal 
structures of human albumin with the R-(+) and S-(-) enantiomers of the anticoagulant 
warfarin bound have been elucidated [41]. Figure 1.4 shows the structure of warfarin. 
The crystal structure confirms that the drug binds to site I, with both enantiomers 
adopting similar conformations, making many of the same specific contacts with the 
same amino acid side-chains. The packing of all six helices of subdomain hA form the 
binding pocket. The pocket has two sub-chambers that accommodate different portions 
of the warfarin molecule. The benzyl group binds in a sub-chamber made by Phe211, 
Trp214, Leu219, and Leu238, with additional contacts from Arg218 and His242. The coumarin 
moiety binds in the larger sub-chamber furthest from the entrance. Leu219, Arg222, Phe223, 
Leu234, 11e264, Leu257 and Ile 290  make up this compartment, with only the 11e260, 11e264 and 
Ile 290  residues making contact with the coumarin ring. 
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Figure 1.4 Structure of the anticoagulant, warfarin (3-(a-acetonylbenzyl)-4-
hydroxycoumarin). 
Site II is frequented by a much wider range drugs and small molecules than site I. In fact 
several molecules such as aspirin and triiodobenzoate bind to both sites [1]. In addition 
site II also binds fatty acids, tryptophan [58] and anions such as chloride, iodide, bromide 
and thiocyanate. Interestingly, site II as well as being a major ligand-binding site also 
shows esterase activity [59]. A variety of p-nitrophenyl esters has been cleaved at this 
site [60]. The esterase activity of serum albumin is greater in humans than in any other 
organism, suggesting that it has not evolved to carry out an important physiological 
function, but exists through a chance arrangement of the amino acids in this region of the 
human protein. The activity has been localised to Tyr4' 1,  the same residue implicated in 
cyanide detoxification [61]. 
1.3.4 The Cys34 Site 
This site is arguably the most intriguing of all albumin's binding sites. Not only is it the 
binding site for a wide variety of biologically and clinically important small molecules, 
but it also provides antioxidant [13] and antiperoxidant [62] activities and is the site of 
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dimerisation. Cys34 is the only cysteine residue in the protein that is not involved in 
disulfide bridging. It is characterised by an extremely low pKa of around 7 compared to a 
value of 8.5 for free cysteine [63]. Consequently, the thiol group of Cys34 is 
predominantly in the S form at physiological pH. Albumin is responsible for the largest 
fraction of free sulthydryl in blood serum [1]. 
Much of the interest directed toward this site is due to potentially strong interactions with 
"soft" metal ions such as those in the anticancer drug, cisplatin, the antiarthritic drug, 
auranofin and mercurials. Other ligands, which show affinity toward this site, include 
heterocyclic, aromatic and small thiol-containing compounds (redox reactions to form 
disulfides). Recent crystallographic studies of albumin show that Cys34 is situated within 
a hydrophobic, sterically hindered pocket, approximately 9.5 A deep, as shown in Figure 
1.5. This agrees well with the previous observations, that Cys34 binds to heterocyclic 
compounds with greater affinity than to aromatic compounds [64], and that compounds 
with five-membered rings are more reactive than six-membered rings [65]. 
So far, without exception, all mammalian and avian albumins sequenced to date contain a 
free cysteine residue. However, both salmon and cobra albumins differ at this and near-
by residues [66,67]. In salmon albumin, Cys34 is replaced by serine, and in cobra 
albumin, it is replaced by alanine. Additionally in both these species, His39 (located 
close-by in the native protein, as can be seen in Figure 1.5) is substituted by leucine. 
Consequently albumin from these species should show a much-decreased affinity toward 
the aforementioned ligands. 
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Figure 1.5 Environment of the Cys34 residue in human albumin. Above: Tyr 
84  and 
His39 residues are located near Cys34. Below: The space-filling model of albumin (below) 
shows the Cys34  residue (yellow) to be buried within a crevice in the molecule. 
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Many preparations contain a significant proportion of albumin in dimeric form; it still 
remains unclear as to whether this form exists in blood plasma [9]. Dimerisation is 
thought to take place at Cys34; blocking of the thiol group with agents such as 
iodoacetamide, cysteine or glutathione prevent albumin dimers from forming [8]. 
Alternatively, dimerisation is said to be induced by linking the single thiols of two 
albumin molecules with Hg 2+  [68], but the dimerisation mechanism still remains poorly 
understood. 
'H NMR studies have revealed that upon ligand binding to the Cys34 thiol (or oxidation of 
the thiol to a sulfenic acid) a conformational change is invoked, where the residue moves 
from a buried to a solvent-exposed state [69,70]. This alteration in structure is coupled to 
a movement of His 3. The cysteine in the unbound reduced form may be stabilised in the 
buried state by the nearby His 39. A schematic representation of this conformational 
change upon binding of the antiarthritic drug, auranofin is shown in Figure 1.6. 
Interestingly, a naturally occurring genetic variant of albumin has been identified which 
has no free thiol at Cys34 [71]. This variant discovered in Asola, Italy, contained a point 
mutation, which led to the introduction of a cysteine residue in place of Tyr 14'. This new 
cysteine residue was found to form a new disulfide bridge with the thiol group of Cys34, 
resulting in 18 disulfide bridges and consequently, no free thiol. 















Figure 1.6 Change in the Cys34 environment upon ligand binding. It is proposed that 
upon ligand binding or oxidation, the Cys34 residue moves from a buried to a solvent-
exposed state. In this example the ligand is the antiarthritic drug, auranofin. The 
conformational change appears to be coupled to a movement of the His  residue. 
Diagram taken from ref [72]. 
1.3.5 The N-terminal Binding Site 
The N-terminus of human albumin is a strong binding site for Cu2 and Ni2 with 
association constants of 1016 M-1  [73] and 3.98 x 109 M-1  [74], respectively. Cu2+  was 
first known to bind at this site when it was discovered that the presence of CuC12 blocked 
the aspartyl u-amino group of albumin from reacting with the Sanger reagent, 
fluorodinitrobenzene (FDNB) [75]. Following this, peptide binding studies showed that 
Cu2 binds to the BSA peptide fragment of residues 1-24 (and even to the BSA peptide 1-
4, Asp-Thr-Ala-Lys) as strongly as to BSA itself [76]. 
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The binding of Cu" to albumin has been investigated for several species and has been 
found to bind strongly only to those, which contain His3 [9]. 'H NMR studies have also 
implicated a lysine residue (presumably Lys4) as being a key residue in the arrangement 
of the Cu2 and Ni2 binding site [77]. Binding of Cu2 and Ni2 to this site is currently 
believed to involve a four-nitrogen coordination of the metal with the a-amino nitrogen 
of Asp', the two backbone amide nitrogens of Ala2 and His3 and an imidazole nitrogen of 





Figure 1.7 N-terminal binding site. A view of the proposed structure of the N-terminal 
Cu2 and Ni2 binding site of human albumin. The metal ion is coloured yellow and 
residues Asp', Ala 2, 1_1i S3 and Lys4 are shown. 
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1.4 Aims of this Thesis 
Most studies of the chemistry of human albumin have been carried out on albumin 
isolated from blood plasma. Such albumin is often highly heterogeneous, in particular a 
large proportion of Cys34 is often oxidised. The recent availability of recombinant 
albumin has provided an opportunity to study the chemistry of a more defined form of 
albumin, especially with regard the free thiol at Cys34. 
The aims of this work were as follows. 
To investigate the ligand binding properties of Cys34 with a range of different 
physiologically important molecules. 
To examine the roles neighbouring residues play in controlling the reactivity of Cys34, 
using site-directed mutagenesis and recombinant methods. 
To investigate the metal binding properties of albumin and identify new metal-derived 
sites. 
To attempt to crystallise albumin in the hope of producing crystals of metal-
derivatives that diffract x-rays at high-resolution for structural determination. 
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2.1 Recombinant Albumin 
Recombinant albumin was supplied by Delta Biotechnology Ltd as a 250 mg mU' 
solution containing 145 mM NaCl, 15 mg U' tween 80 and 40 mM octanoic acid. Prior 
to use, the solution was divided into 5 mL aliquots and stored at —20 °C. When required, 
an aliquot was thawed and dialysed using dialysis tubing with a 30 kDa molecular weight 
cut-off (BioDesign Inc.), in 5 L of 100 mM ammonium bicarbonate for 24 hours. The 
protein solution was then dialysed again in a fresh solution for a further 24 hours. This 
process is sufficient in the removal of salt from the preparation; it is thought that some of 
the octanoic acid (< 4 mol moL') does remain bound to the protein. The solution was 
then frozen in liquid nitrogen and freeze-dried. The albumin powder was stored at 4 °C 
ready for use. Mutated albumins were also treated in this way following purification. 
2.2 Albumin Concentration Determination 
2.2.1 UV Absorption Spectrophotometry 
Proteins are chains of 20 common amino acids that absorb light at a number of different 
wavelengths. The peptide bond itself absorbs in the 190 to 230 nm range. Protein 
quantification by this means is complicated because Asp, Glu, Asn, GIn, Arg and His 
side-chains also absorb in this region, as do many compounds present in buffers. 
Aromatic residues such as Phe, Tyr and Trp have side-chains that undergo ir-ir" 
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transitions, absorbing around 280 nm (see Table 2.1) [1]. Measurement of absorption 
around this wavelength is one of the most commonly used methods for protein 
concentration determination. 
Wavelength (nm) Extinction (Absorbtion) 
Coefficient (M' cm) 
Phenylalanine 257.4 197 
Tyrosine 274.6 1420 
Tryptophan 279.8 5600 
Table 2.1 Spectroscopic properties of the aromatic amino acids at neutral pH. Table 
drawn from [2]. 
In accordance with the Beer-Lambert Law, protein concentration is directly proportional 
to light absorbed at a fixed path length (the length of sample the light passes through). 
The law states that the absorbance, A, is equal to the product of the extinction coefficient, 
E, the concentration of the protein, c and the path length, 1, A=ccl. 
However, because this method uses the absorption of light from a small number of amino 
acid types only, it is very sensitive towards the amino acid composition of the protein. 
Surface amino acids absorb more than buried amino acids; therefore this technique is also 
sensitive to the tertiary structure of the molecule. These factors consequently mean that 
the extinction coefficient differs for all proteins and must be known (or calculated) prior 
to the assay. 
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Albumin concentrations were determined from the absorbance 279 nm using either a 
Shimadzu UV250 1PC or a Cary 300 scan spectrophotometer. The extinction coefficient 
was assumed to be 0.531 units mg-1 cm' [3], and for each assay a suitable blank (or 
control) solution was prepared. This consisted of another solution with the same 
composition without albumin present and was measured and subtracted from the 
albumin-containing sample, in order to eliminate any background absorbance. 
2.2.2 Gel Permeation Chromatography 
Gel permeation chromatography (GPC) is a well-defined method for separating proteins 
according to their molecular weight but it can also be used to determine protein 
concentrations indirectly. 
The method uses a column containing finely divided porous particles made of polymeric 
resin with a continual flow of solvent passing through. The analyte is injected at the top 
of the column and washed through by the solvent. Protein molecules that are smaller 
than the pore sizes in the particles can enter the pores, and therefore have a longer path 
and longer transit time than the larger molecules that are unable to enter the pores. Thus, 
the larger molecules elute earlier, while the smaller molecules elute later [4]. After the 
protein leaves the column its presence is measured quantitatively by its absorbance (280 
nm is the detectable wavelength for albumin). The resultant chromatogram (absorbance 
against time) contains peaks corresponding to the proteins injected. The peak height is 
directly proportional to its concentration in the sample injected. This linear relationship 
means that albumin solutions of known concentration can be run in order to relate peak 
height to concentration. This method has an added advantage of being able to detect both 
monomeric and dimeric albumin quantities as they are separated on the column. 
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For this method to be accurate it must be reproducible. Reproducibility of GPC can be 
affected by the flow rate of the solvent, temperature, solvent composition, column size 
and the particle size within the column. Therefore it is important that these variables 
remain constant for each set of samples. 
Separations were performed using either a Shimadzu SCL-6B or a Hewlett-Packard 1100 
series liquid chromatography system, both fitted with UV/vis spectrophotometric 
detectors. For each assay, 25 .xL of sample was loaded onto a TSKgeI 3000 SWXL 
column (TosoHaas), dimensions 7.8 mm x 300 mm, pore size 5 tm. The column 
temperature was kept at a constant 30 °C and the solvent flow rate was 1 mL mind . 
Assays were calibrated in triplicate against a 10 mg mU' albumin standard (Delta 
Biotechnology Ltd.). The running solvent was a phosphate buffer, pH 7.0 and consisted 
of 71 g L' Na2SO4 (0.5 M), 13.5 g L' Na2HPO4.2H20 (76 mM), 7.5 g U' 
NaH2PO4.2H20 (48 mM), 32.5 mg U' NaN3 (500 jtM). 
2.2.3 Rocket Immunoelectrophoresis 
This is a quantitative method, which has the advantage of being specific toward a single 
protein only as it relies on antibody-antigen recognition [5]. An antibody (Ab) is 
incorporated in a gel, and the antigen (Ag) mixture is added to the well and run into an 
electric field. This produces a rocket-shaped precipitation zone, the height of which is 
proportional to the concentration of Ag (or albumin) in the sample (see Figure 2.1). 
Albumin standards of known concentration can be run simultaneously in order to relate 
rocket height to concentration. This method was used exclusively for quantifying 
recombinant albumin produced in yeast cultures. 
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Figure 2.1 Diagramatic representation of rocket immunoelectrophoresis. The 
electric field causes the protein (antigen) to migrate into the gel and form a rocket-shaped 
precipitate with the antibody. The height of which is proportional to the initial antigen 
concentration in the well. 
The gel consisted of 40 mL of 1% agarose, 0.01% Triton-X and was melted and cooled 
until clear. A vial of goat anti-albumin (Sigma, A- 115 1) was reconstituted in 5 mL of 
H20 and 250 ..tL was added to the melted gel. The gel was poured onto Gelbond Film, 
124 mm x 258 mm (Pharmacia) and allowed to set. Holes, 3 mm in diameter were then 
punched in the gel, 20 mm from the edge along its longest side. To each hole, 4 L of 
sample or standard were added. Delta Biotechnology Ltd supplied the standards. The gel 
was placed in an electrophoresis tank containing rocket buffer. The rocket buffer 
consisted of 9.8 g U' trizma base (81 mM), 4.3 g U' tricine (24 mM), 1.06 g U' calcium 
lactate (3.4 mM) and 0.2 g U' sodium azide (3.1 mM). Wicks were used to allow a flow 
of charge from the buffer across the gel. The gel was run at 450 V for approximately 90 
mm. It was then blotted with absorbant paper to remove excess Ab and stained with 
coomassie brilliant blue gel stain. Coomassie brilliant blue, the most widely used stain 
for this purpose, is applied by soaking the gel in an acidic, alcohol solution containing the 
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dye. This fixes the protein in the gel by denaturing it and complexes the dye to the 
protein. Excess dye is removed by extensively washing the gel with an acidic solution 
[6]. Different gel stains have different sensitivities toward proteins. An example of this 
can be seen in Figure 3.7, where an SDS-PAGE gel (see Section 2.2.4) has been stained 
with coomassie brilliant blue and with silver stain. The silver stain allows much greater 
visual detection of low-level proteins than the coomassie stain. The gel was then 
destained with destain-solution and allowed to dry to the film. Albumin concentrations 
were then calculated by comparing the height of the rockets of samples with the 
standards. 
2.2.4 Quantitative SDS-Gel Electrophoresis (SDS-PAGE) 
Sodium dodecyl sulphate (SDS) is an anionic detergent, which denatures proteins by 
altering the balance of the weak non-bonding forces that maintain the native structure. 
SDS binds to proteins fairly specifically in a mass ratio of 1.4:1 and confers a negative 
charge to the polypeptide in proportion to its length [6]. This charge is so large that the 
intrinsic charge of the protein is masked. By loading wells in the gel with a sample 
containing protein and placing it in an electrical field it can be separated according to the 
charge it carries. Larger proteins carry more negative charge so move a shorter distance 
than smaller proteins. It is usually necessary to reduce disulphide bridges in proteins 
before they adopt the random-coil configuration necessary for separation by size. In 
denaturing SDS-PAGE separations therefore, migration is determined not by intrinsic 
electrical charge of the polypeptide, but by molecular weight. By running a sample 
against a solution containing proteins of known molecular weight, it is possible to 
determine the molecular weight of an unknown protein or indeed, identify a protein's 
presence within a mixture as a horizontal band on the gel. Proteins, as previously 
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mentioned can be visualised on a gel by staining. The intensity of the stain of a protein 
band is proportional to the concentration of protein present in the band. 
Standards of recombinant albumin at 50, 100, 150 and 200 mg mU1 (Delta 
Biotechnology Ltd.) and samples were diluted two-fold in 2x SDS buffer. The 2x SDS 
buffer consisted of 20 mM tris, pH 8.0, 2 mM EDTA, 5% (w/v) SDS and 0.0 1% (w/v) 
bromophenol blue. The samples were then boiled for 2 min and electrophoresed using 
the PhastSystemTM (Amersham). An aliquot (1 L) was loaded onto a Phastgel® and the 
gel was run at 72 V for about 1 h. The gel was stained with coomassie brilliant blue gel 
stain solution and destained overnight. The gel was scanned using an Epson GT-9600 
scanner and the band intensities measured and compared using Gel Works Advanced 4.01 
(UltraViolet Products). This method (like with the rocket immunoelectrophoresis 
method) was only used for quantifying recombinant albumin produced in yeast cultures. 
2.3 Albumin Thiol Determinations 
The Cys-34 residue of human albumin makes up most of the free thiol of blood plasma 
and the importance of this group calls for special consideration when studying reactions 
at this site. A variety of ligands can bind to albumin at this site in the circulatory system. 
When isolated from plasma, approximately 28% of albumin molecules carry a half-
cystine and 7% a half-glutathione as a mixed disulfide on this residue [7]. 
Recombinant albumin also contains heterogeneity at this site, although to a much lesser 
extent (Delta Biotechnology, unpublished data). This means that different preparations 
of human serum albumin and recombinant albumin contain different percentages of free 
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thiol. It is therefore important to know how many moles of free thiol are present per 
mole of albumin. 
Thiol determinations were performed using a modified method based upon that of Eliman 
[8]. This is a spectrophotometric method, which uses 5,5'-dithiobis(2-nitrobenzoic acid), 
also known as DTNB or Ellman's reagent, to form a mixed disulfide with the free 
albumin thiol, Figure 2.2. The other product of this reaction is 5-thio(2-nitrobenzoic 
acid), TNB. This compound has a characteristic absorbance at 412 nm (c = 13.9 mM' 
cm'). Measuring the TNB concentration produced during the reaction also gives the free 
thiol content of the sample because one molecule of TNB is formed for every molecule 
containing the mixed disulfide. This allows the number of moles of free thiol present per 
mole of albumin to be calculated. 
For each thiol determination, a solution of DTNB in methanol was prepared (ca. 4000x 
more concentrated than the albumin to be analysed). The albumin (ca. 1 mg mU') was 
prepared in 1 mL of 100 mM Tris buffer, pH 8.0. To each sample 10 1.iL of the DTNB 
solution (equal to 40 mol equivalents) was added and the reaction was allowed to proceed 
until the absorbance at 412 nm reached a maximum. A sample blank was also prepared 
with the same concentrations of Tris buffer, pH 8.0 and DTNB alone. The absorbance 
difference between the sample blank and the reaction was recorded and the thiol content 
was calculated. 
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Figure 2.2 Reaction of albumin thiol with DTNB. DTNB reacts with the free thiol of 
albumin to form a mixed disulfide and 5-thio(2-nitrobenzoic acid) (TNB). 
2.4 De-Fatting and Fatty Acid Loading 
Albumin is the main transport protein for fatty acids in the circulatory system. 
Consequently, serum albumin isolated from plasma contains a significant amount of fatty 
acid bound. In addition to this, recombinant albumin contains a high proportion of 
octanoic acid, which is added to stabilise the molecule during purification. For some 
experiments in this thesis it was necessary to remove bound fatty acids from the albumin 
molecule and load with (sometimes several) equivalents of a particular fatty acid. This 
was particularly true during attempts to crystallise albumin. Fatty acids are known to 
invoke significant conformational changes in the molecule, see section 1.3.2. It is 
therefore important to be able to remove and add fatty acid to the albumin molecule. 
2.4.1 Charcoal De-Fatting of Albumin 
Albumin was modified using charcoal treatment, which was a modified version of that of 
Chen [9]. Approximately 5 g of albumin was dissolved in 100 mL of de-ionised H20 and 
3.75 g of activated charcoal (Sigma) washed with de-ionised H20 was then added. The 
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preparation was mixed to give a homogenous suspension and the pH was adjusted to 2.75 
by addition of HCI. The suspension was then incubated with stirring at 4 °C for 4 hours. 
The mixture was then centrifuged at approximately 20,000 g for 30 min at 4 °C, the 
supernatant was poured off and filtered through 0.2 im filter. Following this, the pH was 
raised to 5.5 with KOH to provide protection against acid ageing. Recovery of albumin 
was typically between 75-80%. Salt was usually added to protect alterations in the 
heterogeneity during storage. NaCl or KC1 was added to give a final concentration of 30 
mM. 
2.4.2 Fatty Acid Loading of Albumin 
Tetradecanoic (myristic, C14:0) acid (Sigma) was loaded on to albumin. Crystal 
structure co-ordinates of albumin this these molecule bound are available in the 
Brookhaven Protein Databank. The PDB code is 1 BJ5 [10]. Fatty acid loading was 
based upon the method used to obtain this structure. 
The fatty acid was added to 20 mM phosphate, pH 7.5, to achieve a nominal 
concentration of 2.5 mM. This suspension was heated to 55 °C to allow the dispersion of 
the fatty acid. The solutions were cooled slightly before addition of the recombinant 
albumin (Delta Biotechnology). Albumin-fatty acid complexes were prepared by mixing 
50 mL of 2 mM albumin with 480 mL of the fatty acid suspension and allowed to bind at 
room temperature for 1 hour. Excess fatty acid was removed by filtering through a 0.2 
jim syringe filter. The solution was then concentrated to a final volume of 100 mL and 
dialysed using a 10 kDa molecular weight cut-off LV centramate filter (Pall) coupled to a 
peristaltic pump into a solution containing 0.1 mM of the respective fatty acid in 20 mM 
phosphate, pH7.5. Solutions were concentrated to approximately 100 mg mL-1 using 
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Jumbosep centrifugal concentrators (Pall) with a molecular weight cut-off of 10,000 Da, 
filter sterilised and stored at —20 °C. 
2.5 Mass Spectrometry 
Aqueous solutions of test proteins were desalted/concentrated using either reversed phase 
(RP-) HPLC or reversed phase solid phase extraction (SPE) with recovered protein at 
concentrations of similar to 20 jiM. The RP-HPLC method utilised a 5-70% gradient of 
acetonitrile in 0.1% TFA through a Brownlee Aquapore C8 column. Detection was by 
UV absorbance at 280nm. The SPE protocol employed mobile phase flow through 
cartridges (1ST 25mg, 1000A) under vacuum. Protein samples were loaded in aqueous 
solutions and eluted using 70% acetonitrile in 0.2% formic acid. 
Solutions of proteins were introduced into a triple quadrupole mass spectrometer 
(Micromass Quattro), equipped with a conventional geometry AP-ESI source in positive 
ion mode, using flow injection analysis (FIA) and 20 scans were typically averaged. For 
protein analysis MS 1 was calibrated against the protonated molecular ions of myoglobin 
(Sigma, horse heart) with resolution set to similar to 2000. Peptide samples were 
introduced using custom nanoelectrospray ion sources (both continuous flow/on-line and 
off-line nanovial configurations) in positive ion mode. MS and MSMS product ion 
spectra were acquired with significant scan averaging and the analysers were calibrated 
against protonated and sodiated ions from a mixture of polyethylene glycol (PEG). 
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2.6 Circular Dichroism 
The phenomenon of circular dichroism is very sensitive to the secondary structure of 
polypeptides and proteins. Circular dichroism (CD) spectroscopy is a form of light 
absorption spectroscopy that measures the difference in absorbance of right- and left-
circularly polarised light (rather than the commonly used absorbance of isotropic light) 
by a substance. It has been shown that CD spectra between 260 and approximately 180 
nm can be analysed for the different secondary structural types: alpha helix, parallel and 
antiparallel beta sheet, turn, as well as others [11]. 
The simplest way of extracting secondary structure content from CD data is to assume 
that a spectrum is a linear combination of CD spectra of each contributing secondary 
structure type (e.g., "pure" alpha helix, "pure" beta strand etc.) weighted by its abundance 
in the protein's conformation [12]. A drawback of this approach is that there are no 
standard reference CD spectra for "pure" secondary structures. Synthetic 
homopolypeptides used to obtain reference spectra are in general, poor models for the 
secondary structures found in proteins. For example, the CD of an alpha helix has been 
shown to be length dependent and no homopolypeptide system has been found that is a 
good example of the beta sheet structure found in proteins. Several methods have been 
developed which analyse the experimental CD spectra using a database of reference 
protein CD spectra containing known amounts of secondary structure. 
Albumin was diluted to approx. 1.5 mg mU1 in 200 mM potassium phosphate, pH7.4. 
All spectra were recorded by Dr. Sharon Kelly (Scottish Circular Dichroism Facility, 
University of Glasgow). The instrument used was a JASCO J-600 spectropolarimeter. 
Secondary structure estimations were calculated using the SELCON procedure [13,14]. 
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2.7 pH and Conductivity Measurements 
2.7.1 pH Measurements 
The pH measurements of buffers and solutions were performed using either a Corning pH 
meter 145 or a Coming pH meter 240 fitted with a glass calomel combination electrode 
(Aldrich) with a pH range of 0-14. This was with the exception that the pH 
measurements of NMR samples were performed using a Orion pH/ISE 710A meter fitted 
with a 4 mm diameter glass electrode (Aldrich). All electrodes were standardised with 
pH 4.0, 7.0 and 10.0 buffers (Aldrich). Values for 2H20 (D20) solutions are termed pH* 
and are uncorrected for the effect of deuterium on the glass electrode. 
2.7.2 Conductivity Measurements 
Conductivity measurements were performed at room temperature using a Radiometer 
CDM 83 conductivity meter fitted with a CDC 304T probe and was standardised with salt 
solutions of known conductivity. 
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Chapter 3 
Site-Directed Mutagenesis of rHA 
3.1 Introduction 
As discussed in Section 1.3.4, the Cys34 site is very important in the binding of a 
variety of metallodrugs to albumin. The binding properties at this site are largely 
attributed to the low PKa of Cys34 (ca. 7) [1]. This abnormally low pKa means that the 
free thiol group predominantly exists in the S form at physiological pH and hence is 
very reactive. Cys34 is deeply buried within the molecule but is thought to flip out 
upon ligand binding (Figure 1.6). The crystal structures of human albumin [2,3] 
reveal that residues His 39  and Tyr 84  are located very close to Cys34 in the non-liganded 
state and therefore may play a role in stabilising the S form of the thiol. The aim of 
this study was to alter the primary structure of human albumin through the technique 
of site-directed mutagenesis at these two candidate amino acids to ascertain their 
importance within this binding site and in albumin as a whole. 
An important factor when deciding which amino acids were to be substituted within 
the Cys34 binding cleft is that a dramatic alteration could lead to a major disruption in 
protein conformation in this region. Therefore the change made had to be relatively 
subtle with regard to the substitution of amino acids. The amino acid chosen to 
replace His39 was leucine. Replacement of histidine with another positively charged 
amino acid such as lysine or arginine was ruled out as these residues have long 
hydrophobic chains, which could produce large conformational changes at the Cys34 
site. Leucine was chosen because it is structurally similar to histidine; both amino 
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acids have a CH2CH- branch but the leucine has two branched methyl groups attached 
rather than an imidazole ring. A choice of substitute for Tyr 84  was more obvious. 
Phenylalanine differs from tyrosine only by the lack of a single oxygen atom, in the 
para position. A Cys34 to alanine mutant had previously been synthesised by Delta 
Biotechnology Ltd. and was also expressed and purified. All three substitutions are 
shown in Figure 3.1. 
Additionally, molecular modelling based on the crystal structure of albumin [3] (PDB 
1A06) suggested that a multi-metal binding site may involve a region at the interface 
of domains I and II, in which His67, Asn99, His247 and Asp249 are clustered (as 
discussed in Chapter 5). In order to determine whether this cluster is a metal ion 
binding site the His 67  residue was mutated to an alanine, removing an imidazole ring 
and potential nitrogen ligand for metal coordination. This substitution is shown in 
Figure 3.2. 






































Figure 3.1 Amino acid substitutions around the Cys34 site of human albumin. 
The side-chains of the residues in each substitution are shown in red. 













Figure 3.2 Amino acid substitution at F1is67 of human albumin. The side-chain of 
the residue substituted is shown in red. 
3.2 Synthesis of Mutated Human Albumin 
E.coli Expression Vectors 
3.2.1 His39Leu and Tyr84Phe Mutant Albumins 
The DNA sequence of the alb gene [4] was studied and it was found that CAT and 
TAT codons encode the His and Tyr 84  residues respectively. Only a single base pair 
change in each codon was therefore required to encode Leu and Phe residues 
(CAT—CTT and TAT—*TTT respectively). 
The highly efficient method of site-directed mutagenesis described by Thomas 
Kunkel [5] was chosen, in order to minimise the need for DNA sequencing when 
screening for the mutated plasmid. This method is based upon the use of pQC262e, a 
single-stranded circular DNA template containing the albumin coding sequence and 
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an E. coli origin of replication (Figure 3.3). In order for the mutagenic reaction to 
occur, the template must have a proportion of uracil bases in place of thymine bases 
within its DNA sequence. 
The uracils are incorporated by transforming the vector into a mutant strain of E. coli. 
This strain has 2 genes knocked out, dut and ung, which encode dUTPase and uracil 
N-glycosylase respectively. E. coli strains which lack the enzyme dUTPase contain 
elevated concentrations of dUTP [6,7], which effectively competes with dTTP for 
incorporation into DNA. E. coli strains, which also lack uracil N-glycosylase cannot 
remove incorporated uracil from DNA [8]. It should also be noted that for in vitro 
reactions uracil-containing templates are indistinguishable from normal templates 
since dUTP has the same coding potential as dTTP [9]. Uracil is non-mutagenic. 
Following transformation of pQC262e and growth of the mutant strain, the uracil-
containing vector can be isolated and used as a template for the production of a 
complementary strand that contains the desired sequence alteration but contains only 
TMP and no dUTP bases. 
Mutagenic primers were designed for each desired mutation. Each mutagenic primer 
is a 35 bp DNA fragment, which is complementary to the alb gene at 34 of the 35 bp. 
The remaining base lies central within the primer and is complementary to the desired 
mutation. The mutagenic primers for the His39Leu and Tyr 84Phe mutations were 5'-















PRB1p 	 / • HinthII,838 
3546,NaeI 
3222,ClaI Nolt,3185 
3211 ,Xhol Pac 1,3193 
3207,89111;  
3201 ,Bam HI 
Figure 3.3 Map of pQC262e, the DNA template used for the mutagenesis 
reactions. The 6,397 base pair template contains the coding sequence for human 
albumin (rHA) with a promoter (PRB1p), terminator (ADHt) and fusion leader 
sequence (FL) conferring protein secretion in yeast. It also includes an E. coli origin 
for replication (on) and confers ampicillin resistance (Amp res). Various restriction 
endonuclease sites are also shown. 
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3.2.1.1 Phosphorylation of Mutagenic Primers and Template 
Binding 
The mutagenic primers (supplied by Delta Biotechnology Ltd.) were phosphorylated 
to allow later the 5' addition of dNTPs. For each mutation the following reaction 
mixture was prepared: 1 jtL respective 20 tM primer solution, 2 pL T4 
polynucleotide kinase x 1 buffer solution, I pL 20 mM ATP, 1 jiL T4 polynucleotide 
kinase, 15 jtL H20. The reaction mixtures were then incubated at 37 °C for 60 mm. 
Following the phosphorylation reaction 3 jtL of 0.1 M ETDA (pH 7.5) was added, 
they were then heated at 65 °C for 10 mm. The pQC262e template, 0.6 pL of 33 iM 
(Delta Biotechnology Ltd.) and 1.2 jiL of 20x sodium citrate/sodium chloride (SSC) 
were then added to the mixtures. The mixtures were then placed in a beaker of water 
at 65 °C and allowed to cool at room temperature. The annealed primer/template 
mixtures were stored overnight at 20 °C. 
3.2.1.2 Mutagenesis 
The annealed primer/templates consist of a single-stranded loop of uracil-containing 
DNA with a single non-uracil-containing 35 bp complementary fragment bound. In 
order to make the loop double-stranded the following reaction mixture was prepared: 
24.8 RL template/primer mixture, 10 p.L 0.2 M Hepes, pH 7.8, 10 p.L 20 mM 
dithiothreitol, 10 pL 0.1 M M902, 5 jiL dNTPs (10 mM of each dATP, dCTP, dGTP 
and dTTP), 5 jiL 20 mM ATP, 2 p.L T4 DNA polymerase (2 units pL'), 1 pL T4 
DNA ligase (5 units tL 1), 35 p1 H20. Reactions were placed on ice for 5 min then 
allowed to stand at room temperature for 5 mm. This was followed by incubation at 
37 °C for 2 h before the mixtures were again placed on ice. 
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Each double-stranded DNA was then transformed into DH5a (wild-type) E. coli cells. 
A 50 j.tL aliquot of each reaction mixture was added to 250 jtL of competent DH5a 
cells and put in ice for 45 mm. The cells were then heat shocked at 42 °C for 90 
seconds to allow cellular uptake of the plasmid vector then placed on ice for 2 mm. 
LB (700 1.iL) was then added to each mixture. The mixtures were then spread on LB 
agar plates containing ampicillin (100 .tg mU'). The plates were then incubated 
overnight at 37 °C. These resulted in 12 possible His 39  to Leu mutant colonies and 28 
possible Tyr 84Phe mutant colonies. 
Due to the presence of the ampicillin in the plates only DH5a cells, which have 
successfully incorporated the vector, can form colonies on the plate. In addition, 
DH5a cells contain both the dut and ung genes and therefore can make both dUTPase 
and more importantly uracil N-glycosylase. The glycosylase renders certain sites on 
the uracil-containing strands of the plasmids to become apyrimidinic (AP) sites [10]. 
These AP sites are lethal lesions, which block DNA synthesis [8] and are sites for 
incision by AP endonucleases which produce strand breaks [10]. These render most 
of the template strand to be biologically inactive. Thus the majority of the cells' 
progeny arise from the complementary strands, which contain the desired mutations. 
This results in a high efficiency of mutant production, typically >50% [5]. Screening 
for mutations was carried out by DNA sequence analysis. 
3.2.1.3 Mutant Screening 
Of the resultant colonies from the mutagenesis reaction, 4 were picked for each 
mutation. These were then grown overnight in 25 mL of LB containing 100 tg mL' 
ampicillin at 37 °C. The cells were harvested by brief centrifugation and the plasmids 
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were isolated using a QIAGEN QIAfilter plasmid kit. The plasmids were then 
resuspended in 200 .tL of H20 and stored at -20 °C. A 20 tL aliquot of each plasmid 
DNA solution was diluted into 980 tL and the concentrations were then measured by 
absorbance at 260 nm. 
In order to screen for successful mutations the coding region of the alb gene was cut 
out using Hindill restriction endonuclease from each of the resulting plasmid DNAs. 
Hindlil restriction sites flank either end of the coding sequence (Figure 3.2). 
Digestion was also carried out with BglII restriction endonuclease as coincidently it 
was found that the histidine to leucine mutation created an extra BglII restriction site, 
5 '-AGATCT-3'. 
For each digestion the following reaction mixture was prepared: 1 pg DNA, 1 pL 10 
units tL' enzyme (Hindll or BglII), 2 !LL of xlO restriction enzyme buffer, H20 was 
then added to bring the final volume to 20 jtL. Reactions were incubated at 37 °C for 
2 hrs. 5 L of gel loading buffer (containing 10 mg/mL RNase A) was added to each 
sample. 20 L of each sample was loaded on a 1% agarose TBE gel containing 
ethidium bromide. DNA ladder (5 jiL of 0.1 mg mL')was also loaded. The gel was 
run at 100 V for approximately 1 h. 
The Hindill enzyme cut the DNA in 2 places yielding 2 fragments (a 4,383 bp 
fragment and an 1,820 bp fragment). The BglII enzyme cut the DNA in 3 places 
yielding 3 fragments (4,796, 1,371 and 36 bp fragments), except where the histidine 
to leucine mutation had occurred. In this case an additional band of 597 bp was seen 
with the 4,796 bp reduced to 4,199 bp. 
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Following the Hindill digest 2 visible bands were seen on the gel corresponding to the 
expected 4,383 and 1,820 bp fragments. The BglII digest yielded 2 bright bands 
corresponding to the 2 larger expected fragments. One colony had an additional 
smaller band, which was consistent with the 597 bp fragment expected for plasmids 
containing the histidine to leucine mutation. Note that on the BglIII gel the 36 bp 
fragment cannot be seen due to its size. This is because ethidium bromide, which is 
used to visualise the bands on the gel is a DNA intercalating agent and therefore the 
UV intensity of a band is dependent upon the size of the fragment, with larger bands 
always appearing brighter. 
Polymerase chain reactions were performed in order to prepare the plasmid DNA for 
sequencing. The polymerase chain reaction (PCR) is a technique used to produce a 
large number of copies of a certain DNA sequence. The reaction uses a temperature-
resistant polymerase from the bacterium Thermus aquaticus, Taq polymerase, which 
catalyses the growth of DNA primers [11]. Double stranded DNA is heat-denatured 
to generate single stranded templates. 	Lowering of the temperature allows 
complementary primers on opposite strands to extend in different directions, toward 
each other, in the presence of the components necessary for polymerisation. Repeated 
cycles of denaturation and synthesis lead to an exponential growth in the number of 
segments replicated. Figure 3.4 shows a representation of the PCR reaction. 
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3' 	 5' 
a' 	 b' 	 c' 




Figure 3.4 The polymerase chain reaction. The original DNA sequence is denoted 
by abcde and the complementary sequence by a 'b 'c 'd'e'. Primer 5 is shown in 
yellow and primer d' in blue. New DNA is shown in red. Diagram taken from [12]. 
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However in this case the PCR reaction performed was slightly different in that as well 
as containing the normal dNTPs which bind to the primers elongating the DNA, 
ddNTPs (dideoxy nucleotide triphosphates) were also present at a concentration 100 
times lower than the dNTPs. Complementary ddNTPs stick to the primer in exactly 
the same way as dNTPs but stop the chain from getting any longer due to the absence 
of the 3' hydroxyl group, necessary to bond with the next dNTP. The consequence is 
that instead of generating millions of copies of the full coding sequence many 
different forms of "stunted" sequences are obtained. The elongation reaction 
proceeds so far before a ddNTP gets incorporated and the chain stops. By the laws of 
probability DNA chains are obtained which are a single base longer than the primer, 2 
bases longer, 3 bases, 4, 5, 6 and so on for many hundreds of bases. Each type of 
ddNTP (i.e. ddATP, ddCTP, ddGTP and ddTTP) also has bound a different coloured 
fluorophore. The DNA sequencer separates all these oligonucleotides by their size by 
capillary electrophoresis. The capillary has a "window" at one end for fluorophore 
detection, smaller chains travel faster along the capillary than long chains. This 
means that the first chains to reach the window have a single additional base with a 
fluorophore attached, the next have an additional 2 bases (the latter with a 
flurophore), the next have an additional 3 bases (again, the latter with a flurophore) 
and so on. As each set of chains pass the capillary window the fluorophore, which is 
present in greatest abundance is detected. This allows the DNA sequencer to put 
together the full DNA sequence as each fluorophore represents a particular base (as 
shown in Figure 3.5). 
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Figure 3.5 DNA fluorescent sequencing. Four different chromophores are used on 
the ddNTPs in the dideoxy termination reactions to put together a sequence. Diagram 
modified from [11]. 
Plasmid DNA from 4 potential tyrosine to phenylalanine mutant colonies was selected 
as was plasmid DNA from the colony yielding the extra Bglll band as this inferred it 
to be a successful histidine to leucine mutant. PCR reactions with the selected 
plasmid DNAs were set up as follows: 8 .iL ABI Prismm big dye terminator cycle 
sequencing ready reaction mixture (with Ampli Taq polymerase for fluorescent 
sequencing), 25 l ig mU' plasmid DNA, 40 nM primers (either TW2 and HSA7 Delta 
Biotechnology Ltd.), which together cover the human albumin coding sequence), H20 
was added to bring the final volume 20 .iL. The PCR reaction consisted of 25 cycles 
76 
Chapter 3 	 Site-Directed Mutaqenesis 
of 96 °C for 10 s, 50 °C for 5 s and 60 °C for 4 mm. The samples were then incubated 
at4°C. 
Following the PCR reaction 2 p.L of 3 M sodium acetate, pH 4.6 and 50 jiL of 95% 
ethanol were added to the mixtures. The samples were then incubated at room 
temperature for 15 min and centrifuged at 13,000 rpm for 20 mm. The supernatants 
were removed and the pellets were washed with 250 tL of 70% ethanol (by vortexing 
and centrifugation at 13,000 rpm for 5 mm). The pellets were then dried in a 95 °C 
heating block and resuspended in 12 p.L of template suppression agent. They were 
vortexed and spun down before sequencing on the Perkin-Elmer ABI Prism 310 
Genetic Analyser. Plasmid DNA isolated from two colonies were found to have 
incorporated the tyrosine to phenylalanine mutation, the other two had not. The DNA 
isolated from the colony with the extra BglII band was confirmed to have 
incorporated the histidine to leucine mutation. 
3.2.1.4 Insertion of Mutation into Fully Sequenced Plasmid 
Before the respective mutant expression cassettes could be inserted into a yeast 
expression vector, it was important that no other mutations had taken place. The risk 
of which was minimised through the use of a plasmid, which had previously had all 
6,397 bp sequenced (pDB2243). Both mutations are located in a region of the 
plasmid flanked at one side by a single NcoI restriction site and at the other a single 
BfrI restriction site (see Figure 3.2). In each of the mutant plasmids this region was 
sequenced, cleaved and ligated into the pDB2243. 
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The region of plasmid DNA from the 3 mutant colonies (1 His34Leu mutant and 2 
Tyr 84Phe mutants) to be cut and ligated, was sequenced as before, with the exception 
that 3 additional primers (HSA8, HSA1 1 and HSA19 (Delta Biotechnology Ltd.)) 
were needed to flank the region which lies between the single NcoI and BfrI 
restriction endonuclease sites on the plasmid. No additional mutations arose within 
two of the colonies. However a plasmid from one of the tyrosine to phenylalanine 
mutants had developed an A to T base change in the coding region of the alb gene. 
Sequence analysis revealed however that this additional mutation is invisible at the 
amino acid level. The respective codon would still code for the amino acid alanine at 
Ala" 5  
Restriction digests with the mutant plasmids and pDB2243 were set up as follows: 2 
p.L xlO restriction enzyme buffer, 4 pL 10 units tL' BfrI, 8 p1 10 units jiL' NcoI, 1 
tg respective plasmid DNA (0.1 jig of pDB2243), H20 was added to bring the final 
volume to 100 jiL. Reaction mixtures were incubated at 37 °C for 2 hours. 40 p1 (2 
x 20 p1) of each were loaded on a 1% agarose TAE gel containing ethidium bromide 
and run as before. 
The larger bands from the pDB2243 digest and the smaller bands from the others 
were cut from the gel with a sterile scalpel blade and the DNA was then purified using 
the Geneclean II kit. To each volume of DNA/gel 3 volumes of sodium iodide 
solution was added. The solutions were then incubated at 50 °C for 5 min to allow the 
DNA/gel to dissolve. 5 jiL of EZ-Glassmilk was added to each solution, before a 
further incubation at room temperature for 5 mm. The solutions were then 
centrifuged at 13,000 rpm for 5 mm; the supernatants were removed and washed 3 
in 
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times with 200 L of wash solution. The DNA was eluted from the pellet with 20 LL 
of elution solution and the supernatants were collected. A 2 jiL aliquot of each 
supernatant was then run on a 1% agarose TBE gel containing ethidium bromide. 
Ligation reactions were set up with each of the smaller mutated plasmid NcoJIBfrI 
fragments with the large pDB2243 NcoI/BfrI fragment as follows: 2 tL lOx ligation 
buffer, 2 jiL 20 mM ATP, 2 pL pDB2243 (containing 0.5 tg DNA), 2 pL of 
respective mutated fragment containing 0.2 jtg DNA, 1 j.iL of DNA ligase and 8 jiL 
H20 
3.2.2 His67Ala Mutant Albumin 
The DNA sequence of the alb gene [4] was studied and it was found that a CAT 
codon encodes the His 67  residue. Therefore a double base pair change in the codon 
was required to encode an Ala residue (CAT—*GCT). 
Unlike the Cys34 site mutations, for the His67 to alanine mutation, the QuikChange® 
Site-Directed Mutagenesis Kit (Stratagene) was used. The kit incorporates a different 
method than that of Kunkel, which allows the mutagenesis reaction to take place in a 
double-stranded DNA template. Also this method is perfomed using PfuTurbo® 
DNA polymerase, a high fidelity polymerase (6-fold higher fidelity than Taq 
polymerase) that replicates both plasmid strands without displacing the mutant 
oligonucleotides primers. 
The basic procedure utilises a supercoiled double stranded DNA (dsDNA) vector 
(based on pQC262e, figure 3.3) and two synthetic oligonucleotides primers containing 
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the desired mutation. The oligonucleotides primers, each complementary to opposite 
strands of the vector, are extended via the polymerase chain reaction (figure 3.4) by 
the PfuTurbo® polymerase. The two primers used for the His 67Ala mutation were 5'-
GCTGAAATTGTGACAAATCACTTGCTACCCTTTTTGGAGACAAATTATGC-
3' and 5 '-GCATAATTTGTCTCCAAAAAGGGTAGCAAGTGATTTGTCACAATT 
TTCAGC-3'. Incorporation of the oligonucleotides primers generates a mutated 
plasmid containing staggered nicks. Following the PCR, the product is treated with 
DpnI. The DpnI endonuclease (target sequence 5'-GAmTC-3') is specific for 
methylated and hemimethylated DNA and is used to digest the parental DNA 
template and to select for mutation-containing synthesised DNA [13]. DNA isolated 
from almost all F. coli strains is dam methylated (the methylase specified by the dam 
gene methylates the N6-position of the adenine in the sequence 5'-GATC-3') [14] and 
is therefore susceptible to DpnI digestion. The nicked vector containing the desired 
mutations is then transformed into competent F. coli cells. 
3.2.2.1 Mutagenesis 
The following mutagenesis reaction mixture was prepared for PCR: 2iL of double 
stranded template (pQC262e), 5 jtL of 1 Ox reaction buffer, 1.25 pL of each primer (at 
100 ng jiL 1), 1iL dNTPs (10mM of each dATP, dCTP, dGTP and dTTP), 39.5 iL 
H20 and 1 tL of PfuTurbo® DNA polymerase. The PCR reaction consisted of 1 
cycle at 95 °C for 30 s, followed by 17 cycles of 95 °C for 30 s, 55 °C for 1 min and 
68 °C for 14 mm. 
Following PCR, 1 p1 of DpnI (10 units p1) was added to the reaction to remove the 
methylated, unmutated, parental strand. The reaction was then mixed and allowed to 
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digest at 37 °C for 1 hour. Following digestion, 1 pL of the reaction was then added 
to 50 i.iL of competent DH5a E. coli cells at 0 °C and incubated on ice for 30 mm. 
The reaction was heat pulsed at 42 °C for 45 s and placed back on ice for 2 min to 
allow transformation to occur. LB broth (0.5 mL) was then added to the reaction and 
it was incubated at 37 °C for 20 mm. The mixtures were then spread on LB agar 
plates containing ampicillin (50 pg mU'). The plates were then incubated overnight 
at 37 °C. Due to the presence of the ampicillin in the plates, only cells that have 
successfully incorporated the vector can form colonies on the plate. These resulted in 
24 possible His67 to Ala mutant colonies. 
3.2.2.2 Mutant Screening 
Of the resultant colonies from the mutagenesis reaction, 3 were picked and were 
screened for successful mutations by fluorescent DNA sequencing. DNA was 
extracted and sequenced as described in Section 3.2.1.3. All were found to contain 
the desired mutation. 
3.2.2.3 Insertion of Mutation into Fully Sequenced Plasmid 
This was carried out using DNA from a colony of cells confirmed to carry the His 67  to 
Ala mutation. The region of DNA carrying the mutation (between the NcoI and BfrI 
restriction endonuclease sites) was sequenced, confirmed to only carry the desired 
mutation, cleaved and inserted into pDB2243 as described in Section 3.2.1.4. 
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3.3 Synthesis of Yeast Vector and 
Transformation into S. cerevisiae cells 
33.1 Introduction 
The S. cerevesiae cells used were of the DXY 1 strain, which contains disruptions in 2 
of its genes, Leu2 and Yap3. Leu2 is a gene encoding an essential enzyme in the 
leucine synthesis pathway. Yeast cells without this gene are unable to make leucine 
and hence cannot grow in the absence of leucine. The Leu2 gene is present however 
on the yeast vector and so this disruption is used as a means of selection (only cells 
with this plasmid can grow). Yap3 encodes a yeast aspartyl protease, which 
proteolytically clips the albumin at a specific site causing fragmentation [15]. 
3.3.2 Insertion of Expression Cassette into Yeast 
Vector 
The yeast expression vector is a pUC9 vector with a single NotI site for insertion of 
the expression cassette (Figure 3.6). The pUC9 plasmid is a versatile vector, which 
can replicate in both E. coli and S. cerevisiae cells. Plasmids from all three mutant E. 
coli colonies were digested to allow insertion of the expression cassette into a yeast 
vector for expression. The expression cassette is the part of the E. coli plasmid, which 
carries the mutated albumin coding sequence and sequences required for transcription. 
The expression cassette is flanked at either side by a NotI restriction endonuclease site 
(Figure 3.3). Digestion with NotI alone would yield two fragments of 3,185 and 
3,212 bp. These fragments are so similar in size that they would not be able to be 
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endonuclease that cuts the 3,212 bp fragment into 1,405 and 1,780 bp and allows easy 
recovery of the 3,185 bp expression cassette from the gel. 
Figure 3.6 The Yeast expression vector, pSAC35. The vector contains the Leu2 
gene as means of phenotypic selection and the pUC9 sequence. There is a NotI 
endonuclease site for insertion of the mutated expression cassette. Various other 
restriction endonuclease sites are also shown. 
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Restriction digests were set up as follows: 10 jiL of lOx digestion buffer, 3 iL of 
respective plasmid DNA (1.5 pg mU'), 5 L NotI (10 units jtL'), 5 tL Scal (10 units 
iL') and 77 jiL of H20. The digests were incubated at 37 °C for 1 hour and were ran 
on a 1% (w/v) agarose TAE gel containing ethidium bromide as previously described. 
The 3,185 bp fragment was cut from the gel and purified as described in Section 
3.2.1.4. 
The expression cassettes were then ligated into the pSAC35 yeast vector, which had 
previously been linearised with the NotI endonuclease. The reaction was set up as 
follows: 1 iL of lOx ligation buffer, 1 j.tL of pSAC35 (1.5 jig mU'), 5 p1 of 
respective expression cassette (purified from gel), 1 p1 of T4 DNA ligase and 2 j.iL 
H20. A control was also set up with 5 j.tL of H20 instead of the expression cassette. 
Reactions were incubated at room temperature for 2 hours. To the ligation mixtiures, 
100 jiL of competent DH5a cells were added and the suspension was than placed on 
ice for 30 mm. The cells were then heat-shocked at 42 °C for 40 s and placed back on 
ice for 2 min to allow transformation to occur. To each transformant, 200 p1 of LB 
broth was added. They were then incubated at 37 °C for 15 mm. The transformants 
were then plated onto LB agar plates containing 100 jig mU' ampicillin and incubated 
at 37 °C overnight. 
Large numbers of colonies grew following ligation and transformation for each 
respective mutant. No colonies grew on the control plate, suggesting that most if not 
all of the colonies on the ligation/transformation plates had successfully incorporated 
the expression cassette. Twelve colonies from each respective mutation were then 
grown overnight in 25 mL of LB broth containing 100 jtg mU' ampicillin at 37 °C. 
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The cells were harvested by brief centrifugation and the plasmids were isolated using 
a QJAGEN QiAfilter plasmid kit. 
Restriction digests with Nod and EcoRI enzymes (set up as previous digests) were ran 
on a 1% (w/v) agarose TBE gel containing ethidium bromide and confirmed the 
presence of and fragments sizes expected of the final yeast vector. 
3.33 Transformation of Yeast Vector into S. cerevisiae 
DXYI Cells 
S. cerevisiae DXY1 cells were grown in YEPD to late log phase/early stationary 
phase. The YEPD media consisted of 10 g U' yeast extract (Difco), 20 g U' 
Bactopeptone (Difco) and 2 % glucose. 20 mL of cells were harvested and washed 
three times with H20 at 4 °C then resuspended in 2 mL of H20 and cooled to 0 °C. 
Electroporation cuvettes (2 mm gap, BioRad) were cooled to 0 °C. In each of them 20 
pL of respective vector, 100 jiL of cells and 50 p.L of 40% (w/v) polyethylene glycol 
3000 were added. 
Each was then pulsed (resistance = 1 k1, capacitance = 25 tFD and voltage = 800 V) 
using a Gene Pulsar Electroporator (BioRad). To each cuvette, 0.5 mL of 20% (w/v) 
sucrose was added and mixed. Each were then plated on BMMS agar plates. The 
BMMS plates consisted of 1.7 g U1 yeast nitrogen base (w/o amino acids and 
ammonium sulfate), 5 g U' ammonium sulfate, 36 mL U' of 1 M citric acid, 126 mL 
U' of 1 M di-sodium hydrogen orthophosphate, 15 g U' bacteriological agar and 2% 
(w/v) sucrose. Plates were than incubated at 30 °C. After 4 days, approximately 20 
to 100 colonies had grown on each plate. 
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3.3.4 Mutant Protein Expression 
Protein expression of the yeast strains was checked using the techniques of rocket 
immunoelectrophoresis and quantitative SDS-PAGE. Yeast cells were inoculated into 
both YEPD and BMMS (made as BMMS agar but without the bacteriological agar) 
liquid media and the flasks were incubated at 30 °C with shaking for 4 days. Cultures 
were then spun at 3,000 rpm for 15 min and the supernatant was collected and 
assayed. Rocket immunoelectrophoresis was performed as described in section 2.2.3 
and quantitative SDS-PAGE as described in Section 2.2.4. Expression levels were 
typically between 150 to 200 mg mutant albumin per mL of culture when grown in 
YEPD and 200 to 300 mg mutant albumin per mL of culture when grown in BMMS. 
All assayed colonies expressed the desired protein. 
3.3.5 Trehalose Stocks for Fermentation 
Yeast colonies were grown in BMMS liquid media to mid log phase to create 
trehalose stocks for fermentation. Following growth, 100 mL of each culture was 
spun at 3,000 rpm for 15 mm, 75 mL of supernatant was removed and the pellet was 
resuspended. To the suspension, 25 mL of 40% D(+) trehalose was added. The 
suspension was then mixed, dispensed into 1 mL aliquots and stored at —80 °C ready 
for use. 
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3.4 Fermentation 
To maximise yeast growth and protein production, it is first important to understand 
yeast growth. Four phases of growth are normally observed. First is the lag phase, 
the phase in which the cells adapt to their new environment. This would include 
induction of several metabolic pathways, before growth can start. This is followed by 
the exponential growth phase. Once the yeast has adapted to the new conditions the 
number of cells (or biomass) will increase exponentially until the carbon and/or 
nitrogen source has been consumed. After which, no growth occurs - this is the 
stationary phase. In Saccharomyces cerevisiae cultures following consumption of the 
sugar a phase, which looks like a stationary phase, is apparent. However, after a few 
hours the biomass increases exponentially again (although at a lower rate). This is 
due to the fact that during the first exponential phase, ethanol and acetate are 
produced and during the few hours of "stationary phase", the yeast adapts its 
metabolism by inducing enzymes that are needed for growth on these carbon sources. 
This type of growth is called diauxic growth. The final phase of yeast growth is the 
death phase where the cells lyse. 
The production of the cloned protein is dependent on the biomass present within the 
fermenter. Yet if the cells have a vast supply of the carbon source, mass production 
of toxic fermentation products such as ethanol and acetate occurs. If the levels of 
these products become too high it is be sufficient to limit growth or even kill the cells. 
For this reason cells are grown under carbon limitation. This is achieved by having a 
batch medium and a feed medium. The batch medium is the initial source of nutrients 
for the cells after inoculation into the fermenter. When all of the sugars and ethanol 
in the batch medium have been used up, any acetate present is utilised by the cells. A 
RIM 
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feed medium is then added at such a rate that the carbon source concentration is kept 
limiting. This therefore limits the rate of growth, preventing ethanol and acetate 
building up. 
Yeast growth is also very sensitive to pH. As the yeast metabolise the carbon source 
they produce CO2 as a by-product. CO2 in solution forms a carbonic acid and hence 
the pH in the fermenter drops. The optimum pH for growth is 5.5; a solution of 
17.5% ammonia is added when necessary to raise the pH. Conversely, during phases 
of acetate utilisation the pH increases. This is brought back down to optimum by the 
addition of 2 M H2SO4. 
The batch medium was prepared in a 10 L fermenter as follows. An autoclaved 50% 
(wlv) carbon source, sucrose solution (200 mL) was added to 2560 mL distilled water 
and filtered using a 0.22 tim, SuporCapTM sterile capsule into the fermenter. A 
vitamin stock solution (50 mL, which contained 6 g U' calcium pantothenate, 10 g U' 
nicotinic acid, 6 g U' m-inositol, 1.5 g U' thiamine-HC1 and 30 mg D-biotin) and 600 
mL of a salt mixture (containing 28 g U' KOH, 40 g U' H3PO4, 7.17 g U' 
MgS04 7H20, and 0.75 g U' CaC12 2H20) were mixed with 40 mL of distilled water. 
The mixture was filtered using a 0.22 pm, Durapore filtration unit, then added to the 
fermenter. The filter was then flushed with 125 mL of distilled water. A trace 
element solution (45 mL, which contained 63.07 g U' H2SO4, 3 g U' ZnS04 7H20, 10 
g U' FeS04 7H20, 2.42 g U' MnSO4 H20, 79 mg U' CuS04 5H20, 0.5 g U' 
Na2MoO4 2H20 and 0.56 g U' CoCI2 6H20) was filtered into the fermenter using the 
same device as used for the vitamin stock-salt solution mixture. The filter was 
flushed with 125 mL of distilled water. 
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Trehalose stocks of S. cerevisiae DXY1 cells, containing the respective mutated 
plasmids were inoculated into 100 mL of BMMS and grown to approximately 1 g 
cells per litre of culture. Approximately 60 mg of cells were then inoculated into the 
batch medium in the 10 L fermenter. 
The feed medium was made as follows. Vitamin stock (120 mL), 250 mL of salt 
solution and 30 mL of distilled water were mixed and filtered using a 0.22 jim, 
Durapore filtration unit. The filter was then flushed with 100 mL of distilled water. 
Trace element solution (105 mL) was added to 295 mL of distilled water and filtered 
as was the vitamin stock-salt solution. The filter was again flushed with 100 mL of 
distilled water. The combined salts, vitamins and trace elements were added to 4 L of 
62.5% (w/v) sucrose and made up to 5 L with sterile water. The feed was added 
following batch growth at a rate that increased to carbon limitation. The fermentation 
was completed when the entire feed medium had been added. 
3.5 Purification 
The S. cerevisiae DXY1 cell cultures, following fermentation were centrifuged at 
3,000 rpm for 30 mm. The supernatants were then removed and filtered. The 
recombinant protein was concentrated from the supernatant, using cation-exchange 
chromatography. An SP-sepharose Fast Flow cation-exchange column (column 
volume = 225 mL) was equilibrated with 4 column volumes of a 30 mM sodium 
acetate buffer, pH 5.5. The filtered supernatants were split into two batches of 
approximately 3 L. Both batches were purified for His39Phe and Tyr 84Phe mutants 
but only one batch of Cys34Ala and His67Ala due to time restrictions. Sodium 
me 
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octanoate was added (7.5 mL of a 2 M solution) to each batch and the pH was 
adjusted to 4.5 with acetic acid and the conductivity was adjusted to 5.5 mS cm 1 with 
deionised water before loading onto the column. After loading, the column was then 
washed with 8 column volumes of 50 mM acetate, 8 mM NaOH, pH 4.0 and 4 
column volumes of a 27 mM sodium acetate buffer containing 2 M NaCl, pH 4.0. A 
third wash was carried out with 10 column volumes of the equilibration buffer. 
Finally the column was eluted with 2 column volumes of 85 mM sodium acetate 
containing 5 mM octanoic acid, pH 5.5. 
The recombinant albumin content of the filtered supernatant and the eluent were 
determined by high-performance liquid chromatography (as decribed in Section 
2.1.2). The average albumin concentrations of the supernatants and eluents were 2.5 
g U' and 5.5 g U1, respectively. The mean purification yield was approximately 
76%. 
SP-sepharose Fast Flow eluents were then further purified by anion-exchange 
chromatography on a DEAE fast flow column (column volume = 167 mL). The 
column was equilibrated with 15 column volumes of 30 mM acetate, 27 mM NaOH, 
pH 5.5. The conductivity of SP-sepharose eluents was adjusted to 3.0 mS cm-1 with 
deionised water before loading onto the column. After loading the column was then 
washed with 5 column volumes of 15.7 mM K2B407 4H20, pH 9.2. The column was 
eluted with 0.75 column volumes of 85 mM acetate, 110 mM K2B407 4H20, pH 9.4. 
HPLC revealed the average albumin concentrations of the eluents to be 11.4 g U'. 
The mean purification yield was calculated to be approximately 107%. However, the 
HPLC method for albumin quantification measures monomer concentration only, and 
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during this purification step some dimeric albumin is thought converts back to 
monomer. 
DEAE eluents were then purified further by affinity chromatography on a Delta Blue 
Agarose column (column volume = 423 mL). Delta Blue matrix was supplied by 
ACL. The column was equilibrated with 2 column volumes of a 250 mM ammonium 
acetate buffer, pH 8.9 before loading the DEAE eluent. After loading, the column was 
then washed with 5 column volumes of the equilibration buffer. The column was 
eluted with 2 column volumes of 50 mM phosphate buffer containing 2 M NaCl, pH 
6.9. HPLC revealed the average albumin concentrations of the eluents to be 6.0 g L'. 
The mean purification yield was approximately 76%. 
Delta Blue eluents were then concentrated using a 10 kD MWCO Pall Filtron LU 
Centramate filter connected to a peristaltic pump. Overall it was determined that 6.38 
g of Cys34Ala, 6.41 g of His39Leu, 7.61 g of Tyr 84Phe and 4.25 g of His67Ala albumins 
were recovered. A sample of concentrated solution from each of the purified products 
was diluted to 5 mg mU' and 10 tL of each were applied to an SDS-PAGE gel. Gels 
were made and run using the standard method of Laemmli [16]. The gels were 
stained with both coomassie blue stain and silver stain. A gel showing the His 39Leu 
and Tyr 84Phe purification products can be seen in Figure 3.7. The gels revealed no 
other proteins to be present at the 1% level (therefore proteins are approximately 99% 
pure) 
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Figure 3.7 SDS-PAGE of purified products. The coomassie stained gel shows no 
other significant proteins to be present at the 1% level. The silver stained gel shows 
the presence of trace impurities within the purified products. The bands around 135 
kD in the silver stained gel could be albumin dimer. 
3.6 Characterisation of Mutant Albumins 
3.6.1 Mass Spectrometry of Purified Proteins 
In order to check that the proteins produced were of the expected molecular weight, 
ESI-mass spectrometry was carried out. Samples were diluted to 1 mg mLT and were 
prepared and analysed as described in Section 2.5. The resultant spectra are shown in 
Figure 3.8. The resultant masses were very close to the theoretical values and 
confirmed the mutant proteins to be the expected size in each case. 
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66416 
66374 66406 \66'1 66442 
Figure 3.8 ESI-mass spectra of purified products. The spectra show measured 
masses of native and mutant proteins. Theoretical masses for native (black), Cys34Ala 
(green), His39Leu (blue), His67Ala (purple) and Tyr84Phe (red) albumins are 66438, 
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3.6.2 Peptide Mapping of Mutant Albumins 
In order to ensure the mutations had occurred at the correct site, peptide mapping of 
His39Leu and Tyr 84Phe albumins was attempted. 
3.6.2.1 Tryptic Digestion 
Mutant albumins (0.5 mg of each) and reference standard in 100 pL were added to 
100 L of M guanidine-HC1 in 2 mM EDTA, 0.5 M Tris-HC1, pH 8.0. The samples 
were reduced by the addition of 5 1iL of 100 mM dithiothreitol then were mixed and 
incubated for 1 hour at 37 °C. The samples were diluted by the addition of 200 jtL of 
water. The digestion commenced with the addition of 10 tL of 1 mg mU' trypsin. 
The samples were incubated overnight at 37 °C in a shaking incubator. The following 
morning and then in the afternoon another 10 tL of 1 mg mU' trypsin was added and 
incubation of the samples was continued at 37 °C for 48 hours. They were 
centrifuged for 5 mm, 400 pL of the supernatant was removed, transferred to a fresh 
tube, mixed with 400 tL of 0.1% TFA in water, mixed again and then centrifuged for 
a further 5 minutes. 
3.6.2.2 HPLC Separation of Tryptic Fragments 
The digests were chromatographed on a Waters HPLC system. The reversed-phase 
column was a Vydac C18 (dimensions 4.6 x 250 mm). Detection was performed at 
214 nm. Two solvents were used solvent A (0.1% TFA) and solvent B (0.085% TFA 
in 70% acetonitrile). Initially sample was run with a linear gradient of 95% solvent A 
and 5% solvent B to 100% solvent B for 2 hours. Injection volume was 100 L 
(equivalent to 65 tg of digest) and flow rate was 0.5 mL min 1. 
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Some peak differences between the control and Tyr84Phe albumin were noted, notably 
the appearance of a novel peak at 53 min and the absence of a peak at 57 min in the 
Tyr84Phe rHA as shown in Figure 3.9. The novel peak was collected manually from 
the eluent of the HPLC detector for sequencing. The other mutant, His39Leu, was a 
little more elusive. About 6 peak changes were found but it is unknown which is 
caused by the residue change. The actual tryptic peptide containing the His39Leu 




20 	40 	60 	80 	100 
Minutes 
Figure 3.9 Reverse-phase IIPLC trace of the (A) control nRA and (B) Y84F 
mutant digestion products. A new peak can be seen in the mutant digest, indicated 
by the arrow. 
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3.6.2.3 Amino-Terminal Sequence Analysis 
Sequence analysis was performed on an Applied Biosystems 494 Procise sequencer. 
A 60 p.L aliquot of a collected peak was loaded onto a precycled filter and sequenced 
using a pulsed-liquid cycle. The 53 min peptide, thought to correspond to the 
Tyr84Phe mutation, was sequenced and the mutation was confirmed (Figure 3.10). 
Two peaks suspected to be His39Leu mutant peptides were sequenced, but were found 
to be of mixed sequences. This means that there was more than one peptide in the 
peak, and a number of missed cleavage sites were also found, where the trypsin failed 
to cleave the protein at a Lys or Arg residue. 
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Figure 3.10 Sequence analysis of the novel peptide found in the Y84F mutant 
digest. The elevated level of phenylalanine following cleavage of the third residue 
confirms the mutation. 
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3.6.3 Circular Dichroism 
Circular dichroism (CD) spectra were recorded of native, Cys34Ala, His39Leu, 
His67Ala and Tyr 84Phe albumins (Figure 3.11) and secondary structure estimations 
were made (Table 3.1) as described in Section 2.6. 
The secondary structure estimations calculated from the CD spectra reveal little 

























C34A 54.1 3.7 6.4 13.8 23.3 101.4 
H39L 45.2 7.9 7.4 14.2 25.5 100.3 
H67A 60.3 3.4 4.4 14.7 17.4 99.7 
Y84F 45.8 7.9 7.7 14.1 25.8 101.3 
Table 3.1 Secondary structure estimations of native and mutant albumins. The 
native protein structure content was calculated twice, once with His 39Leu and 
Tyr 84Phe mutants (top value) and with Cys34Ala and His67Ala mutants (bottom value). 
97 















190 200 	 220 	 240 	 260 
Wavelength (mn) 
Figure 3.11 Circular dichroism spectra of native and mutant albumins. In (a) 
circular dichroism spectra of wild type (pink), His39Leu (blue) and Tyr84Phe (red) 
albumin are shown. In (b) circular dichroism spectra of wild type (pink), Cys34Ala 
(blue) and His67Ala (red) albumin are shown. 
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Chapter 4 
Reactions at Cys34 
4.1 Introduction 
As discussed in Section 1.3.4, Cys34 is the binding site for a wide variety of 
biologically and clinically important small molecules and is also responsible for the 
largest fraction of free sulfhydryl groups in blood serum [1]. Therefore, the kinetic 
and thermodynamic properties of the free thiol group are of great physiological 
significance. 
Although a number of crystal structures of human albumin have been solved (as 
summarised in Table 1.3). These do not provide much information as to the dynamics 
of Cys34 and its surrounding residues in solution. Over the years, a wide range of 
techniques have been used to probe the microenvironment surrounding Cys34, some 
examples are summarised in Table 4.1. Such studies have provided invaluable data 
with regard to the Cys34 site. 
In solution, Cys34 has been shown to be accessible to Hg2 [2] but to lie in a 
hydrophobic sterically hindered pocket, 9.5 A deep [3-5]. It is proposed that upon 
ligand binding or oxidation, a conformational change is invoked with Cys34 moving 
from a buried to a solvent-exposed state. The conformational change appears to be 
coupled to a movement of the His3 residue, which could be observed using 2-
dimensional 'H NMR [6]. Interestingly, an in vitro reaction between albumin and 
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auranofin appeared to follow first order kinetics, with the reaction rate being 
independent of auranofin concentration [7]. This was proposed to be due to an altered 
albumin conformation where-by domain IA of the protein is open, increasing Cys34  
accessiblity and allowing gold binding. It was concluded that Cys34 is on the surface 
of the protein following the binding of thiol-specific fluorescent probe, acrylodan [8] 
and fatty acid binding to the protein affects this site [8,9]. Perhaps the most interesting 
study is that of Kratz et al. [9]. They investigated binding of derivatives of the anti-
cancer agent, doxorubicin hydrazone containing differing lengths of aliphatic spacers 
(2, 3, 5 and 7 carbons) as shown in Figure 4.1. Cys34 reacted slower as the chain-
length increased in the absence of fatty acid (2 > 3 > 5 > 7). In the presence of 
myristate the 5-carbon derivative reacted fastest (5 > 3 > 2 > 7). This shows that the 
binding of fatty acid at other sites on the molecule can alter the binding specificity of 
the Cys34 site. 
¶1 	10 
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Figure 4.1 General structure of doxorubicin hydrazone derivatives. Structures 1-4 
contain 2, 3, 5, and 7 carbon atoms respectively as aliphatic spacers. Modified from 
[9] 
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Technique / Method Findings Authors 
Hg 2+  binding The free thiol of albumin is accessible to Hg 2+  and can give Kay and Edsall, 
dimeric albumins linked through the free thiol group. 1956 [2] 
Absorbance and optical The free thiol group sits at a border between a polar helical Ohkubo, 
rotary dispersion (ORD) segment and a hydrophobic area with two tyrosyl groups (one 1969 [3] 
measurements buried, one exposed) nearby. 
EPR spin-labelling Using nitroxide compounds of differing chain-length, it was Cornell et at, 
concluded that the free thiol lies in a crevice 9.5 A deep. 1981 [4] 
Aromatic and Compounds containing 	5-membered 	heterocyclic rings react Gosselet ci al., 
heterocyclic disulfide more readily than 6-membered aromatic rings, suggesting that 1990 [5] 
binding Cys34 lies in a sterically restricted environment. 
H NMR Binding at Cys34 envokes a change in His 	proton resonances. Christodoulou el at., 
From this it was concluded that upon binding, Cys34 moves from 1995 [6] 
a buried to an exposed state. 
Penefsky spin column The reaction between the anti-arthritic gold complex, auranofin is Roberts ci al. 
chromatography and first order with respect to albumin. 	It was concluded that the 1996 [7] 
31P-NMR rate-determining step involves a conformational change of the 
protein. 
Cys34-specific fluorescent Following the binding of acrylodan, Cys34 was found to be Narazaki ci at, 
probe present on the surface of human albumin. 	Oleate binding 1997 [8] 
affected the fluorescence of the acrylodan-albumin complex. 
Doxorubicin hydrazone Binding of doxorubicin hydrazone derivatives with differing Kratz ci al., 
derivatives as probes lengths of aliphatic spacers were investigated (2, 3, 5 and 7 2002 [9] 
carbons). 	Cys34 reacted slower as the chain-length increased in 
the absence of fatty acid (2 > 3 > 5 > 7). 	In the presence of 
myristate the 5-carbon derivative reacted fastest (5 > 3 > 2 > 7), 
showing that fatty acid-binding affects the Cys34 site. 
Table 4.1 Summary of some studies of the dynamic properties of the free thiol 
group of Cys34. 
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4.2 Reactions with DTNB 
4.2.1 Ionisation Behaviour of Cys34 thiol 
As previously mentioned, the kinetic and thermodynamic properties of the free thiol 
group are of great physiological significance. Thiol interchange can occur between the 
reduced Cys34 thiol and an oxidised disulfide. The compounds 5,5'-dithio-bis(2-
nitrobenzoic acid) (also known as Ellmanvs  reagent [10] or DTNB) and 2,2'-
dithiodipyridine (DTDP) are commonly used for protein thiol determinations and are 
useful for studying kinetics at the Cys34 site, as the reactions can be quantified 
spectrophotometrically [11,12]. The structures of DTNB and DTDP are shown in 
Figure 4.2. 
(a) 
02N 	 S - S 	 N 02 
ooc 	 coo- 
(b) 
) — S—S C—  N 
Figure 4.2 Structures of (a) DTNB and (b) DTDP. 
During disulfide interchange (Equation 4.1), the formation of RS-SR' must be more 
stable (and therefore its formation more favourable) than RS-SR. This reaction is 
thermodynamically more favourable for disulfides with higher redox (reduction) 
potentials than albumin (Equation 4.2). The respective redox potentials at pH 7 (E°') 
of cystine/cysteine and GSSGIGSH are -245 and -262 mV, respectively, relative to the 
standard hydrogen electrode [13]. 
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RS-SR + R'SH 	10 RS-SR' + RSH 	 [4.1] 
AG = -nFE° 
	
[4.2] 
where AG is the free energy change, n is the number of electrons, F is Faraday's 
constant (23.062 kcal) and E° is the redox potential. 
A number of studies have used such disulfide interchange reactions to investigate the 
ionisation of the thiol of Cys34 and have estimated pKa values [12,14-16]. The results 
are summarised in Table 4.2. 
Pedersen and Jacobsen investigated the kinetics for exchange between an aromatic 
disulfide (2,2'-dithiodipyridine, DTDP, Figure 4.2b) and the thiol group of human and 
bovine albumin over the pH range of 3-9 [12]. They found that the reactivity of Cys34 
in both albumins rapidly increases between pH 5 and 8 and suggested that Cys34 of 
human albumin is characterised by an extremely low pKa of approximately 7 
compared to a pKa value of 8-10, which is typical for a free cysteine side-chain [12]. 
Bovine and human albumins were found to have a similar reactivity at physiological 
pH, although the bovine protein reacted 10 times faster than the human protein at pH 
>9. 
A similar approach to Pedersen and Jacobsen [12] was followed by both Wilson et al. 
[15] and Svenson and Carlsson [16]. They investigated the kinetics for exchange 
between bovine albumin and the aromatic disulfides DTNB and DTDP, respectively, 
over the pH ranges 1 - 8 and 7 - 9. Both studies found that reactivity is dependent on 
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pH and both estimated pKa values based upon their reactivity data of around 8.5. A 
value that is fairly typical for cysteinyl sulfur [16]. 
Albumin Estimated thiol Method used Authors 
pKa 
Human and 7 (both) Reaction with 2,2'-dithiodipyridine over Pedersen and 
Bovine the pH range 3 - 9 Jacobsen, 1980 
[12] 
Bovine <5 Potentiometric difference titration with Lewis et al., 1980 
methyl methanethiosulfonate [14] 
Bovine 8.5 Reaction with 5,5'-dithiobis(2- Wilson et al., 
nitrobenzoic acid) over the pH range 7 - 9 1980 [15] 
Bovine 8.5 Reaction with 2,2'-dithiodipyridine over Svenson and 
the pH range 1 - 8 Carlsson, 1975 
[16] 
Table 4.2 Reported pKa values for albumin free thiol. 
Lewis et al. speculated that the pKa of bovine Cys34 thiol is even lower, and is less 
than 5 [14]. They measured the ionisation behaviour of albumin Cys34 (as well as 
glutathione, cysteine, 2-mercaptoethanol, 3-mercaptopropionic acid, 2-
mercaptoethylamine, cis-2-mercaptocyclobutamine, 2-aminothiophenol and 5-
mercapto-2-nitrobenzoic acid) by a potentiometric difference titration method they had 
previously used to measure the pKa of the Cys25 thiol of papain [17]. In order to 
determine the pKa, they determined the protons that were released during the reaction 
of methyl methanethiosulfonate (MMTS) with the thiol group (Equation 4.3). 
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RSH + CH3SO2SCH3 	10 RSSCH3 + CH3SO2_ + H 	[4.3] 
The pH dependence of the difference in proton content between an unmodifed albumin 
and the methylthio derivative was used to characterise the ionisation behaviour of the 
thiol. The protons released were measured by back-titrating with KOH using a pH 
electrode. They also found that indicator dyes could be successfully used for this 
purpose with the smaller thiol-containing compounds. The smaller thiol-containing 
compounds yielded sigmoidal curves with values relating exclusively to the ionisation 
state of the thiol group in each case. The mid-points of each agreed well with 
previously determined pKa values in the literature. With bovine albumin their findings 
were not so straightforward. The best fit of their titration curves suggested that the 
ionisation of the Cys34 thiol also depends on three other groups, two with pKa values 
of 7.9 and another with a pKa >10 and that Cys34 itself has a pKa <5. They could not 
however, eliminate the possibility that the changes in Cys34 ionisation they observed 
were due to pH-induced conformational changes, but do provide evidence that a 
decrease in rate of reaction may well reflect a decreased reactivity of the thio late anion 
caused by the protonation of other groups. In light of this, it cannot therefore be 
assumed that kinetic data alone can be used to study the ionisation of thiol groups in 
proteins. 
If the albumin thiol does have an abnoramily low pKa then it will be predominantly in 
the S form at physiological pH. The residues His 39  and Tyr 84  are located very close to 
Cys34 (Figure 1.5) in the X-ray crystal structure of albumin in the non-liganded state 
and therefore may play a role in stabilising the S form of the thiol. Interestingly, 
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studies have also shown that the binding of fatty acid molecules to albumin can 
increase the rate of Cys34oxidation [18,19]. 
The aims of this section are to determine whether His39Leu and Tyr84Phe mutations 
have an effect on Cys34  reactivity. Previous studies have also shown fatty-acid 
binding to have an effect on Cys34  reactivity [8,9], whilst several crystal structures 
show an increase in Cys34  accessibility in the presence of bound fatty acid [20-22] 
(Figure 4.3). Recombinant human albumin in the presence of 10 mot equiv of 
octanoate was also examined to determine whether elevated fatty acid binding affects 
the kinetics of reaction of DTNB at this site. The rates of reaction of the dithiol, 5,5'-
dithio-bis(2-nitrobenzoic acid) with rHA, high octanoate rHA (10 mot mot-'), 
His39Leu and Tyr 84Phe albumins were determined over a range of pH values between 
6 and 10. The reaction is shown in Figure 4.4. 
Figure 4.3 Space-filling representation of the environment around Cys34 in (A) 
unliganded albumin and (B) albumin with 5 myristates bound. Drawn from PDB 
1A06 [23] and 1BJ5 [20], respectively. 
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Figure 4.4 Reaction of albumin thiol with DTNB. DTNB reacts with the free thiol 
of albumin to form a mixed disulfide and 5-thio(2-nitrobenzoic acid) (TNB). 
During a study of this kind it is important to be aware of the PKa values of the 
(de)protonatable groups in the disulfide compounds. This is because the reaction rate 
is likely to be dependent on the overall charge on the molecule. Brocklehurst and 
Little have shown that the acid dissociation constants of DTNB are 1.57 and 2.15 [24] 
and the pKa of the thiol of TNB is 4.50 [15], therefore the carboxylate groups will all 




rHA (15 jtM) was incubated with 40 mol equiv of DTNB in 100 mM potassium 
phosphate, pH 8.0 for 1 hour. A mass spectrum of the product was recorded as 
detailed in Section 2.5. 
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Reactions of albumins with DTNB 
Reactions mixtures were set up as follows: 1350 tL of respective buffer, 1350 p.L of 
50 mM KC1, 150 jtL of 15 mM DTNB (dissolved in methanol). The following buffers 
were used: 0.2 M potassium phosphate (pH range 6.0-8.0), 0.2 M Tris-HCI (pH range 
8.0-9.0) and 0.2 M CAPS, 3-(cyclohexylamino)-1-propanesulfonic acid (pH 9.0-10.0) 
range. The ionic strengths of the buffers were kept constant and were adjusted to that 
of phosphate (0.466 M) with KCI when necessary. The reaction mixture was 
equilibrated in the cuvette at 10 °C whilst mixing. Following equilibration, the 
reaction was started by addition of 150 tL of 150 LM albumin, at 10 °C. The reactions 
were performed at 10 °C in order to slow down the reaction rate as it was found that 
the rates at room temperature were extremely fast and difficult to measure accurately. 
All reactions were carried out in 1 cm pathlength cells with stirring and were followed 
by the change in absorbance at 412 nm on a Cary 300 Scan spectrophotometer fitted 
with a Peltier dual cell temperature controller. The thiol contents of the proteins were 
calculated as described in Section 2.3 and were 0.68, 0.80, 0.63 and 0.63 mol mol' for 
rHA, fatty rHA, His39Leu and Tyr 84Phe albumins, respectively. 
42.3 Results and Discussion 
Mass spectometric analysis, following the reaction of rHA with DTNB, detected a 
peak of 66643 mass units (Figure 4.5). This is consistent with the formation of the 
albumin-TNB mixed disulfide, which has a theoretical mass of 66645 mass units. 
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Figure 4.5 Mass spectrum of rHA following incubation with 40 mol equiv of 
DTNB. Reaction was carried out in 100 mM potassium phosphate, pH 8.0. The 
theoretical mass of the albumin-TNB mixed disulfide is 66645 mass units. 
The reactions of DTNB with rHA, rHA in the presence of 10 mol mol-1 octanoate and 
with His39Leu and Tyr 84Phe albumin mutants were carried out at a range of pH values 
(pH 6.0-10.2) at 10 °C. 
The reaction between bovine albumin and DTNB has previously been shown to follow 
second order kinetics [15]. The general second-order rate law for 1:1 stoichiometry is 
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where [I] = albumin thiol concentration, [II] = DTNB concentration, k2 = second order 
rate constant and t = time. 
Equation 4.4 approaches a limiting case if reactant II is in excess, then 
—d[I] = kt[I] 
dt 
where k1 = pseudo-first order rate constant (= k[II]). Integration yields: 
ki= 
2.303 log— [J]O 
t 	[I] 
[4.6] 
where [1]0  = initial albumin thiol concentration. 
A plot of log([I]°/[I]) against time gives a straight line with a slope equal to k1. In all 
cases the albumins were reacted with high excess of DTNB (100:1), and were treated 
with the assumption of pseudo-first order kinetics. Appendix 1 shows the increase in 
absorbance at 412 nm with time and a plot of log([I]°/[I]) vs time. 
The pseudo-first order rate constants for the reaction between DTNB and the wildtype, 
fatty-acid-bound and mutant albumins increased with pH and are tabulated in Table 
4.3 and plotted in Figure 4.6. 
[4.5] 
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His39Leu Tyr 84Phe 
6.0 8.0x10 4 1.0x10 3  0 2.9x10 3  
6.2 9.0x10 4 1.2x10 3  0 4.0x10 3  
6.6 2.5x10 3  3.0x10 3  5.0x10 4 9.4x10 3  
7.0 5.5x10 3 6.0x10 3  1.8x10 3  2.2x10 2 
7.2 7.8x10 3  9.7x10 3  3.7x10 3  2.8x10 2 
7.5 1.1x10 2 1.5x10 2 7.4x10 3  5.0x10 2 
8.0 2.2 x 102 2.7 x 10 2 1.6 x 102 1.5 x 10' 
8.4 5.0x10 2 5.8x10 2 7.4x10 2 1.0 
8.8 5.2 x 102 5.8 x 102 1.4 x 10' 6.5 
9.1 5.6x10 2 5.9x10 2 1.7x 101 8.2 
9.5 6.1x10 2 5.3x10 2 1.9x101  9.7 
10.2 6.4x 102 9.2x 102 1.9x 101 10.8 
Table 4.3 Effect of pH on the pseudo-first order rate constant for the reaction 
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5.0 	6.0 	7.0 	8.0 	9.0 	10.0 	11.0 
pH 
Figure 4.6 Effect of pH on the pseudo-first order rate constant for the reaction 
between DTNB and . MA (low octanoate), o high octanoate MA, • Tyr 84Phe 
and ü His39Leu. Non-logarithmic plots of the data are shown in Appendix 2. 
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The rate constants for the reaction of wild-type albumin with DTNB followed a 
similar trend to those observed by Pedersen and Jacobsen [12] in their kinetic study of 
the reaction of albumin with the uncharged DTDP molecule. The reactivity of Cys34 
appears to rise steadily for all albumins between pH 6 and 8. The Tyr 84Phe mutation 
was found to have a marked effect on the reactivity of Cys34. Over this pH range the 
rate of reaction is approximately 4 times greater for the Tyr 84Phe mutant than for the 
wild-type protein. At pH 6, the His 39Leu mutant reacts with DTNB much slower than 
the wild-type protein but has a similar rate constant at pH 8. Between pH 8 and 8.5 
there is a larger increase in reactivity for each of the albumins. This is most 
pronounced for the Tyr 84Phe mutant. Cys34 reactivity in wild-type albumin appears to 
reach a maximum at around pH 8.4, whilst significant increases in Cys34 reactivity in 
the His39Leu and Tyr 84Phe mutants are observed at pH values up to 9. At pH 10.2 the 
reaction is 3 times faster with the His39Leu mutant and 170 times faster with the 
Tyr 84Phe mutant with the compared with that of the wild-type protein. 
The binding of excess octanoate to albumin appeared to have very little effect on Cys34 
reactivity. The rate constants for octanoate-bound albumin were generally slightly 
higher than that of rHA. This however, could be attributed to the higher thiol content 
of the octanoate-bound protein used in these experiments (0.80 mol mol' compared 
with 0.68 mol mol-1). The rHA used in this study was dialysed prior to use and may 
still have contained as much as 4 mol mol-1 of octanoate, although it is not thought that 
this is a high enough level of fatty acid to affect the conformation of domain I 
dramatically. Fatty acid molecules bound to dialysed rHA were found not to perturb 
metal binding at a site on the interface of domains I and II, although 10 mol mol-1  
octanoate did (see Section 5.2.7). Conformation changes affecting both the metal 
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binding site (Section 5.2.7) and the Cys34 site appear to be caused by fatty acid binding 
at so-called site 2 [20]. 
The rate of the reaction between albumin and DTNB is dependent upon a number of 
factors. First it depends upon the accessibility of the Cys34 sulfur to the DTNB. 
Secondly, the rate also depends upon the ionisation of the thiol. The thiolate anion is 
more reactive than the protonated thiol [12]. This is because the thiolate anion carries 
a negative charge and is therefore more likely to participate in nucleophilic attack. 
The rate also depends upon the environment of Cys34. The charge distribution of 
nearby side-chains will influence the reaction rate; this in turn depends upon the 3-
dimensional structure around the site. 
The increase in activity of the albumins between pH 6 and 8 is probably due to the 
change in ionisation of the Cys34 sulfur and/or nearby residues. Albumin undergoes a 
structural transition at pH 8 from the N to B state (as discussed in Section 1.2.2). This 
transition is characterised by a 10% loss in the helical content of the protein [25] and 
may account for the steep rise in activity between pH 8 and 8.5. At high pH, the 
activity reaches a maximum for each of the albumins. Wildtype albumin reactivity 
appears to have reached its maximum around pH 8.4, while for both mutants the pH 
value of maximum activity is >9. This could mean that the pKa of the free thiol is 
higher in both mutants than for the wild-type protein and that both His 39  and Tyr 84 
contribute in stabilising the thiolate anion. The structure of albumin is extremely 
flexible and it is possible that both residues could be involved in H-bonding to the 
Cys34 sulfur as shown in Figure 4.7. Likewise it is also possible that the effect on 
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reactivity is a consequence of the mutations changing the ionisable groups around 
Cys 34  
Analysis of the crystal structures of unliganded albumin (all structures are summarised 
in Table 1.2) shows that accessibility to the Cys34  thiol is partially restricted by 3 
residues, Asp38, Va177 and Tyr84  (Figure 4.3). This at least partially explains why the 
DTINB reaction occurs so much faster with the Tyr84Phe mutant than with the wildtype 
protein. Mutation of tyrosine to a phenylalanine removes the oxygen atom partially 
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Figure 4.7 Possible H-bonding scheme for stabilisation of Cys34 thiolate. 
The lowered reactivity toward the His39Leu mutant at pH is < 8 may be due to a steric 
effect. The substitution of histidine by leucine could mean that Cys34 becomes more 
buried. Also there may be a change in the ionisation of the thiol over this pH range. 
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The data presented here suggest that Tyr 84  plays a major role in determining the 
reactivity of Cys34 towards the disulfide DTNB. At pH values between 6 and 8 the 
Tyr 84Phe mutant is Ca. 4 times more reactive, and at pH 10.2 is 170 times more 
reactive. This can be explained by the existence of strong H-bonding between the 
Tyr 84  OH group and the deprotonated Cys34 thiolate. The rate of reaction of both 
wildtype and mutant proteins studied here is highly sensitive to pH in the 
physiologically relevant range of pH 6 to 8. The pH control of Cys34 may therefore be 
important in vivo. 
These findings show that His 39  and Tyr 84  play a role in controlling reactivity of DTNB 
at Cys34. This has a number of implications, as it may be possible to synthesise mutant 
albumins, which have faster or slower reaction rates at this site. Such proteins could 
be useful for scavenging reactive oxygen species or could be administered to increase 
the efficacy of Cys34-specific therapeutics. 
4.3 Peroxidase Activity of Albumin 
4.3.1 Production and Physiological Importance of 
Hydrogen Peroxide 
Hydrogen peroxide (11202) is a product of many enzyme-catalysed reactions in the 
body. In particular, enzymes which break down certain amino acids and fatty acids 
such as D-amino acid oxidase [26] and acyl-CoA oxidase [27] make significant 
amounts of hydrogen peroxide. Hydrogen peroxide can form hydroxyl radicals that 
are damaging to normal tissue, and so these enzymes are kept inside specialised 
organelles in the cells called peroxisomes. The peroxisomes contain large amounts of 
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catalase to break down the hydrogen peroxide before it can escape [28]. Other 
enzymes that make significant amounts of hydrogen peroxide are plasma amine 
oxidase [29] and xanthine oxidase [30]. These reactions do not produce hydrogen 
peroxide directly, but rather superoxide (02). In order to get rid of superoxide, the 
body also contains superoxide dismutase, an enzyme that converts 02 into H202 and 
H20 [27]. 
Another interesting source of superoxide and peroxide (as well as other harmful 
oxygen species) in the body, is that produced by leukocytes (white blood cells) when 
they encounter harmful microorganisms. The leukocytes produce large amounts of 
superoxide, hydrogen peroxide, singlet oxygen (1 02) and hypochiorite (OCF) in order 
to kill pathogenic bacteria [31]. 
Sulfur-containing amino acids in proteins have previously been shown to have 
hydrogen peroxide destroying activities [32]. The Cys34 residue of serum albumin has 
previously been implicated in the sequestration of hydrogen peroxide in blood [33]. 
Albumin has also been shown to catalyse the reaction between tert-butyl 
hydroperoxide and 2-nitro-5-mercaptobenzoic acid [34]. A study by Finch and 
colleagues identified 6 modified sites on the albumin molecule following treatment 
with hydrogen peroxide using peptide mapping [35]. They found that Cys34, Met123, 
Met"', Met446 and Met548 residues were modified to sulfoxides. 
In order to confirm these sites of modification, the experiment was repeated using a 
similar method. It was hoped however, that some extra sites would be identified by 
using a higher-resolving HPLC method (described in Section 3.5.2.2). The better the 
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separation of the tryptic fragments on the column, the easier it is to identify changes in 
peak pattern from the chromatogram and to isolate the fragments for amino acid 
sequencing and mass spectrometric analysis. 
4.32 Experimental 
Recombinant human albumin, rHA (2.5 mL of a 0.3 mM solution) was incubated at 
room temperature for 60 mm, following addition of 50 pJ of 10% (v/v) H202. A 
control rHA solution was also set up as above but with the addition of 50 tL of H20 
instead of H202. Prior to digestion, samples were desalted using solid phase extraction 
(SPE), employing mobile phase flow through cartridges (1ST 25mg, 1000A) under 
vacuum. Protein samples were loaded and eluted using 70% acetonitrile in 0.2% 
formic acid. Both samples were digested with trypsin as decribed in Section 3.5.2.1 
and tryptic fragments were separated by HPLC as described in Section 3.5.2.2. Seven 
peaks from the H202-treated albumin digest were collected, which corresponded to 
new peaks not present in the control, as indicated in Figure 4.8. These fractions were 
identified by amino acid sequencing as described in Section 3.5.2.3 and analysed by 
mass spectrometry as described in Section 2.5. 
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Figure 4.8 HPLC chromatograms of control (above) and H202-treated (below) 
tryptic peptides. The seven peaks collected from the H202-treated albumin digest are 
numbered (1-7). 
4.3.3 Results and Discussion 
Amino acid sequences from the seven peaks are shown in Table 4.4. The fraction 
containing peak 5 did not give good sequence data and so this peptide could not be 
identified. Peak 7 was found to correspond to the peptide containing Cys34. Of the 
other six peaks, four were found to correspond to methionine-containing peptides. 
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Peak 3 corresponds to a peptide containing neither a cysteine or methionine residue. 
Mass spectrometry data for the six sequenced peaks are summarised in Table 4.4. 






1 ETYGEMADCCAK 82-93 1320.5 None detectable 
2 LVRPEVDVMCTAFHDNEETFLK 115-136 2594.0 2791.5 
3 HPDYSVVLLLR 338-348 1311.6 1466.4 
4 SHCIAEVENDEMPADLPSLAADFVESK 287-313 2918.2 3487.8 
6 DVFLGMFLYEYAR 324-336 1623.9 1637.8 
7 ALVLIAFAQYLQQCPFEDHVK 21-41 2433.9 2516.7 
Table 4.4 Summary of sequencing and mass spectrometry results. Amino acid 
sequences and the corresponding albumin residue numbers for the six sequenced 
peaks. Also theoretical and measured masses for the six peaks are compared. 
With the exception of peak 1 for which no mass was detected, mass spectrometry 
reveals large differences between the theoretical and measured masses, suggesting that 
peroxide-induced modifications had taken place. As previously mentioned, hydrogen 
peroxide is a strong oxidising agent and has been shown to target the sulfur-containing 
amino acids of albumin [36]. Cysteine can be oxidised to sulfenic (RSOH), sulfinic 
(RS02H) or sulfonic (RS03H) acids. Whilst methionine, can be oxidised to a 
sulfoxide (RSOCH3) or sulfone (RS02CH3). These oxidised derivatives are shown in 
Figure 4.9. 
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Figure 4.9 Oxidised derivatives of cysteine and methionine. 
The mass increase of peak 6 is 13.9 mass units and is consistent, within error, of 
methionine oxidation to methionine sulfoxide. The mass increases of peaks 2, 3, 4 and 
7 are too large to be attributed to a single modification. The increases of peaks 2 and 4 
could partially be due to missed cleavage sites on the protein. Peroxide modifications 
on the protein could cause trypsin to fail in cleaving the peptide bond. Peaks 2 and 4 
have mass differences of 197.5 and 569.6 mass units respectively. If tryptic cleavage 
failed to occur at Lys 136  then peak 2 would carry the extra lysine, Lys137 which would 
correspond to an increase in 147.2 mass units. Likewise, if tryptic cleavage failed to 
occur at Lys313  then the peptide corresponding to peak 4 would carry the extra amino 
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acids Asp314, Va1315, Cys316 and Lys317 in its chain, corresponding to an increase in 
521.6 mass units. 
Further modifications may be attributed to radical-induced damage. Hydrogen 
peroxide can form hydroxyl radicals in the presence of trace amounts of metal ions 
such as copper [36] which the albumin solutions may have contained. It has been 
demonstrated that under certain circumstances an electron-transfer mechanism may 
exist, leading to the transfer of the radical species from the initial site of damage to 
amino acids located elsewhere in the protein and in particular to tyrosine, tryptophan 
and cysteine residues [37]. These result in the generation of phenoxyl, tryptophanyl 
and thiyl radicals, respectively. 
Davies and colleagues investigated the effects of peroxide-derived radical-damage to 
bovine albumin using EPR spin trapping [38]. They found that when hydroxyl 
radicals react with bovine albumin, damage can be transferred from the thiol group of 
Cys34 to carbon sites on the protein. Under the same conditions, blocking of the free 
thiol group markedly reduces the number of carbon-centred radicals. This process is 
represented in Figure 4.10. It has shown that free radical-induced damage of proteins 
can lead to a range of non-sulfur site protein modifications. For example, carbonyl 
derivatives of some amino acid residues are formed. Proline and arginine residues can 
be converted to glutamylsemialdehyde residues, lysine residues to 2-amino-
adipylsemialdehyde residues, histidine residues can be converted to asparagine and/or 
aspartyl residues, whilst proline residues can be converted to glutamyl or pyroglutamyl 
residues [39]. Additionally, radicals are also known to induce crosslinking between 
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induced damage from Cys34 to other sites on the molecule could explain the large mass 
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Figure 4.10 The thiol-dependent transfer of radical species to carbon sites. 
Radicals can be transferred from the thiol (or other initial site of damage) to both 
backbone and side-chain carbons. Modified from ref [38]. 
It should be noted that two of the four methionine residues (Met"' and Met298) found 
within the sequenced peptides, were previously implicated as sites of modification by 
Finch et al. [35]. The other two (Met 87  and Met329) are potentially previously 
unidentified sites of modification. Analysis of the crystal structure of albumin [23] 
revealed that all four of the methionine residues highlighted in this study (as well as 
Cys34) would be easily accessible to oxidation. The locations of these residues on the 
albumin molecule are shown in Figure 4.11. 
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Figure 4.11 Sulfur-containing residues implicated as sites for hydroxyl radical-
induced modifications. Drawn from PDB 1A06 [23]. 
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4.4 Reactions of Nitric Oxide with Low- 
Molecular Weight Thiols and Albumin 
4.4.1 Generation of Nitric Oxide and its Physiological 
Importance 
Nitric oxide (NO) is a key endogenous mediator in the cardiovascular system. 
Synthesised by nitric oxide synthase in the vascular endothelium from L-arginine [41], 
NO is associated with vasodilatory and antiplatelet bioactivities (Figure 4.12), as well 
as being a regulator of epithelial permeability. NO is also thought to be involved in 
smooth muscle cell relaxation and mitogenesis [42]. It is thought that these properties 
occur through the activation of guanylate cyclase, a haem-containing heterodimeric 
enzyme which catalyses the synthesis of cyclic GMP from GTP (Equation 4.7). NO 
has a high affinity for Fe 
2+ 
 and activates the enzyme by binding to the iron centre in 
the haem moiety. 
GTP 	10 cyclic GMP + PPi 	[4.7] 
Inhibition of cGMP phosphodiesterase has been shown to down-regulate platelet 
adhesion [43]. There is also evidence to suggest that cyclic GMP is involved in 
regulating cervical epithelial permeability [44]. 
NO concentrations in the circulatory system are quite low due to scavenging by 
haemoglobin [45]. However, NO has also been shown to bind to the free thiol group 
in albumin in vitro [46] and is thought to exist primarily in the circulatory system as an 
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S-nitroso adduct of serum albumin [47]. S-nitrosoalbumin has been shown to have the 
vasodilatory [48] and antiplatelet [49] properties associated with NO. These results 
suggest that albumin may provide a means for delivery of nitric oxide to the haem 
centre of guanylate cyclase. 





Smooth muscle cell toge:flesis 
Figure 4.12 Synthesis of nitric oxide (NO) from L-arginine (L-Arg) by 
endothelial nitric oxide synthase (eNOS) and effects on vascular smooth muscle 
cells, platelets and monocytes. Taken from Ref: [42]. 
Additionally, smaller S-nitrosothiol compounds are easily prepared in solution which 
can spontaneously decompose producing NO [50]. Although these compounds are 
generally unstable in solution, the most stable appears to be 
S-nitroso-N-acetyl-penicillamine (SNAP) [51]. SNAP has been shown have similar 
properties to S-nitrosoalbumin being both a vasodilator [52] and able to prevent 
platelet aggregation [53]. 
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The decomposition of S-nitrosothiols has been shown to be catalysed by trace amounts 
Of Cu2 (ca. < 10 tM) in solution [54]. In vivo, decomposition may also be accelerated 
by direct transfer of NO to reduced tissue thiols (transnitrosation) [55-58] to form 
unstable intermediates like S-nitrosocysteine or S-nitrosoglutathione, or via interaction 
with ascorbate [59,60] or even 02  [61]. The enzyme y-glutamyl transpeptidase 
('y-GT), has been shown to be involved in the decomposition of S-nitrosoglutathione 
(GSNO) [62]. Potential mechanisms of NO generation from this class of compound 
are shown in Figure 4.13. 
Cu" hv enzymes? 
, 
2 RSNO 	 RS-SR + 2N0 
2 RSNO + 2CysSH 	RS-SR + 2N0 _fast Cys-Cys + 2N0 
y-GT 	 ____ 2 GSNO 	 2 Glu +2 Gly-Cys-NO fast 2 NO + Gly-Cys-Cys-Gly 
Figure 4.13 Potential mechanisms of NO generation from RSNO compounds. 
Taken from Ref: [42]. 
In order to determine the role thiols (particularly albumin) play in the delivery of NO 
to enzymes such as guanylate cyclase, thiol nitrosation of albumin and the low-
molecular weight thiol compound, N-acetyl-L-cysteine were investigated. Studies 
were also carried out in order to elucidate whether transnitrosation can take place 
between low-molecular weight thiols and albumin. 
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4.4.2 S-Nitrosation Reactions of Albumin and low-
molecular weight thiols 
The technique of 'H NMR spectroscopy was adopted to monitor the nitrosation of the 
low-molecular weight thiols, N-acetyl-L-cysteine (NAC) and glutathione (GSH) but 
not albumin due to the strong 'H background signal that is present for large proteins. 
The nitrosation reaction utilised sodium nitrite as a source of NO (see Equation 4.8) at 
low pH (< PH 4) [63]. 
RSH + NaNO2 + H 	10 RSNO + H20 +Na 	[4.8] 
Also '5N NMR spectroscopy, using '5N-labelled sodium nitrite and mass spectrometric 
methods, were adopted to investigate nitrosation of low-molecular weight thiols and 
albumin and nitro so-interchange between the low molecular weight thiols S-
nitrosoglutathione (GSNO) and S-nitroso-acetyl-penicillamine (SNAP) with albumin. 
Both GSNO and SNAP are known to have NO-donor properties [56]. 
4.4.2.1 Experimental 
1H NMR Studies 
'H-NMR studies on N-acetyl-L-cysteine (Sigma) and GSH (Sigma) were carried out 
using 10 mM solutions of the thiol (or cystine) with 100 mM NaNO2 (BDH) in D20. 
The pH*  was adjusted to 3 by drop-wise addition of Dcl. pH*  denotes a pH meter 
reading for a D20 solution. 'H NMR spectra of NAG and GSH were recorded before 
and after addition of NaNO2. A 'H NMR spectrum of oxidised cysteine (cystine) was 
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also recorded under the same conditions in order to ascertain whether NO catalysed 
the formation of the disulfide. 
1D 'H NMR spectra (500.13 MHz, Bruker DMX500) were acquired using a 5 mm 
TBI probe. Spectra were acquired over a sweep width of 20 ppm into 16 k complex 
data points, with a pulse width of 8.0 .is (90 0)  64 k transients, an acquisition time of 
0.82 s and a recycle delay of 3 s. Prior to Fourier transformation, the FID was 
apodised by exponential multiplication (0.3 Hz line broadening). 
15N NMR Studies 
1 H-NMR studies on NAC, GSH and rHA were carried out using 100 mM solutions of 
NAC or GSH (2 mM with rHA) with 10 mol equiv '5N-labelled NaNO2 (99% isotopic 
purity, Aldrich) in 10% D20, 90% H20. A spectrum was also recorded of 100 mM 
'5N-labelled NaNO2 under the same conditions. The pH*  was adjusted to 3 by drop-
wise addition of HCI. '5N NMR spectra were recorded after addition of NaNO2. 
1D '5N NMR spectra (50.71 MHz, Bruker DMX500) were acquired using a 5 mm TBI 
probe. Spectra were acquired over a sweep width of 200 ppm into 64 k complex data 
points, with a pulse width of 40.0 ps (90 0)  64 k transients, an acquisition time of 3.20 
s and a recycle delay of 1 s. Prior to Fourier transformation, the FID was apodised by 
exponential multiplication (25 Hz line broadening). 
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Mass Spectrometry 
Recombinant human albumin (150 tM) was nitrosylated by addition of 1.5 mM 
NaNO2 in H20. The pH was adjusted to 3 by drop-wise addition of HC1. The sample 
was stored at —20 °C for 48 h. The sample was thawed and mass spectrum was 
recorded as described in Section 2.5. Also 15 pM of wildtype, His39Leu and 
Tyr84Phe rHAs were reacted with 1 mol equiv of either S-nitrosoglutathione (GSNO) 
or S-nitroso-N-acetylpenicillamine (SNAP) (both purchased from Sigma) in 50 mM 
phosphate buffer, pH 7.5. Mass spectra were recorded following addition of S-
nitrosothiol as described in Section 2.5. 
4.4.22 Results and Discussion 
'H NMR spectra of NAC (Figure 4.14a) and GSH (Figure 4.14b) before and after 








1 	H2 	H2 	11 	 11 	H 	 11 
NH2 	 H2C 	 H 
SH (b) glutathione 
Figure 4.14 Structures of (a) N-acetyl-L-cysteine, NAC and (b) glutathione, GSH. 
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In the spectrum of NAC and GSH the PCH2 protons give a multiplet signal at 2.90 
ppm (shown in Figure 4.15 by the blue box). Following the addition of NaNO2 to the 
NAC and GSH samples, two new broad signals appeared at 4.10 and 4.25 ppm (shown 
by the red box). These peaks are likely to be caused by a change in the environment of 
the PCH2  protons, which would be consistent with nitrosation of the thiol group. 
Similarly, two doublets of doublets appeared at 3.05 and 3.40 ppm (shown by the 
green box). These signals are also present in the cystine spectrum suggesting that 
oxidation of the thiols of NAC and GSH to a disulfide occurs. 
N-acetyl CH. 
NAC 
NAC + NaNO2 
GSH 
GSH + NaNO2 
I3CH2 cystine () cysti n  
4.5 	4.0 3.5 3.0 2.5 2.0 ppm 
Figure 4.15 ifi  NMR spectra of (a) NAC, (b) NAC + NaNO2, (c) GSH, (d) GSH + 
NaNO2 and (e) cystine. 
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15N NMR spectra of NAC, GSH and albumin before and after addition of 15N-labelled-
NaNO2 and of 100 m 15N-labelled-NaNO2 are shown in Figure 4.16. Both NAC and 
GSH in the presence of NaNO2 gave rise to two peaks, a sharp peak around 580 ppm 
and a broader peak at around 745 ppm. These peaks correspond to free acidified NO 2 
(see Figure 4.16c) [45,65] and the S-nitrosothiol compound respectively [66]. 
Unfortunately no peaks could be seen on the spectrum of albumin in the presence of 
NaNO2. The detection of '5N with albumin is most likely to be limited by the low 
concentration of the protein. This means that '5N NMR is not suitable for 
investigating nitrosylation reactions with albumin under the conditions described here, 
in contrast to previous findings [46]. 
: 
:
(a) NAC + 1 
T: ONa
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(d) MA + 10 NaNO2 
760 740 720 700 680 660 640 620 600 ppm 
Figure 4.16 '5N NMR spectra of (a) NAC + 10 NaNO2, (b) GSH + 10 NaNO2, (c) 
100 mM NaNO2 and (d) MA + 10 NaNO2. 
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Nitrosylation of albumin was however detectable by mass spectrometry. Figure 4.17 
shows an ESI-mass spectrum of rHA following the addition of acidified NO2 . The 
spectrum shows that not all the albumin present has nitric oxide bound. This is most 
likely to be due to degeneration of the nitric oxide species, as the NO groups in S-
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Figure 4.17 ESI-mass spectrum of MA following the addition of acidified NO 2. 
Theoretical masses of MA and rHA-NO are 66438 and 66467 respectively. 
The transfer of nitric oxide from the low-molecular weight S-nitrosothiols, GSNO and 
SNAP to albumin and the His39Leu and Tyr 84Phe mutants were also investigated using 
mass spectrometry (Figure 4.18). Nitrosylation of albumin thiol leads to a mass 
increase of 29 Da. Such an increase can only be seen in the Tyr 84Phe mutant on 
addition of SNAP, the smaller of the two S-nitrosothiols (GSNO and SNAP have 
molecular masses of 336.3 and 220.2 Da respectively). As discussed in Section 4.1 
Tyr 84  is extremely critical in controlling the reactivity of the Cys34 thiol. Hence 
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DTNB reacts at the Cys34 thiol of the Tyr 84Phe mutant at a far greater rate than 
wildtype. These data do not demonstrate that the transfer of NO from S-
nitrosoglutathione or S-nitroso-N-acetyl-penicillamine to native albumin occurs. 
Figure 4.18 ESI-mass spectra of MA and the His39Leu and Tyr 84Phe mutant 
albumins following the addition of GSNO or SNAP. Nitrosylation of albumin thiol 
would lead to a mass increase of 29 amu. 
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4.5 Conclusions 
The disulfide exchange reaction between Cys34 and DTNB was studied over a range of 
pH values (pH 6.0-10.2) for native rHA, octanoate-rHA and His 39Leu and Tyr 84Phe 
mutants. A large increase in reactivity toward DTNB was observed for the albumin 
mutant Tyr 84Phe, over this pH range. Tyr 84  is therefore important in the control of 
Cys34 reactivity. Wildtype albumin appears to become fully deprotonated around pH 
8.4, whilst the His39Leu and Tyr 84Phe mutants become fully deprotonated around pH 
9.1. This suggests that the pKa of the free thiol may be higher in both mutants than in 
the wildtype protein and that both His 39  and Tyr 84  contribute to the stabilisation of the 
thiolate. Elevated fatty acid levels had no effect on significant effect on Cys34 
reactivity. 
Albumin is a physiologically important antioxidant. Reactions of albumin with H202 
and NO have been studied. Peptide mapping studies of albumin following reaction 
with H202, revealed that the residues Cys34, Met123, Met298 Met" and Met329 are 
potentially sites of peroxide-induced modification. 'H and 15N NMR studies are 
shown to be useful techniques in the study of the S-nitrosylation reactions between 
low-molecular weight thiols and acidified '5N-labelled NaNO2 but were unsuccessful 
in detecting S-nitrosylation of albumin. Mass spectrometry was found to be a suitable 
technique in the study of albumin-NO reactions. However, no transfer of NO from the 
low-molecular weight S-nitrosothiols, GSNO or SNAP to native albumin was 
observed for the conditions described. 
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Chapter 5 
Interactions of Metals with Albumin 
5.1 Introduction 
About 25 chemical elements are thought to be essential for mammalian life, 15 of these 
elements are metals. These metals perform a wide range of important physiological 
functions within the body including the maintenance of ionic gradients, the carrying of 
oxygen in the blood as well as playing key roles at the active sites of many enzymes. 
These are summarised in Table 5.1. In addition to these essential metal elements, a 
variety of metallodrugs, metal-containing therapeutics and diagnostic agents are 
commonly used in modern medicine (Table 5.2). Albumin is known to transport metal 
ions and metallodrugs in the circulatory system [1] and the binding of these to the protein 
has been well studied. 
5.1.1 Metal Ion Binding 
Perhaps the most notable example of metal ion binding to albumin is that of Cu2 and 
Ni2 at the N-terminus. These metals bind more specifically and more tightly to albumin 
than other metals [1]. Cu 2+  and Ni2 N-terminal binding is discussed in Section 1.3.5. 
Calcium and magnesium are also known to bind to albumin. The first study of Ca 2+  ion 
binding to albumin was carried out in 1934 [2]. Albumin binds 1-2 Ca 2+  ions per 
molecule and although the interaction is relatively weak (Ka = 1.5 x iO3 M' [3]) it is 
highly significant from a physiological and clinical standpoint. 
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Non-Metals Metals 
H, C, N, 0, F, Si, P, S, Cl, Se and I Na, Mg, K, Ca, V, (Cr,) Mn, Fe, Co, Ni, 
Cu, Zn, Mo and Sri 
Table 5.1 The elements thought to be essential for mammals. Source: ref [4]. 
Chromium is shown in brackets as there are conflicting views on whether it is an 
essential element [5-7]. 
Therapeutic/Diagnostic Agent Metals Used 
radiopharmaceuticals 991nTc and 186  Re 
diagnostic agents MRI (e.g. Gd, Mn) 
X-ray (e.g. Ba) 
anti-infective agents Ag, Sb and Fe 
superoxide dismutase mimics Mn and Fe 
cardiovascular therapeutics Fe and Ru 
insulin mimetics V and Cr 
photodynamic therapeutics Sri and Lu 
anti-cancer agents Pt and Ru 
anti-arthritic drugs Au 
anti-ulcer drugs Bi 
Table 5.2 Some metals and their use in medicine. Source: ref [8]. 
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It is thought that 45% of the 2.4 mM of circulating calcium is free, another 45% is 
albumin bound, whilst 10% is complexed to small molecules such as citrate and 
phosphate [1]. Magnesium is bound to albumin with less affinity than calcium (Ka = 1 X 
102 M-1 [9]). Also the concentration of magnesium is about half that of calcium, and 
again about 45% is bound by proteins. The binding of magnesium to albumin has 
received very little attention but is thought to parallel calcium in terms of binding site [1]. 
Another essential metal in the body is zinc present in plasma at a concentration of 
approximately 19 tiM. Zinc is present in over 300 enzymes, including alcohol 
dehydrogenase and a number of alkaline phosphatases. Zinc binds to albumin with an 
association constant of 3.4 x 107 M1  [3]. Around 65% of zinc present in plasma is 
loosely bound to albumin [10] and albumin has been shown to modulate the uptake of 
zinc into endothelial cells [11]. 
It has been shown that 1.08 mol Zn2 and 2.08 mol Cd 2+ bind per mol albumin [9]. 
Although, Zn 2+  and Cd 2+  sites are uncharacterised, 113  Cd NMR studies have revealed that 
zinc competes with cadmium at one site. The 113  Cd chemical shift suggests that this site 
contains 2-3 histidine residues. The other cadmium site is thought to be composed 
mainly of oxygen atoms [12]. Viles and Sadler have shown that both these cadmium 
sites are conserved in several mammalian albumins with similar 113  Cd chemical shifts for 
human, bovine, murine, canine, sheep and equine albumins [13]. Although cobalt 
concentrations in blood plasma are less than 0.01 jiM, it is an important component of 
vitamin B12 and is often used as a probe for Zn2t Several studies have investigated 
2+ 	 3 cobalt-albumin binding. Co has been found to bind to albumin (Ka = 6.5 X 10 M 
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[14]) and has 3 principal binding sites [15]. 'H NMR perturbations in the presence of 
CO2 are consistent with binding at the N-terminal copper-nickel site [16]. 
A13 	and Mn 2+  ions also bind to albumin but have a much stronger affinity toward serum 
transferrin [1,17]. Normally A13 concentration in plasma is less than 0.4 jiM but can 
increase to as much as 5 jiM in patients on renal dialysis. In such extreme cases as much 
as 34% of A13 has been shown to be albumin bound [18]. The Ka for Mn 2+  binding to 
albumin is 2.4 x 104 M' [19]; only about 5% of added 54  Mn has been found to be 
associated with albumin in plasma. Additionally Hg2 has been shown to bind at Cys34 
and reportedly is able to link single albumin thiols forming dimers [20]. 
5.1.2 Metallodrug Binding 
A variety of metallodrugs rely on albumin to carry them through the circulatory system to 
their target site(s). Perhaps the longest-established of these compounds are the Au(I) 
thiolates used in the treatment of rheumatoid arthritis [21]. Early in the last century gold 
complexes were used in the treatment of tuberculosis. In 1929, a French physician noted 
that these compounds had a greater efficacy in the treatment of arthritis [22]. These early 
therapeutics were soon abandoned due to their serious toxicity and were replaced by 
cortisone as the preferred treatment. Cortisone itself had serious side effects and with the 
advent of available atomic absorption spectroscopy to monitor serum gold levels, gold 
therapies began resurgence in the 1970s [21]. 
Perhaps the most notable of these therapies are the anti-arthritic drugs, auranofin, 
myochrysine and solganol. The structures of these 3 drugs are shown in Figure 5.1, the 
latter two form gold(I)-sulfur oligomers. Auranofin by contrast is a well-defined 
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monomeric complex with triethyiphosphine (Et3P) and 2,3,4,6-tetra-0-acetyI-3-1-D-
thioglucose (Atg) ligands. The mode of action of these drugs still remains unknown, 
mainly because ligand exchange reactions at Au(I) occur rapidly [23]. The Cys34 residue 
of albumin has been shown to be the preferred binding site for auranofin, forming a 
triethyl phosphine Au(I) adduct at the cysteinyl sulfur (see Reaction 5.1) [23]. 
A1bSH + Et3PAuSAtg -* A1bSAuPEt3 + HSAtg (5.1) 
The Au(I)-sulfur oligomeric complexes, myochrysine and solganol, are also thought to 
bind at Cys34. None of these three drugs undergo ligand exchange reactions with 
methionines or disulfide bridges in proteins in the body, although auranofin has been 
shown to react with albumin disulfide bridges in vitro if the drug is in excess [23]. 
Competition studies have eliminated the possibility of the drug binding at sites I and II 
[21] 
Albumin also plays an important role in the metabolism of the platinum anti-cancer drug 
cisplatin (cis-[PtC12(NH3)2]). Cisplatin is used extensively for the treatment of ovarian 
and testicular cancers as well as a variety of solid tumours [24]. The cytotoxic effect of 
this drug is due to attack on DNA bases following hydrolysis of the complex, inducing 
apoptosis within cancer cells [25]. Albumin's importance in the efficacy of these drugs 
has been highlighted by a number of studies. Hypoalbuminaemic patients have shown 
poor response to cisplatin treatment [26]. Whilst the administration of preformed 
albumin-cisplatin complexes has shown cytotoxicity, increasing patient survival time 
[27] 
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CH2OAc 

















myochrysine 	 solganol 
Figure 5.1 Three clinically used anti-arthritic gold(I) complexes. Note that 
myochrysine and solganol form oligomeric chains through their bridging thiolate sulfurs. 
'5N NMR studies of the reaction between '5N-labelled cisplatin and Cys, Met and His 
modified albumins have revealed that the major cisplatin binding sites on the protein 
involve methionine residues. Binding was also detected at Cys34, and at a site involving 
a nitrogen ligand, in the form of an S, N macrochelate. In the later stages of reaction the 
release of NH3 was found to occur due to the strong trans influence of the Met sulfur, 
weakening the Pt-NH3 bonds. Protein cross-linking through platinum was also observed 
[24]. These reactions are represented in Figure 5.2. 
151 
Chapter 5 	 Interactions of Metals with Albumin 
H3NN ,Cl Hydrolysis H3 	OH  
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H3N"  Cl 
H3N 	,SCys34 
Pt 
H3N" 	CI N"3 loss 
- Cl 	+ N ligand 	 + MA 
H3NN% Smet 
Pt 
H3V N--'N J 
NH3 loss 
	rHA cross-linking 
Figure 5.2 Reactions of cisplatin with albumin. Modified from ref [24]. 
H3N% //  ri-IA 
rHA7  Pt C1 
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5.2 Identification of a Binding Site on Human 
Albumin for Zinc and Other Metal Ions 
5.21 Background 
Zinc is among the most important of the trace elements in human nutrition. The 
remarkable ability of this metal to participate in flexible and easily exchangeable ligand 
binding with organic molecules underlies the extraordinary extent to which zinc has been 
incorporated into a wide range of biological systems. Zinc is essential for gene 
expression and nucleic acid metabolism [28], which accounts in part for its importance 
for cellular growth and differentiation, in which it may actually have a regulatory role. 
Its ligand binding properties are utilised effectively at the catalytic sites of a wide range 
of enzymes [29,30]. Zinc also has many structural roles in biological membranes, cell 
receptors, enzymes and other proteins. One much-quoted example is the "zinc finger" 
that is present in certain transcription proteins [28]. 
Albumin transports zinc and copper in the blood. Albumin has been shown to modulate 
zinc uptake by endothelial cells [11] and receptor-mediated vesicular co-transport across 
the endothelium has been demonstrated with albumin-zinc complexes in vitro [31]. The 
binding sites for Zn2 on albumin have not been specifically located, even though 
albumin is believed to be the main zinc transport protein in the circulation. 
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5.2.2 Zinc Binding 
An indication of where Zn2 binds on albumin has come from 113CdNMR studies 
[12,13,32,33]. Several mammalian albumins have two strong binding sites for Cd2 with 
chemical shifts characteristic of NIO coordination (Figure 5.3). For human albumin, 
113 C shifts of 24 and 114 ppm (relative to Cd(Cl04)) [13] are indicative of sites 
containing a single imidazole nitrogen and 2-3 imidazole nitrogens, respectively. Zn2 , 
Cu2 	and Ni 2+  ions can displace Cd2 from the latter of these sites on human albumin 
[13] 
Examination of the X-ray crystal structure of fatty-acid free human albumin (PDB 1 A06) 
revealed that only one potential site on the albumin molecule has 2 histidine side-chains 
within 5 A from each other, His67 and His247. The identification of other residues 
around this site revealed that Asn99 and Asp249 were also close enough to provide 
oxygen ligands for metal binding. Asn99 could also potentially provide a nitrogen ligand 
from the amide group of its side chain. (Figure 5.4). These 4 residues are highly 
conserved in all mammalian albumins sequenced to date (Table 1.2). 
The aim of this study was to use site-directed mutagenesis and 111 C NMR spectroscopy 
to determine whether the cluster of amino acid side-chains, His 67, Asn99, His247 and 
Asp 
249  (Figure 5.4) is involved in Zn2 binding. 
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Figure 5.3 113 C NMR spectra of mammalian albumin (2 mM) in the presence of 2 
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Figure 5.4 The structure of human albumin as reported in PDB 1A06, in the region 
of the proposed metal binding site. CPK colours are used for the amino acid side- 
chains. 
5.2.2.1 Experimental 
Synthesis of Mutant Albumins 
Mutant albumins were synthesized and characterized as described in Chapter 3. 
111Cd NMR Studies 
"Cd-NMR studies were carried out using 1.5 mM recombinant human albumin (rHA) or 
respective mutant protein (Cys34Ala or His67Ala) at the same concentration, in 50 mM 
Tris, pH 7.1, 100 mM NaCl, 10% D20 with 2 mol equiv of "CdC12 at 21 °C. Various 
equivalents of ZnC12  (Acros) were added for metal titration experiments, the pH was 
156 
Chapter 5 	 Interactions of Metals with Albumin 
checked and adjusted (if required) after each addition. Dissolution of "CdO (95.11% 
isotopic purity, Oak Ridge National Laboratory, Tennessee, USA), generated "CdC12 
and "Cd(C104)2 in the appropriate amount of 1 M HCI or HC104, respectively. 
1D "Cd-{'H} NMR spectra (106.04 MHz, Bruker DMX500) were acquired using a 10 
mm BBO (direct observe) probe head with the help of Dr. Claudia Blindauer. Inverse-
gated proton decoupling was achieved by composite pulse decoupling using GARP [34]. 
Typically, spectra were acquired over a sweep width of 30 kHz (280 ppm) into 4 k 
complex data points, with a "Cd pulse width of 17.5 .ts (900),  36 k transients, an 
acquisition time of 0.10 s, and a recycle delay of 0.30 s. Prior to Fourier transformation, 
data were zero-filled to 16 k data points and apodised by exponential multiplication (120 
Hz line broadening). 
5.2.2.2 Results and Discussion 
The "Cd-NMR studies on 1.5 mM recombinant human albumin (rHA), in 50 mM Tris, 
pH 7.1 with 2 mol equiv of 111CdC12 confirmed binding at 2 sites (A and B) with peaks at 
131 and 27 ppm (relative to Cd(C104)), respectively. Under the same conditions the 
His 67Ala mutant gave rise to a single peak at 29 ppm (Figure 5.5). The Cys34Ala, 
His39Leu and Tyr 84Phe mutants gave rise to two peaks identical to that of the wild type 
(Figure 5.6). Addition of 0.5 and 1 mol equiv of ZnC12 to rHA in the presence of 2 mol 
equiv of 111Cd2 resulted in a decrease in intensity of the peak at 131 ppm (Figure 5.5). 
These results confirm that zinc can displace cadmium from site A. They also show that 
Cys34 is not involved in the binding of Cd2 . Cadmium does not bind to the His67Ala 
mutant at siteA, which implicates His 67  to be a key residue in the binding of cadmium 
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and zinc at this site and provides evidence for the aforementioned cluster of amino acids 
(shown in Figure 5.4) to be the site of binding. 
rHA +2111cd 	 B 
rHA+2 111Cd+O.5Zn 
rHA +2 111Cd + I Zn 
H67A rHA +2 111Cd 
I 	I 	I 	I 	I 	I 	I 	I 	I 
160 120 80 40 0 ppm 
Figure 5.5 '11Cd NMR spectra of native rHA with various mol equiv of ZnC12 and 
mutant rHA. All are in the presence of 2 mol equiv of '11CdC12, in 50 mM Tris, 100 
mM NaCl, pH 7.1. (a) Native rHA, (b) rHA plus 0.5 mol equiv ZnCl2, (c) rHA plus 1 
mol equiv ZnCl2, and (d) mutant His67Ala rHA. 
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(a) Tyr84Phe 
(c) Cys34Ala 
150 	100 	50 	0 ppm 
Figure 5.6 "Cd NMR spectra of mutant rHAs. All are in the presence of 2 mol equiv 
of "CdC12, in 50 mM Tris, 100 mM NaCl, pH 7.1. (a) Tyr 84Phe rHA, (b) His39Leu rHA, 
(c) Cys34Ala rHA. All are similar to the 111 C spectrum of native rHA shown in Figure 
5.5(a). 
5.2.3 Copper and Nickel Binding 
CU 
2+  and Ni2 are known to bind to a second site on the albumin molecule as well as the 
N-terminus [35]. "Cd NMR spectroscopy and UV/vis spectrophotometry were used to 
determine whether these metals are also able to bind at the zinc and cadmium binding site 
described above. 
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5.2.3.1 Experimental 
111Cd NMR Studies 
These studies were carried out as described in Section 5.2.2.1 with the exception that 
aliquots of 0.1 M CuCl2 (Fisons) or NiC12 (Acros) solution were added to the samples in 
the metal titration experiments. 
UV-Vis Spectrophotometry 
Aliquots of CuC12 solution (in 0.2 mol eq steps) were added to 2 mM solutions of rHA 
and the H67A mutant in 200 mM potassium phosphate, pH 7.4. Spectra were recorded 
using a Shimadzu UV250 1PC spectrophotometer between 400 to 800 nm using 1 cm 
pathlength cells at 25 °C. 
5.2.3.2 Results and Discussion 
Copper Binding 
2+ • • The addition of 1 mol equiv of CuCl2 did not affect Cd binding. This is most likely due 
to the high affinity of Cu2 for the N-terminus, with Cd2 displacement occurring only 
after saturation of binding at this site. Addition of 2 and 3 mol equiv of CuC12 to rHA in 
the presence of 2 mol equiv of 111CdCl2 appeared to affect Cd2 binding at site A and led 
to the formation of a new 111  C peak at 37 ppm (Figure 5.7). 
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rHA + 2 111Cd 
J \ W A\ WVI  
rHA + 2 111Cd + I Cu 
rHA + 2 111Cd + 2 Cu 
1HA+2hh1 %C p 
140 120 100 80 60 40 20 	ppm 
Figure 5.7 "Cd NMIR spectra of rHA in the presence of 2 mol equiv of "CdC12, in 
50 mM Tris, 100 mM NaC1, pH 7.1 with increasing concentrations of Cu2 . (a) 
Native rHA, (b) rHA plus 1 mol equiv CuCl2, (c) rHA plus 2 mol equiv CuC12, and (d) 
rHA plus 3 mol equiv CuC12. 
The number of nitrogen ligands coordinating to Cu2 in peptides [36] and proteins [37] is 
known to affect the wavelength of the d-d absorption bands of these complexes. An 
absorption band at 525 nm appeared after the first addition of CuC12 (Figure 5.8), 
indicative of N-terminal loading of the proteins by Cu2 , characteristic of 4 N 
coordination to Cu2 [36]. However a marked difference in absorption was observed after 
the further addition of 1 mol equiv CuC12 to each of the proteins. The native protein 
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broader band at 750 nm (Figure 5.8B). These bands suggest coordination of Cu 2+  to 2 N 
and 1 N respectively [37]. Absorption maxima were identified by normalising the 0.2 
mol equiv spectrum with the 2 mol equiv spectrum for that of the first species then by 
subtraction of the normalised spectrum from the 2 mol equiv spectrum for that of the 
second species. These results show that site A has a greater affinity for Zn2 than Cd2 , 
and that Cu 2+  binds competitively at this site. The results and also suggest the 
involvement of His 67  in metal coordination. 
+ 	 A 
500 	600 	700 	800 
Wavelength (nm) 
Figure 5.8 UV-vis absorption spectra of native MA (A) and H67A MA (B) with 0.2 
to 2 mol equiv of CuC12, in 0.2 mol equiv steps (bottom to top) in 200 mM potassium 
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Nickel Binding 
Addition of 2 and 3 mol equiv of NiC12  to rHA in the presence of 2 mol equiv of "CdC12 
had a similar effect to Cu2 on Cd2 binding at site A (Figure 5.9). However, addition of 
Ni2 did not lead to the formation of a new "Cd peak. As with the copper salt, the 
addition of 1 mol equiv of NiC12  did not affect Cd2 binding. This (as with copper) can 
be attributed to the high affinity of Ni2 for the N-terminus, with Cd2 displacement 
occurring only after saturation of binding at this site. It is therefore apparent that Cd2 
binding site A is a secondary binding site for Cu 2+  and Ni2 as well as being a site for 
Zn2 . Whereas the addition of Cu2 led to the formation of a new peak, the addition of 
2+ Ni 	did not. 
(a) rHA + 
:  
(b)MAjjj111NJ 
140 	120 100 80 60 40 20 p p m 
Figure 5.9 "Cd NMR spectra of rHA in the presence of 2 mol equiv of "CdC12, pH 
7.1 with increasing concentrations of Ni2 . (a) Native rHA, (b) rHA plus 1 mol equiv 
NiC12, (c) rHA plus 2 mol equiv NiC12, and (d) rHAplus 3 mol equiv NiC12. 
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5.2.4 Chloride Coordination to Albumin-Bound Cadmium 
It was noticed that the "Cd chemical shift of peak A in these experiments differed from 
the shift in the 113Cd albumin studies of Sadler and Viles [13]. Peak A was found to have 
6 = 131 whilst they found 6 = 114. Since the magnetic properties of "1Cd and 113 C 
isotopes are so similar [38], no differences in chemical shifts would be expected. Closer 
investigation of the Sadler and Viles studies revealed that their studies were carried out 
without added NaCl in their buffered albumin solution. In order to ascertain whether the 
"Cd chemical shift of peak A was dependent on chloride concentration (and whether 
chloride itself could co-ordinate to the metal) spectra were recorded at a range of NaCl 
concentrations. 
5.2.4.1 Experimental 
"Cd NMR studies were carried out as described in Section 5.2.2.1 with the exception 
that 1.5 mM rHA was dissolved in 100 mM potassium phosphate, pH 7. 1, 10% D20 with 
2 mol equiv of 111CdC12 at a range of NaC1 concentrations. The chemical shift of peak A 
in each case was recorded. 
5.2.4.2 Results and Discussion 
Titrations of Cd2-rHA with chloride ions suggested that a fifth ligand is involved in site 
A. Chloride induced large low-field shifts of peak A, but not peak B (Figure 5.10) 
consistent with weak Cl- binding (log K = 0.23±0.05) at this site. Since the affinity of Cl-
towards 
F
 Zn2 in low-molecular weight complexes [39] is about an order of magnitude 
smaller than for Cd2 , it is likely that physiologically, water would dominate as the fifth 
ligand for Zn2 bound to albumin (Cl- concentration in blood Ca. 104 mM). It should also 
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be noted that the values for the chloride-induced shifts are consistent with the findings of 
Sadler and Viles [13]. 
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Figure 5.10 Effect of chloride concentration on the "Cd NMR chemical shift of 
peak A of Cd2-rHA. The binding is weak (fast exchange on the NMR time scale) and 
analysis of the curve as a 1:1 complex (by Dr. Claudia Blindauer) gave Ka = 0.66±0.27. 
Peak B moves to low field by only 4.7 ppm over the same range of chloride 
concentrations. 
5.2.5 Molecular Modeling 
Using the results from the 111 C NMR studies, a model of the proposed site with a zinc 
atom bound was created with the help of Dr Claudia Blindauer. An initial model of Zn-
containing albumin was built based on the published crystal structure [40] (pdb accession 
code 1A06) using WebLab Viewer v4.0 (Acceirys). The zinc site was modelled as 5-
coordinate with the 4 amino acid cluster and with water as the fifth ligand. 
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The model was imported into Sybyl v6.8 (TRIPOS Inc.) for energy minimisation to 
optimise geometry, using the TRIPOS force field, after some specific parameters for zinc 
had been defined. Bond lengths for Zn2 bound to histidine (2.00 A) and aspartate (2.00 
A), and water (2.06 A) were taken from ref [41], and a Zn-O bond length for the Asn-
Zn2 interaction (2.15 A) was estimated based on the crystal structures of calcineurin, 5'-
endonucleotidase and kidney bean purple acid phosphatase, which were obtained from 
the Brookhaven Protein Databank (pdb accession codes 4KPB, 1AUI and 1TCO). Force 
constants were taken from the TRIPOS force field. Bond angles around zinc were not 
constrained at all, because for Zn2 with a coordination number of 5, no regular or 
uniform angles were to be expected. 
In a first step, the geometry around the zinc was optimised by 200 steps of energy 
minimisation of the zinc atom, the four protein ligand residues, and the water molecule 
only. A further 10 steps of energy minimisation were then employed on the entire protein 
to remove bad geometries and Van der Waals contacts which had been introduced 
through the atom movements in the first step. The r.m.s.d. values between the original 
protein structure and the modified model is 0.13 A for all atoms, and 1.21 A for the 
ligands residue atoms only. The final model is shown in Figure 5.11. 
The building of a model of a tetrahedral Zn2 site containing only N ligands from the 
side-chains of His67 and His 247,  and 0 ligands from Asn99 and Asp249 was also attempted 
by force-field based energy minimization based on the published crystal structure. 
Despite applying angle constraints, this yielded a geometry that resembled a distorted 
trigonal bipyramid. This suggests that the 5-coordinate model would be the most stable. 
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These findings provide a rational for the design of therapeutic recombinant albumins for 
controlling the levels of available zinc in blood and its delivery to target tissues. 
Mutagenesis of appropriate residues around this site could be used to produce albumins 
with decreased or increased Zn affinity. This could have particular implications for the 
control of zinc deficiencies, the activity of infectious agents [42,43] and for the design of 
zinc-activated pharmaceuticals [44,45]. 
Figure 5.11 Energy-minimized model of the proposed Zn2 binding site on human 
albumin (CPK colors). Zn2  binding requires only small movements of the amino acid 
side-chains, as can be seen from the comparison with the superpositioned X-ray structure 
of apo-human albumin (PDB 1A06, magenta). 
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5.2.6 Cadmium Binding to Albumins from Other Species 
Although Cd2 binds at two sites (A and B) on a range of mammalian albumins (Figure 
5.3), there are some exceptions. Porcine albumin appears to bind Cd2 significantly only 
at site B, while fatty acid-bound sheep albumin has 2 binding sites but the chemical shift 
of site A shifts is approximately 30 ppm upfield [13]. These observations suggest that 
porcine albumin lacks site A and that the cadmium bound at this site to fatty acid-sheep 
albumin is in a different environment from the other mammalian albumins. All 4 of the 
residues implicated at site A are completely conserved in both pig and sheep albumin. 
Sequence comparisons between different species revealed the 4 amino acid cluster to be 
poorly conserved in non-mammalian albumins. The aims of this study were to confirm 
that porcine albumin lacks site A, to determine whether the fatty acid bound to sheep 
albumin in Sadler and Viles' experiments [13] had an effect on the Cd2 binding and to 
determine whether Cd2 can bind to non-mammalian albumins. 
5.2.6.1 Experimental 
"Cd NMR studies were carried out as described in Section 5.2.2.1 with the exception 
that 1.5 mM of the respective albumin was dissolved in 100 mM potassium phosphate, 
pH 7. 1, 10% D20, 50 mM NaCl with 2 mol equiv of' "CdCl2. 
Fatty acid free porcine and sheep albumins were purchased from Sigma (A-1 173 and A-
6289, respectively). Of the non-mammalian albumins in the protein sequence database 
only chicken albumin (NBS Biologicals) was easy to obtain commercially. The chicken 
albumin purchased was Cohn fraction V [46], purified from chicken blood and is 
therefore likely to have fatty acid molecules bound. The chicken albumin was dialysed 
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as described in Section 2.1 and lyophilised prior to use. Porcine and sheep albumins 
were used as bought. 
5.2.62 Results and Discussion 
111 C NMR spectra of chicken albumin and fatty acid free porcine and sheep albumins in 
the presence of 2 mol equiv of 111CdC12 are shown in Figure 5.12. Neither free 111 Cd21 or 
the two "Cd peaks associated with human albumin were observed for chicken albumin, 
suggesting that ll2+  ions bind to chicken albumin but are in intermediate exchange (on 
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Figure 5.12 "Cd NMR spectra of (a) chicken, (b) porcine and (c) sheep albumins in 
the presence of 2 mol equiv of 111CdC12, pH 7.1. 
The "Cd NMR spectra of fatty-acid-free porcine albumin again revealed only Cd2 
binding at site B, despite having all the residues associated with metal binding at site A 
conserved. Closer analysis of the residues around the proposed site A in human albumin 
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reveals that Tyr 30  (located only 3-4 A away) is a histidine in the pig sequence. Tyr 30  is 
within H-bonding distance of Asn99 and is therefore likely to play a role in holding the 
Asn99 side-chain in place for metal binding. The lack of this H-bond in the pig albumin 
may disorientate the binding site. Alternatively, another histidine around this site could 
provide an alternative ligand for metal binding. This could mean that "Cd2 still binds 
to the proposed site in porcine albumin but is in intermediate exchange with other sites 
and cannot be seen by NMR. 
The "Cd NMR spectrum of fatty acid free sheep albumin was identical to human 
albumin. The upfield shift of peak A observed by Sadler and Viles [13] was most likely 
an effect caused by fatty acid binding. The effects of fatty acid binding are discussed in 
the next section. 
52.7 Fatty Acid-Induced Switch of Site A 
It has been noted in published studies that the fatty acid content of serum albumin 
influences the appearance of 113 C peak A [13]. The aim of this section was to compare 
"Cd NMR spectra of Cd2-rHA with high (ca. 8 mol mol') and low (< 4 mol mol') 
octanoate content. 
5.2.7.1 Experimental 
"Cd NMR studies were carried out as described in Section 5.2.2.1 with the exception 
that each rHA (both supplied by Delta Biotechnology Ltd) was dissolved to a 
concentration of 1.5 mM in 100 mM potassium phosphate, pH 7. 1, 10% D20 with 2 mol 
equiv of 111CdC12. 
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5.2.4.2 Results and Discussion 
It was observed that peak B was not affected by the variation in fatty acid loading, but 
peak A was not present in the high octanoate samples (Figure 5.13). The 12 X-ray crystal 
structures of fatty-acid loaded albumin were examined and it was found that the 
preorganisation of site A is disrupted in all of them. This arises from the binding of a 
fatty acid anion in so-called site 2 [47]. Fatty-acid-binding at this site also affects the 
Cys34 site (Section 4.2.2). 
Cd2rHA (low octanoate) 
Cd2rHA (high octanoate) 
- --- - - 
200 	14' 	100 	ii' 	,'PPM 
Figure 5.13 "Cd NMR spectra of rHA in the presence of 2 mol equiv of 111CdC12, 
pH 7.1. (a) rHA with a low octanoate content, (b) rHA with a high octanoate content. 
The carboxylate end of fatty acid in site 2 interacts with Arg257 and 5cr287 (both 
subdomain IA), Tyr 150  (subdomain TB) and the methyl end with subdomain IA. To 
accommodate a fatty acid anion, the long helix connecting domains I and TI bends and the 
two half sites in unliganded rHA move by more than 10 A to form a continuous cavity 
[47]. This results in a movement of residues His247 and Asp249 (Figure 5.14) by 4-7 A 
away from the other two residues in the proposed Zn2 site, His67 and Asn99. 
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Asp 249  also appears to change its side-chain conformation in order to maintain the H bond 
to N62 of His67, and forms an additional H bond to Asn99 (Figure 5.15). His247, which is 
H-bonded to Asn99  in the unliganded structure, forms an H-bond with Glu'°° in the fatty-
acid bound structures. 
Figure 5.14 Overlay of the structures of human albumin without (blue, PDB 
accession code 1A06) and with bound myristate (magenta, PDB accession code 
1BJ5). The 4-7 A movement of His247 and Asp249, which are situated in the loop 
connecting the two helices, away from the metal site. The overlay was generated (by Dr. 
Claudia Blindauer) in Swiss PDB Viewer (v. 3.6) by aligning the backbone atoms of 
His67 and Asn99 
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Figure 5.15 H bonding network around the proposed Zn2 binding site (A) without 
and (B) with fatty acid bound . The orientation of Asn99  is the same in both figures. 
The network of disulfide bonds (Figure 5.16) partially rigidifies the frameworks on which 
the proposed Zn ligands are based and also provides a mechanism for inter-helix 
communication of binding events in this region. The result is a spring-lock mechanism, 
which engages or disengages the His67/Asn99 and His247  /Asp  249 upper and lower jaws of 
the metal binding site. Under normal physiological conditions, human serum albumin 
carries 1-2 molecules of long-chain fatty acid (C16-C20) [1], but up to 8 binding sites have 
been identified [48]. Two of the three high-affinity sites are thought to be located in 
domain III, and one in domain I. Fatty acid site 2 appears to be a low-affinity site that 
only becomes populated when fatty acid anions are abundant. 
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Figure 5.16 Effect of fatty acid binding to site 2 on the proposed metal binding site 
in human albumin without (blue, PDB accession code 1A06) and with bound 
myristate (magenta, PDB accession code 1BJ5). (A) Domain and secondary structure 
plus cystine-bridge network around the metal site. The cystine residues (yellow) and the 
zinc ligands (CPK) are shown as stick models. (B) The tilting of the two-helix-bundle in 
domain II induced by fatty acid binding in myristate site 2 (1BJ5); myristate (green) is 
shown as a space-filling model. 
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5.3 Metal Complex Binding to Albumin 
5.3.1 Binding of Two Cytotoxic Ruthenium Complexes to 
Albumin 
5.3.1.1 Introduction to RMII6 and RM175 
Investigations into ruthenium complexes as potential anticancer drugs are of much 
current interest. This is largely due to the drug NAMI-A (Na[transRuCl4Me2SO(I1U)]), 
which is currently undergoing clinical trials. NAMI-A, may become the first anti-
metastatic drug on the market [49,50]. 
Two 	ruthenium(II) complexes (RM 116, [( 6-p-cymene)RuCl(H2NCH2CH2NH2- 
N,N)] PF6 and RM175, [0i6-C6H5C6H5)RuCl(H2NCH2CH2NH2-N,N)]PF6 ), have 
demonstrated cytotoxicity, even toward cisplatin resistant tumour cells [51]. 	The 
mechanism of action of RM116 and RM175 is unknown but may involve an interaction 
with DNA, like cisplatin. The structures of RM1 16 and RM175 are shown in Figure 
5.17. 
Albumin is recognised as being a key protein in the delivery of drugs through the 
circulatory system (see Section 1.1). A wide range of metallodrugs and compounds are 
known to bind to the Cys34 residue of albumin. The aim of this study was to determine 
whether either of the two complexes bind to albumin and hence determine whether or not 
albumin may be involved in their delivery to tumour cells. 
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Figure 5.17 Structures of the cations in the Ru2 arene complexes RM116 and 
RM117, which contain p-cymene and biphenyl ligands respectively. PF6 acts as the 
counter ion to both complexes. 
5.3.1.2 Experimental 
The binding of RM116 and RM175 (synthesised by Haimei Chen) to rHA was 
investigated by HPLC. The thiol content of the recombinant human albumin (Delta 
Biotechnology Ltd.) used was determined via a standard DTNB assay (see Section 2.3) as 
0.7 mol mol'. 
The HPLC was carried out using a Shodex KW-803 porous silica 8 mm x 300 mm gel 
permeation column on a Hewlett-Packard 1100 series HPLC. Detection was measured at 
320 nm as both complexes absorb at this wavelength. Note that the protein is not 
detected at this wavelength. The mobile phase was the same as that used for the albumin 
quantification assay, Section 2.2.2. By this method, the protein separates from the 
complex due to its large size, and binding can be seen as a decrease in the free complex. 
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Solutions containing various concentrations of albumin in the SH-form (from 13.1 tM to 
105.0 tM) and RM1 16 (52.5 M) in water were incubated for 24 h at 37°C. Aliquots 
(100 il) of each reaction were loaded onto the column. The above reactions were 
repeated with various concentrations of free thiol human albumin (from 12.6 iM to 100.8 
tiM) and RM175 (50.4 tM). 
5.31.3 Results and Discussion 
The resultant HPLC chromatograms show the decrease of free RM116 and RM175, 
respectively in the presence of increasing concentrations of albumin (Figure 5.18). 
RM116 is present as a single peak with a retention time of Ca. 13.7 min in A. RM175 
appears to be represented by two peaks with retention times of 13.5 and 15.0 minutes 
respectively in B. The first of these two peaks is most likely to be a phosphate complex 
(Dr Fuyi Wang, personal communication). From these results it is clear that both RM1 16 
and RM175 bind to human albumin. 
Further work carried out in our laboratory by a BSc project student, Frank Toner using 
ICP-AES (inductively coupled plasma atomic emission spectrometry) to measure 
albumin-bound ruthenium gave Ka values of 2.7 x 109 M1  and 6.2 x 109 M' for RM116 
and RM175 respectively. He also determined the respective Bmax values of 4.98 nmol 
mg' and 3.35 nmol mg' (Toner, unpublished data). These Ka and Bmax values are only 
valid if the ruthenium compounds bind albumin at a single site. It is possible that either 
of the compounds may bind at more than one site with different affinities. Toner also 
investigated competitive binding of both ruthenium compounds with DTNB, see Section 
4.2. He found that the DTNB greatly inhibited binding of RM1 16 to albumin but had no 
effect upon the binding of RM175 to albumin (Toner, unpublished data). This result 
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suggests that Cys34 is the main binding site for RM1 16. It is possible that RPvII75 binds 
to either or both of binding sites I and II. These sites are often thought of as being the 
main binding sites for small organic compounds and are described in more detail in 
Section 1.3.3. RM175 is likely to be too large to be able to fit into the hydrophobic 
























Figure 5.18 HPLC analysis of ruthenium complex binding. A and B show the 
decrease in free RM116 and R1v1175 respectively upon addition of of albumin. 
5.3.2 Binding of an aminophosphine platinum(II) 
complex to albumin 
5.3.2.1 Introduction to [Pt(NP3)CI]CI 
Aminophosphine Pt(H) complexes can bind to the DNA bases guanine and thymine via 
ring-opening reactions and are cytotoxic to cancer cells [52,53]. The target for cytotoxic 
platinum complexes is usually thought to be DNA, but they can also react with many 
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other biomolecules such as the sulfur-containing amino acids methionine and cysteine. 
The cysteine-containing tripeptide glutathione (y-L-Glu-L-Cys-Gly, GSH) is known to 
interact with cisplatin and its analogues and competes with nucleobases for platinum 
binding [54]. Additionally, sulfur-donor ligands can be used as rescue agents to 
minimise the toxic side effects of these therapeutics [55]. 
The square-planar platinum(II) complex, [Pt(NP3)Cl]Cl, where NP3 = N(CH2CH2PPh2)3, 
has previously been shown to react with thiol-containing biomolecules such as N-acetyl-
L-cysteine (NAC) and GSH [56] and to generate new strong absorption bands which are 
potential probes for such interactions. The aim of this study was to determine whether 
this platinum complex shows affinity toward the free thiol of albumin. 
5.3.2.1 Experimental 
The complex [Pt(NP3)Cl]Cl has previously been shown to have an extinction coefficient 
of 20700 M 1 cm at 256 nm. The complex upon binding to cysteine has extinction 
coefficients of 1775.0, 3567.5 and 10020 M' cm-1 at 500, 398 and 325 nm, respectively 
[56]. 
A small amount of [Pt(NP3)Cl]Cl (synthesised by Inés Garcia-Seijo) was dissolved in 
methanol, the concentration of the solution was determined spectrophotometrically to be 
1.38 mM. This solution was diluted to 230 p.M with methanol and 300 p.L was reacted 
with 300 p.L of 15 p.M rHA in aqueous 100 mM Tris-HC1, pH 7.4 at 25 C. The albumin 
thiol content was determined to be 0.65 mol moL' as described in Section 2.3. The 
formation of an albumin-complex product was observed at 398 nm against a blank 
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containing 230 tM [Pt(NP3)Cl]Cl in 50:50 methanol:100 mM Tris-HCI, pH 7.4 using a 
Shimadzu 1JV25 0 1 PC spectrophotometer. 
5.32.2 Results and Discussion 
The absorbance at 398 nm was found to increase over time indicating binding of 
[Pt(NP3)Cl]Cl to albumin, Figure 5.19. If binding only at Cys34 is assumed then under 
the conditions described, with [Pt(NP3)C1]Cl in high excess, the reaction should follow 
pseudo-first order kinetics and a rate constant could be calculated. This assumption 
would mean that only one molecule of complex could bind per free thiol group. Using 
the extinction coefficient for cysteine-complex binding (at 398 rim), it seems unlikely that 
the above assumption is correct, as the change in absorbance is too large. After 70 
minutes, 81.6 nmol of Cys34-complex would have to be present. This is not possible, as 
only approximately 1.5 nmol of free-thiol containing albumin is initially present. 
The change in the UV spectrum indicates that the complex does bind to albumin. 
However, the value of the extinction coefficient suggests that binding at Cys34 is only a 
minor contributor to this change in absorbance (if at all) and that a different site on 
albumin is involved in binding of the complex. 
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Figure 5.19 Reaction of MA with 20 mol eqiv [Pt(NP3)C11C1 per free thiol in 100 
mM Tris-HCI, pH 7.4. As monitored by a change in absorbance at 398 nm. 
5.4 Conclusions 
Albumin is the major transport protein in blood for Zn2 , a metal ion required for a 
variety of physiological processes and which various drugs and toxins recruit. It has been 
proposed that zinc binding to albumin involves at least 2 histidine ligands, but no 
structural model of the site had been reported. Here Zn2 and other metal ion binding to 
recombinant human albumin have been studied through competition with 111Cd2 using 
"Cd NMR. 
Analysis of the X-ray structures of unliganded human albumin in the PDB led to the 
identification of only one potential metal site containing at least two His residues. It lies 
at the interface of domains I and II, and two additional potential ligands (Asp and Asn) 
are situated nearby, poised to form a 5-coordinate site with a low molecular weight ligand 
such as water or CL in the fifth coordination site. Weak CL binding to Cd2 in this site 
181 
Chapter 5 	 Interactions of Metals with Albumin 
was detected for rHA. The amino acids contributing to this site are highly conserved in 
mammalian albumins. The trigonal bipyramidal site is apparently "preformed" in 
unliganded albumin, although none of the reported X-ray structures appear to contain a 
metal ion bound here. Mutation of His67 to Ala disrupted the binding of both Cd2 and 
Cu2 , known competitors for the major zinc site. 
Analysis of the available X-ray crystal structures of albumin and the 'Cd NMR data 
presented here suggest that fatty acids disrupt metal binding to site A. This triggers a 
movement of two of the proposed ligands (His247 and Asp249) by about 5 A away from 
His67 and Asn99, the two other proposed protein ligands in the Zn2 site. It will now be 
of interest to explore the possible consequences of the interactive binding of Zn2 and 
fatty acids to albumin. The proposed switching of the zinc site in human albumin by 
fatty acid binding is an intriguing example of an allosteric interaction between an organic 
nutrient and an essential metal ion. It might be possible to exploit this in drug design and 
therapy. 
Albumin binding studies involving two cytotoxic ruthenium(II) complexes ([(716-p-
cymene)RuCl(H2NCH2CH2NH2-N,N)]PF6 and [(r 6-C6H5C6H5)RuCl(H2NCH2CH2NH2-
N,N)]PF6 ) and a novel platinum(II) complex ([Pt(NP3)Cl]Cl) previously shown to have 
affinity toward low-molecular weight thiol compounds were carried out. Gel permeation 
chromatography showed that peaks corresponding to the free Ru(ll) complexes, 
decreased upon the addition of albumin, indicative of binding. The absorbance of 
albumin at 398 nm following the addition of [Pt(NP3)Cl]Cl increased, showing binding to 
have occurred. 
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Chapter 6 
Crystallisation of rHA 
6.1 Protein Crystallisation 
6.1.1 Introduction 
The main method of elucidating the 3-dimensional structure of a molecule as large as 
human albumin is by X-ray diffraction. As previously mentioned in Chapter 1, several 
X-ray crystal structures of human albumin have been elucidated, in both free [1,2] and 
fatty acid bound forms [3-5] and are summarised in Table 1.3. However, to date no 
structures of albumin have been solved of albumin with either a ligand bound at Cys34, 
a metal bound, or of a mutant albumin. The main aim of this chapter was to develop a 
method of crystallisation so that such structures could be elucidated. 
6.1.2 Crystallisation Theory 
The main hurdle in solving the structure of a protein as large as albumin, is the 
production of a highly diffracting (<3.0 A resolution) protein crystal. The general 
processes by which proteins crystallise are similar to that of salts and small organic 
compounds. To grow crystals, molecules must be brought into a thermodynamically 
unstable state known as supersaturation. This is usually achieved by the gradual 
removal of solvent and proceeds via three stages: nucleation, growth, and cessation of 
growth. 
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Nucleation is the process by which molecules or non-crystalline aggregates that are 
free in solution come together in such a way as to produce a thermodynamically stable 
aggregate with a repeating lattice. Crystallisation is known to lower the free energy of 
proteins by approximately 3-6 kcal mol1  relative to the solution state [6]. The 
formation of crystalline aggregates from supersaturated solutions does not necessarily 
lead to the formation of crystals. The aggregate first needs to exceed a specific size 
(the critical size) defined by the competition of the ratio of the surface area of the 
aggregate to its volume [7,8]. Once this critical size is reached, the aggregate becomes 
a nucleus capable of further growth. If the nucleus decreases in size so that it is 
smaller than the critical size, dissolution occurs. The process of formation of 
crystalline aggregates and non-crystalline precipitates does not involve the 
competition between surface area and volume and so can occur much faster than 
crystallisation. 
The degree to which nucleation occurs is determined by the degree of supersaturation 
of the solutes in the solution. The extent of supersaturation is in turn related to the 
overall solubility of the potentially crystallising molecule. The solubility of a protein 
can be described by a phase diagram (Figure 6.1). Higher solubility allows for a 
greater number of diffusional collisions and so higher degrees of supersaturation 
produce more stable aggregates (due to the higher probability of collision between 
diffusing molecules) and so increase the chances of the formation of stable nuclei. 
When there is a finite number of solute molecules, the production of a large number of 
small crystals usually results. At lower solute concentrations, the formation of 
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Figure 6.1 Typical phase diagram of a protein. The solubility curve divides 
undersaturated from supersaturated areas. On the curve, proteins are in equilibrium 
between solution and crystal, they will not crystallise in the area of undersaturatiOn. 
The supersaturated region is divided into three zones. The metastable zone is where 
the solution may not nucleate for a long time but this zone will sustain growth. It is 
frequently necessary to add a seed crystal. The nucleation zone is where protein 
crystals nucleate and grow. The precipitation zone is where proteins do not nucleate 
or grow in this region but precipitate out of solution. 
Crystal growth generally starts at solute concentrations sufficient for nucleation to 
occur, and can continue at concentrations lower than the nucleation threshold II9l. The 
purity of the protein is one of the most important factors in crystal growth. Proteins 
need not be absolutely pure to give crystals, although crystals from impure solutions 
frequently give poor diffraction data. To obtain good quality crystals, proteins need 
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not only to be reasonably free of contaminating proteins, but be "conformationally 
pure" [9]. Albumin is a particularly difficult protein to crystallise due to its 
heterogeneity and flexibility. Albumin preparations contain a significant amount of 
dimer. Also when isolated from plasma, approximately 28% of albumin molecules 
carry a half-cystine and 7% a half-glutathione as a mixed disulfide on Cys34 [10]. An 
important purity issue is that all traces of protease must be removed from the samples, 
as incubation times are frequently long (days to months). Lin and coworkers 
recommend the use of FPLC (or HPLC) for general purification of proteins and to 
assure homogeneity on both macroscopic and microscopic levels [11]. Lin notes 
several cases where the use of FPLC techniques has improved the reproducibility of 
crystallization as well as the maximum resolution to which protein crystals diffract. 
In order to combat these purity issues, only highly pure recombinant human albumin 
(supplied by Delta Biotechnology Ltd.) was used in the experiments described. Other 
factors, which can affect crystal growth, include pH and temperature [9]. 
Cessation of growth of crystals can occur for a multitude of reasons. The most obvious 
is the decrease in concentration of the crystallising solute to the point where the solid 
and solution phases reach exchange equilibrium. In this case, the addition of more 
solute can result in continued crystal growth. However, some crystals reach a certain 
size beyond which growth does not proceed irrespective of the solute concentration. 
This may be a result either of lattice strain effects or poisoning of the growth surface 
[9]. 
Lattice strain effects in tetragonal lysozyme crystals have been demonstrated by Feher 
and Kam [7]. Halved crystals of hen egg white lysozyme, when placed in fresh 
crystallisation solutions, grew to exactly the same size as the original crystal. This 
suggests that the strain in the lattice effectively prevents addition of molecules to the 
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surface once a certain critical volume is reached. Crystals affected by lattice strain are 
therefore size limited. 
Poisoning of growing faces occurs when foreign or damaged molecules are 
incorporated into the growing crystal face resulting in successive defects that interrupt 
the crystal lattice. An example of this might be the incorporation of a proteolytically 
knicked protein onto the face of an otherwise perfect protein crystal. If the nicked 
molecule is unable to form the same lattice contacts with newly added molecules, as 
would the perfect protein, then its incorporation will cause defects in the growing 
lattice. Since the growth of crystal lattices typically selects for perfect molecules 
(rather than damaged or incorrect molecules) the concentration of these defective 
molecules relative to perfect molecules tends to increase as growth proceeds. Thus, as 
crystals grow larger the likelihood of incorporation of defective molecules into the 
lattice increases (also the increase in surface area contributes). Sato and coworkers 
have used laser scattering tomography to identify lattice defects in large crystals of 
orthogonal hen egg white lysozyme [12]. Their results showed the occurrence of 
defects not only at the surface, but also within the bulk of the crystal itself. 
6.1.3 Methods of Protein Crystallisation 
As previously mentioned, crystal growth is usually achieved through the gradual 
removal of solvent from a protein solution. A common method of doing this is by 
vapour diffusion. In vapour diffusion methods a droplet of protein solution containing 
precipitant is equilibrated with a reservoir of precipitant of higher concentration so that 
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a gradual increase in protein and precipitant concentrations so that a few crystals may 
form. The most common of these are the hanging and sitting drop methods. 
Representations of these are shown in Figure 6.2. 
Hanging Drop 
	 Sitting Drop 
Figure 6.2 Diagrammatic representation of hanging and 
sitting drop vapour 
diffusion. Both techniques utilise a reservoir, containing 
a buffered precipitate 
solution. The drop also contains the same components as the reservoir (usually at half 
the concentration) as well as the protein to be crystallised. 
6.2 Crystallisation Experiments 
In the first crystallisation experiment, the crystallisation method of Sugio et al. 
was 
adopted [2. This is a standard hanging drop procedure. Sugio and coworkers 
managed to crystallise albumin from a drop containing 150-255 mg ML-' protein, 50 
mM potassium phosphate, (pH 5.0-5.5), 30-38% polyethylene glycol 400 and 5 mM 
sodium azide over 2-3 weeks. This crystallisation attempt as well as all others was set 
up in 26-well Linbro plates (ICN). Reservoir solutions were set up as shown in 
Appendix 3. A 2 iL volume of 200 mg mL' rHA (all albumins in this Chapter were 
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supplied by Delta Biotechnolgy Ltd. and were de-fatted as described in Section 2.4.1 
prior to use) was mixed with 2 p.L of each reservoir solution. These mixtures formed 
the drops, which were spotted onto the siliconised coverslips (Molecular Dimensions 
Ltd.). Each coverslip was sealed to the top of the well with vacuum grease as shown 
in Figure 6.2. The plate was stored at 18 °C. No protein crystals grew over a period of 
months. No precipitation was seen. 
The second crystallisation experiment followed the method of Carter et al. [13]. This 
method again utilises the hanging drop procedure. Reservoir solutions were set up as 
shown in Appendix 4. A 2 pL volume of 200 mg mU1 rHA was mixed with 2 jtL of 
each reservoir solution to form the drops. The plate was stored at 18 °C. No protein 
crystals grew over a period of months. Precipitation was seen in some of the wells. 
Crystallisation experiment 3 was slightly more successful. The hanging drop method 
was adopted and the plate was set up as shown in Appendix 5. A 5 L volume of 150 
mg mU' rHA was mixed with 5 pL of each reservoir solution to form the drops. The 
plate was stored at 4 °C. After approximately 2 weeks a tetragonal crystal was found 
in well B5. The X-ray diffraction pattern of the crystal was recorded by Prof. 
Malcolm Walkinshaw (Institute of Cell and Molecular Biology, University of 
Edinburgh). It was found to diffract X-rays only to 6 A resolution. 
The poor resolution of the X-ray data may have been due to a number of factors. 
Because the recombinant albumin used is relatively homogeneous the most likely of 
these are due to its dimer content and "conformational purity" (a consequence of the 
albumin's highly flexible structure). Crystallisation was next attempted using the 
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method of Curry [3-5]. It was thought that the presence of fatty acid within the 
structure of albumin would help to rigidify the structure and lead to the formation of 
higher quality X-ray diffracting crystals. 
In this experiment rHA, was loaded with myristic acid (C14:0) as described in Section 
2.4. This time the sitting drop method was adopted and the plate was set up as shown 
in Appendix 6. A 5 gL volume of 110 mg mL myristate-rHA was mixed with 5 pL 
of each reservoir solution to form the drops. The drops were placed in the sitting drop 
microbridges (Crystal Microsystems) and as with the hanging drops, coverslips were 
sealed on the top of each well with vacuum grease. The plate was stored at 4 °C. Only 
very small rod-shaped crystals grew after a couple of weeks, too small for diffraction 
studies. The size of the crystals may be limited by lattice strain or by surface 
poisoning. 
Crystallisation of native rHA was attempted with a higher molecular weight 
polyethylene glycol, PEG 6000 by the hanging drop method. The plate was set up 
with polyethylene glycol 6000 varying from 1-10% in each well and 50 mM 
potassium phosphate, pH 7.5. A 5 j.iL volume of 50 mg mU' rHA was mixed with 5 
tL of each reservoir solution to form the drops. The albumin in each of the drops 
precipitated out of solution almost immediately. 
The next crystallisation experiment used a crystal screen (Structure Screen 1, 
Molecular Dimensions Ltd.). Such screens are often used to determine initial 
crystallisation conditions and to establish the solubility of a macromolecule in a 
varying range of pH and precipitants. They take the form of a number of solutions 
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selected from previously-published works in which crystallisation of a protein has 
been achieved. 
The screen contained 50 different solutions. Of each solution 1 mL was used as the 
reservoir solution for both hanging and sitting drop experiments. A 5 p1 volume of 
100 mg mL' rHA was mixed with 5 j.tL of each reservoir solution to form the drops. 
The plates were stored at 4 °C. A summary of the solutions used and the results of the 
experiment are shown in Appendix 7. The sitting drop well set up with solution 34 
had an aggregate present, which appeared to be crystalline. 
Well 34 had present 30% PEG 400, 0.1 M Tris pH 8.5 and 0.2 M tri-sodum citrate 
dihydrate. A fresh sitting drop plate was set up with buffer and precipitant 
concentrations varied around those above as shown in Appendix 8. A 5 jiL volume of 
100 mg mL1  rHA was mixed with 5 p1 of each reservoir solution to form the drops. 
The plate was stored at 4 °C. No crystals grew. 
Up to this point the only experiment from which a suitable crystal was obtained for 
diffraction studies was experiment 3. Further crystallisation experiments utilised the 
conditions set up in this experiment. Crystallisation experiments were set up in order 
to grow crystals of the His 39Leu and Tyr 84Phe rHA mutants. Prior to crystallisation 
the mutant proteins were defatted as described in Section 2.4. The plate was set up as 
shown in Appendix 9. A 5 jiL volume of 150 mg mU' the respective mutant rHA was 
mixed with 5 p1 of each reservoir solution to form the drops. The His39Leu mutant 
protein was present in drops in colums 1-3 on the plate and the Tyr 84Phe in 4-6. The 
plate was stored at 4 T. After approximately 2 weeks tetragonal crystals were found 
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in both His39Leu and Tyr 84Phe mutant-containing wells. The crystals ranged in size 
from Ca. 0.3 mm across to 1.0 min across and 0.1 mm deep. 
After harvesting, the crystals were frozen in liquid nitrogen and X-ray diffraction was 
measured by Steve Robinson in the Department of Structural Biochemistry, University 
of Edinburgh. Data were collected for 40 min using a mar345 image plate at 400 mm 
from the crystal on a Nonius 571 rotating anode X-ray generator. The X-ray source 
was a copper anode, wavelength = 1.542 A. It was found that only 3 of crystals (A, B 
and C) produced X-ray diffraction patterns all of which were of the His 39Leu mutant. 
The space group of the unit cell of crystal A was primitive monoclinic with 
dimensions of a=76.08 A, b=185.88 A and c=182.85 A and angles of a=90.47°, 
=93.62° and y=87.78°. The a, b and c values indicate the length of the unit cell in 
each of the three dimensions (or axes). The metric tensor distortion index = 0.93%, 
which agrees with 1A06 [2] in the PDB fairly well (Table 6.1). The best resolution 
was 5.55 A, but was expected be complete only to 7 A or so if collected. The 
diffraction pattern is shown in Figure 6.3. 
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Figure 6.3 Diffraction pattern of crystal A. Note that a hole is cut in the film to 
reduce the overexposure caused by the very intense beam compared to the diffracted 
beams. Diffracted X-rays can be seen as black spots on the film. 
The space group of the unit cell of crystal B was primitive monoclinic with 
dimensions of a=75.35 A, b=182.74 A and c=180.95 A and angles of ct91.85°, 
=94.21° and 7=92.51°.  The metric tensor distortion index = 1.33% and the best 
resolution following diffraction is 5.45 A, but was expected to be complete to less if 
collected. The diffraction pattern is shown in Figure 6.4. 
200 
Chapter 6 	 Crystallisation of rHA 
Figure 6.4 Diffraction pattern of crystal B. 
The space group of the unit cell of crystal C was primitive orthorhombic with 
dimensions of a=158.66 A, b=179.87 A and c=184.60 A and angles of a90.17°, 
J3=89.69° and y=88.09°.  The metric tensor distortion index = 0.80% and the best 
resolution following diffraction is 7.90 A, but will likely be complete only to 10 A or 
so if collected. The diffraction pattern is shown in Figure 6.5. 
201 
Chapter 6 	 Crystallisation of rHA 
Figure 6.5 Diffraction pattern of crystal C. 
The poor resolution of the crystals again is most likely due to the presence of dimer or 
of poor "conformational purity" of the protein because the recombinant albumin used 
is of the highest purity. 
An attempt was also made to crystallise albumin with Cu2 bound at the N-terminus of 
albumin from a number of mammalian species. A plate for a hanging drop experiment 
was set up with reservoir solutions containing 40% PEG 400 and 50 mM potassium 
phosphate, pH 5.5. In these experiments 1 mol eqiv of CuC12 was added to a 150 mg 
mU' solution of the following fatty-acid-free albumins: rHA, bovine (Sigma, A-028 1), 
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murine (Sigma, A-1056), porcine (Sigma, A-i 173) and canine albumins (Sigma, A-
3184). 
A 5 jiL volume of 150 mg mU' of the respective albumin-Cu complex was mixed with 
5 .tL of each reservoir solution to form the drops. On the plate, the drops on the 
coverslips of wells in columns 1 and 2 contained MA, column 3 contained bovine, 4 
murine, 5 porcine and column 6 contained canine albumins. The plate was incubated 
at 4 °C. After 2 weeks, tiny yellowish rod-like crystals formed in all the drops except 
those containing canine albumin. The result is interesting, as it is well known that dog 
albumin has poor affinity toward copper as they lack the His  (Table 1.2) which 
provides 2 N ligands for Cu 2+ binding at the N-terminal site. The crystals were re-
incubated at 4 °C but unfortunately even after a period of months never became large 
enough for diffraction studies to be carried out. 
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The Increase in Absorbance at 412 nm with Time and a Plot of 
Log(IIJ°/I]) vs Time in the Determination of the Pseudo-First Order 
Rate Constant for the Reactions Described in Section 4.1 
As discussed in Section 4.1.1, for the reactions under the conditions described, a plot 
of log ([1 ] 0/[1 ]) against time gives a straight line with a slope equal to the pseudo-first 
order rate constant (where [I] = albumin thiol concentration and [1 ]0 = initial albumin 
thiol concentration). 
For the reaction of rHA with DTNB at pH 8.0, [1]0  = 4.1 x 106  M. This value is 
calculated from the final absorbance, once all the albumin molecules containing a free 
thiol group have been oxidised. Oxidation of Cys34 with DTNB results in the 
stoichiometric (1:1) production of TNB, as the DTNB is reduced (see Section 2.3). 
Therefore the production of TNB and indeed thiol oxidation can be quantified using 
the extinction coefficient of TNB, E = 13.9 units mM' cm-1 at 412 nm. The 
absorption at 412 nm during this reaction is shown in Figure Al. 
The [I] value at each recorded timepoint during the reaction was calculated in a 
similar way as [1]0,  in order to plot log ([J]0/[J])  against time. As the reaction 
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Figure Al The absorption at 412 nm during the reaction between MA and 
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Figure A2 A plot of log (1110/Eli) against time for the reaction between nBA and 
DTNB at pH 8.0. The black line shows a trendline for the data shown in red. The 
trendline is a fit of the data to a straight line, allowing a gradient (and therefore the 
rate constant) to be easily calculated. The resultant equation and R2 value of this line 
are displayed. 
The gradient of the trendline = 0.0225, therefore the pseudo-first order rate constant 




Non-Logarithmic Plots of Rate Constant vs pH for the reaction of 
rHA, high octanoate rHA and His39Leu and Tyr84Phe mutant 
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The 4 plots show the effects of pH on the pseudo-first order rate constants in the 




Recombinant Human Albumin Crystallisation Experiment 1 
60% PEG 400 64% PEG 400 68% PEG 400 72% PEG 400 76% PEG 400 80% PEG 400 
pH 5.0 pH 5.0 pH 5.0 pH 5.0 pH 5.0 pH 5.0 
60% PEG 400 64% PEG 400 68% PEG 400 72% PEG 400 76% PEG 400 80% PEG 400 
pH 5.2 pH 5.2 pH 5.2 pH 5.2 pH 5.2 pH 5.2 
60% PEG 400 64% PEG 400 68% PEG 400 72% PEG 400 76% PEG 400 80% PEG 400 
pH 5.4 pH 5.4 pH 5.4 pH 5.4 pH 5.4 pH 5.4 
60% PEG 400 64% PEG 400 68% PEG 400 72% PEG 400 76% PEG 400 80% PEG 400 
pH 5.6 pH 5.6 pH 5.6 pH 5.6 pH 5.6 pH 5.6 
All wells contained polyethylene glycol (PEG) 400 at the concentrations indicated, 50 




Recombinant Human Albumin Crystallisation Experiment 2 
20% PEG 4000 20% PEG 4000 20% PEG 4000 20% PEG 4000 20% PEG 4000 20% PEG 4000 
pH 7.0 pH 7.2 pH 7.4 pH 7.6 pH 7.8 pH 8.0 
22% PEG 4000 22% PEG 4000 22% PEG 4000 22% PEG 4000 22% PEG 4000 22% PEG 4000 
pH 7.0 pH 7.2 pH 7.4 pH 7.6 pH 7.8 pH 8.0 
24% PEG 4000 24% PEG 4000 24% PEG 4000 24% PEG 4000 24% PEG 4000 24% PEG 4000 
pH 7.0 pH 7.2 pH 7.4 pH 7.6 pH 7.8 pH 8.0 
26% PEG 4000 26% PEG 4000 26% PEG 4000 26% PEG 4000 26% PEG 4000 26% PEG 4000 
pH 7.0 pH 7.2 pH 7.4 pH 7.6 pH 7.8 pH 8.0 
All wells contained polyethylene glycol (PEG) 4000 at the concentrations indicated, 
50 mM potassium phosphate at the pH values indicated and 5 mM sodium azide. 
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Recombinant Human Albumin Crystallisation Experiment 3 
40% PEG 400 40% PEG 400 40% PEG 400 40% PEG 400 40% PEG 400 40% PEG 400 
pH 6.8 pH 6.8 pH 6.8 pH 6.8 pH 6.8 pH 6.8 
40% PEG 400 40% PEG 400 40% PEG 400 40% PEG 400 40% PEG 400 40% PEG 400 
pH 5.5 p115.5 pH 5.5 pH 5.5 pH 5.5 pH 5.5 
The 12 wells contained 40% polyethylene glycol (PEG) 400 and 50 mM potassium 




Recombinant Human Albumin Crystallisation Experiment 4 
25% PEG 3350 25% PEG 3350 25% PEG 3350 25% PEG 3350 25% PEG 3350 25% PEG 3350 
pH 7.5 pH 7.5 pH 7.5 pH 7.5 pH 7.5 pH 7.5 
26% PEG 3350 26% PEG 3350 26% PEG 3350 26% PEG 3350 26% PEG 3350 26% PEG 3350 
pH 7.5 pH 7.5 pH 7.5 pH 7.5 pH 7.5 pH 7.5 
27% PEG 3350 27% PEG 3350 27% PEG 3350 27% PEG 3350 27% PEG 3350 27% PEG 3350 
pH 7.5 pH 7.5 pH 7.5 pH 7.5 pH 7.5 pH 7.5 
28% PEG 3350 28% PEG 3350 28% PEG 3350 28% PEG 3350 28% PEG 3350 28% PEG 3350 
pH 7.5 pH 7.5 pH 7.5 pH 7.5 pH 7.5 pH 7.5 
The wells contained polyethylene glycol (PEG) 400 at the concentrations indicated 




Summary of Solutions and Results of the Crystal Screen (Exp. 5). 
Solution Buffer Precipitant Additional HD SD 
No.  component  
0.1 M Na acetate 30% 2-methyl-2,4 0.02 M calcium P P 
trihydrate pH 4.6 pentanediol chloride dihydrate 
2 0.1 M Na acetate 30% PEG 4000 0.2 M ammonium P P 
trihydrate pH 4.6 acetate 
3 0.1 M Na acetate 25% PEG 4000 0.2 M ammonium P P 
trihydrate pH 4.6 sulphate 
4 0.1 M Na acetate 2.0 M sodium None N N 
trihydrate pH 4.6 formate 
5 0.1 M Na acetate 2.0 M ammonium None P P 
trihydrate pH 4.6 sulphate 
6 0.1 M Na acetate 8% PEG 4000 None N N 
trihydrate pH 4.6 
7 0.1 M tn-sodium 30% PEG 4000 0.2 M ammonium P 
citrate dihydrate pH 5.6 acetate 
8 0.1 M tn-sodium 30% 2-methyl-2,4- 0.2 M ammonium N N 
citrate dihydrate pH 5.6 pentanediol acetate 
9 0.1 M tn-sodium 20% 2-propanol, 20% None N P 
citrate dihydrate pH 5.6 PEG 4000 
10 0.1 M Na citrate pH 5.6 1.0 M ammonium None N N 
dihydrogen 
phosphate 
11 0.1 M Na acetate 20% 2-propanol 0.2 M calcium N N 
trihydrate pH 4.6 chloride dihydrate 
12 0.1 M Na cacodylate 1.4 M Na acetate None N N 
pH 6.5 trihydrate 
13 0.1 M Na cacodylate 30% 2-propanol 0.2 M tn-sodium N N 
pH 6.5 citrate dihydrate 
14 0.1 M Na cacodylate 30% PEG 8000 0.2 M ammoniium P P 
pH 6.5 sulphate 
15 0.1 M Na cacodylate 20% PEG 8000 0.2 M magnesium P P 
pH 6.5 acetate tetrahydrate 
16 0.1 M Na cacodylate 30% 2-methyl-2,4- 0.2 M magnesium N N 
pH 6.5 pentanediol acetate tetrahydrate 
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17 0.1 M imidazole pH 1.0 M sodium acetate None N N 
6.5 trihydrate 
18 0.1 M Na cacodylate 30% PEG 8000 0.2 M sodium acetate P P 
PH 6.5 trihydrate 
19 0.1 M Na cacodylate 18% PEG 8000 0.2 M zinc acetate P 
PH 6.5 dihydrate 
20 0.1 M Na cacodylate 18% PEG 8000 0.2 M calcium acetate N N 
PH 6.5 hydrate 
21 0.1 M Na hepes pH 7.5 30% 2-methyl-2,4- 0.2 M tn-sodium N N 
pentanediol citrate dihydrate 
22 0.1 M Na hepes pH 7.5 30% 2-propanol 0.2 M magnesium N N 
chloride hexahydrate 
23 0.1 MNa hepes pH7.5 28% PEG 400 0.2Mcalcium N N 
chloride dihydrate 
24 0.1 M Na hepes pH 7.5 30% PEG 400 0.2 M magnesium N N 
chloride hexahydrate 
25 0.1 M Na hepes pH 7.5 20% 2-propanol 0.2 M tn-sodium N N 
citrate dihydrate 
26 0.1 M Na hepes pH 7.5 0.8 M K, Na tartrate None N N 
tetrahydrate 
27 0.1 M Na hepes pH 7.5 1.5 M lithium None N N 
sulphate 
monohydrate 
28 0.1 M Na hepes pH 7.5 0.8 M Na dihydrogen None N N 
and 0.8M K phosphate 
dihydrogen phosphate 
monohyd. 
29 0.1 M Na hepes pH 7.5 1.4 M tn-sodium None N N 
citrate dihydrate 
30 0.1 M Na hepes pH 7.5 2% PEG 400, 2.0 M None N N 
amm sulphate 
31 0.1 M Na hepes pH 7.5 10% 2-propanol, 20% None P 
PEG 4000 
32 0.1 M tris HC1 pH 8.5 2.0 M ammoniium ,None N N 
sulphate 
33 0.1 M tris HC1 pH 8.5 30% PEG 4000 0.2 M magnesium P P 
chloride hexahydrate 
34 0.1 M tris HCl pH 8.5 30% PEG 400 0.2 M tri-sodum N A 
citrate dihydrate 
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36 0.1 M tris HC1 pH 8.5 30% 2-propanol 0.2 M ammonium N N 
acetate 
37 0.1 M tris HClpH8.5 30% PEG 4000 0.2 M sodium acetate N P 
trihydrate 
38 0.1 M tris HC! pH 8.5 8% PEG 8000 None N N 
39 0.1 M tris HCI pH 8.5 2.0 M ammonium None N N 
dihydrogen 
phosphate 
40 None 0.4 M K, Na tartrate None N N 
tetrahydrate 
41 None 0.4 M ammonium None N N 
dihydrogen 
phosphate 
42 None 30% PEG 8000 0.2 M ammonium P P 
sulphate 
43 None 30% PEG 4000 0.2 M ammonium p 
sulphate 
44 None 2.0 M ammonium None P 
sulphate 
45 None 4.0 M sodium None N N 
formate 
46 None 20% PEG 8000 0.05 M potassium P P 
dihydrogen 
phosphate 
47 None 30% PEG 1500 None N P 
48 None 0.2 M magnesium None N N 
formate 
49 None 2% PEG 8000 1.0 M lithium N N 
sulphate 
monohydrate  
50 None 15% PEG 8000 0.5 M lithium N N 
sulphate 
monohydrate  
Abbreviations used: HD, hanging drop; SD, sitting drop; A, possible crystalline 




Recombinant Human Albumin Crystallisation Experiment 6 
25% PEG 400 27% PEG 400 29% PEG 400 31% PEG 400 33% PEG 400 35% PEG 400 
pH 7.5 pH 7.5 pH 7.5 pH 7.5 pH 7.5 pH 7.5 
25% PEG 400 27% PEG 400 29% PEG 400 31% PEG 400 33% PEG 400 35% PEG 400 
pH 8.0 pH 8.0 pH 8.0 pH 8.0 pH 8.0 pH 8.0 
25% PEG 400 27% PEG 400 29% PEG 400 31% PEG 400 33% PEG 400 35% PEG 400 
p1-I 8.5 pH 8.5 pH 8.5 pH 8.5 pH 8.5 pH 8.5 
25% PEG 400 27% PEG 400 29% PEG 400 31% PEG 400 33% PEG 400 35% PEG 400 
pH 8.5 pH 8.5 pH 8.5 pH 8.5 pH 8.5 pH 8.5 
The wells contained polyethylene glycol (PEG) 400 at the concentrations indicated, 




Recombinant Human Albumin Crystallisation Experiment 7 
20% PEG 400 20% PEG 400 20% PEG 400 20% PEG 400 20% PEG 400 20% PEG 400 
pH 7.2 pH 7.4 pH 7.6 pH 7.2 pH 7.4 pH 7.6 
22% PEG 400 22% PEG 400 22% PEG 400 22% PEG 400 22% PEG 400 22% PEG 400 
pH 7.2 pH 7.4 pH 7.6 pH 7.2 pH 7.4 pH 7.6 
24% PEG 400 24% PEG 400 24% PEG 400 24% PEG 400 24% PEG 400 24% PEG 400 
pH 7.2 pH 7.4 pH 7.6 pH 7.2 pH 7.4 pH 7.6 
26% PEG 400 26% PEG 400 26% PEG 400 26% PEG 400 26% PEG 400 26% PEG 400 
pH 7.2 pH 7.4 pH 7.6 pH 7.2 pH 7.4 pH 7.6 
The wells contained polyethylene glycol (PEG) 400 at the concentrations indicated 
and 50 mM potassium phosphate at the pH values indicated. 
217 
